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 ABSTRACT 
 
More than 90% of the worldwide population is infected with Epstein Barr virus (EBV). In 
general, the infection remains asymptomatic and the virus persists for life in latently infected 
B cells. During this state, viral activity is reduced to the maintenance of the viral genome such 
that EBV-infected cells are not efficiently recognized by the immune system. However, the 
first days of primary infection are characterized by a period of lytic gene expression that 
contributes to successful virus establishment (Kalla et al., 2010). The abundant expression of 
“foreign” protein renders the infected cell prone to immune recognition and requires viral 
counter-measures to evade immune responses.  
The first part of this work focuses on the importance of two immune evasins of EBV 
during this early phase of infection: BCRF1 and BNLF2a, encoding the viral homologue of 
the anti-inflammatory cytokine IL-10 and a unique inhibitor of epitope loading on MHC I 
molecules, respectively. To study their impact on immune responses to freshly infected B 
cells, I generated recombinant EBV mutants, which are deficient in expressing either BCRF1 
or BNLF2a or both. I observed significant immunological consequences during the first days 
of infection, but, unexpectedly, the MHC I surface pattern of infected B cells was not 
affected. Deficiency in BNLF2a expression in infected cells resulted in a drastically increased 
response of EBV-specific CD8+ T cells. BCRF1 did not participate in this effect, but instead 
severely impaired the cytokine response to viral infection and protected infected cells from 
elimination by NK/NKT cells. Thus, both immune evasins have important functions during 
the early phase of infection and are instrumental for the establishment of latency. Their 
balanced activity illustrates the perfect adaptation of the virus to the host’s immune system.  
The second part of this work builds upon my initial observation that viral transcripts are 
present in the infected cell almost instantly following virus entry. I found that EBV particles 
represent the source of these transcripts as I identified them to contain viral RNA which is 
transferred to and expressed in the infected cell. I could further demonstrate that these 
packaged transcripts exert important biological functions in the infected cells by triggering the 
initial viral transcription program or acting as immune modulators. In sum, delivered RNAs 
apparently create a supportive environment that promotes virus establishment in infected B 
cells. Thus, despite EBV’s classification as a DNA virus, also packaged RNAs are apparently 
essential for its infectious nature. 
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 ZUSAMMENFASSUNG 
Mehr als 90% der weltweiten Bevölkerung sind mit Epstein Barr Virus (EBV) infiziert. In 
B Zellen etabliert das Virus eine latente Infektion, die normalerweise asymptomatisch verläuft 
und lebenslang bestehen bleibt. In Latenz liegt nur sehr begrenzte Virusaktivität vor, die das 
Immunsystem nicht erkennt und infizierte Zellen somit nicht eliminiert. In den ersten Tagen 
nach der Infektion von B Zellen kommt es jedoch zur Expression einer Vielzahl lytischer 
Gene, die wichtig für die erfolgreiche Virusetablierung ist (Kalla et al., 2010). Dies geht 
einher mit einer starken Last an Virusprotein in der Zelle, welche das Risiko einer 
Immunreaktion deutlich erhöht. In dieser Phase sind virale Gegenmaßnahmen zur 
Immunerkennung von besonderer Bedeutung.  
Im ersten Teil dieser Arbeit habe ich den Einfluss und das Zusammenspiel zweier viraler 
Faktoren auf die frühe Immunantwort untersucht: (i) BCRF1, ein EBV-Homolog des anti-
inflammatorischen humanen IL-10, und (ii) BNLF2a, ein EBV-spezifischer Inhibitor der 
Antigenpräsentation auf MHC I. Um ihre physiologische Bedeutung zu erfassen, habe ich 
EBVs hergestellt, die entweder defizient für BCRF1 oder BNLF2a oder beide Gene sind. Die 
Infektion mit diesen Viren verursachte eine stark veränderte frühe Immunantwort: BNLF2a-
Defizienz resultierte in einer bedeutend stärkeren Aktivierung von EBV-spezifischen CD8+ T 
Zellen, während BCRF1 die Zytokin-Antwort im Rahmen einer Infektion zugunsten des Virus 
deregulierte. Darüber hinaus zeigte sich, dass BCRF1 infizierte Zellen vor der Elimierung 
durch NK/NKT Zellen schützt. Somit konnte ich für beide Faktoren wichtige Funktionen bei 
der Umgehung der frühen Immunantwort nachweisen, einem essentiellen Schritt bei der 
Etablierung einer latenten Infektion.  
Der zweite Teil meiner Arbeit basierte auf der initialen Beobachtung, dass EBV-
Transkripte bereits unmittelbar nach Infektion in den Zielzellen präsent sind. Meine 
Experimente zeigen, dass EBV Partikel selbst diese RNA enthalten und bei einer Infektion in 
die Zelle transferieren. Diese Transkripte haben eine wichtige Funktionen im Rahmen der 
Infektion. Sie kodieren zum einen für Initiatoren des frühen lytischen Transkriptions-
programms, zum anderen dämpfen sie das Ausmaß einer antiviralen Immunantwort des 
Wirtes. Der Transfer von RNA generiert offenbar zelluläre Bedingungen, die sich positiv auf 
den Infektionserfolg des Virus auswirken. Somit konnte ich dem klassischen DNA-Virus 
EBV erstmalig auch Eigenschaften eines RNA-Virus nachweisen. 
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 INTRODUCTION 
1. The immune system 
Defense against pathogens is essential for the survival of an organism. Even the most 
basic forms of life exhibit protection mechanisms like restriction of foreign genome 
sequences or phagocytic activity. With the onset of evolution, organisms became more 
complex and developed a dedicated compartment of many different but interacting cell types, 
called the immune system (IS). It can be divided into two subsets: the innate IS and the 
adaptive IS. The innate IS comprises granulocytes, macrophages, dendritic cells, mast cells 
and natural killer cells as effectors whose basic progenitors can already be found in 
invertebrates. These cells carry germline-encoded receptors to target rather invariant 
pathogen-associated molecular patterns (PAMPs), like bacterial lipopolysaccharides (LPS). 
The ability to react immediately on the invasion of pathogens is the major advantage of this 
arm of the IS. Therefore, most of these effectors are located in classical entry tissues, such as 
submucosa, however are also present in lymph and blood flow. 
The innate IS limits pathogen spread but is rarely able to eliminate the invaders on its 
own. Instead, elimination of pathogens is usually achieved by engagement of the second arm 
of the IS, called the adaptive IS. It evolved in higher life-forms starting from jawed 
vertebrates and consists of two major types of effector cells: T lymphocytes that can be 
further subdivided into CD4+ T cells (T helper cells) and CD8+ T cells (T killer cells), as 
well as B lymphocytes. The characteristic feature of lymphocytes is their antigen receptor, 
whose specificity is not germline-encoded but generated by somatic recombination of gene 
segments and is therefore unique to each cell. Expression of these random products leads to 
the development of cells that recognize epitopes of either ‘foreign’ or ‘self’ origin. Self-
reactive cells would result in threatening autoimmunity. Therefore, highly effective processes 
of selection during development of lymphocytes ensure that only cells with non-self 
specificity are engaged in maturation.  
Mature naïve lymphocytes then bear individual non-self reactive antigen receptors, but 
still require the arming of effector functions. This occurs in lymphoid tissue upon primary 
encounter of matching antigen in combination with secondary signals from professional 
antigen presenting cells (APC), or T helper cells. Subsequently, armed cells undergo clonal 
expansion, leave the lymph node and deploy immediate effector function when their antigen 
receptor is triggered (independently of secondary signals). Within five to seven days, this 
INTRODUCTION  1. The immune system 
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process generates a large amount of 
potent effectors with specificity 
against the invading pathogen, 
which is generally sufficient to 
eliminate the infection.  
A further hallmark of the 
adaptive immune response is the 
generation of an immunologic 
memory: A minor subpopulation of 
effector cells acquires a memory 
phenotype during clonal expansion. 
These cells are of extreme 
longevity and reside in the body for 
many years. In contrast to naïve 
lymphocytes, they reactivate and 
undergo clonal expansion 
immediately upon encounter of 
antigen, as they do not need to be 
armed. Hence, re-infection with the 
same pathogen is eradicated in a  
faster and more efficient way, 
frequently without manifestation of 
any symptoms. This principle is 
exploited by vaccination: The IS is triggered to mount immunity to an attenuated or 
inactivated pathogen generating memory cells that provide long-term protection against the 
naturally occurring, infectious pathogen (Janeway, 2005). 
 
1.1 Mediators of cellular and humoral immune response 
The adaptive immune system can evoke cellular and humoral responses. Cellular immune 
responses are mediated by T cells and to some extent also by natural killer (NK) cells, with 
the latter belonging to the innate IS. They confer cytotoxic effector functions through direct 
cellular contact and thereby eliminate infected cells. CD4+ T cells also belong to the cellular 
response, but contribute secondary activating signals by direct cell contact and cytokine 
secretion.  
Figure 1.1: Activation and differentiation of lymphocytes in 
an immune response. The phagocytic uptake of antigen results 
in presentation on MHCI and MHCII on APCs and triggers T 
cell activation. B cells also present antigen on MHCII, which is 
recognized by CD4 Tcells that in turn activate the presenting B 
cell. APC, antigen presenting cell; TCR, T cell receptor; BCR, 
B cell receptor; TH cell, T helper cell; TC cell, cytotoxic T cell. 
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Humoral immune responses are defined by shedding of pathogen-specific antibodies to the 
‘humours’, i.e. any kind of body fluid. This function is accomplished by plasma B cells that 
secrete soluble forms of their respective B cell receptors. As described above, initial 
encounters of matching antigen and costimulatory signals from CD4+ T cells are mandatory 
to trigger this feature. Antibodies deploy neutralizing functions by covering adhesion 
molecules of the pathogen and tagging them for one of two processes: either phagocytosis by 
macrophages, or antibody dependent cellular cytotoxicity (ADCC), carried out by NK cells 
and eosinophils (Metzger, 1990). 
For reasons of clarity, cells of the IS are assigned to functional categories. An efficient 
immune response, however, comprises effectors from all arms of the IS, which operate as 
highly synchronized network of defense. 
 
1.2 CD8+ T cells recognize intracellular infection 
In many instances, pathogens are neither 
sufficiently intercepted nor recognized before they 
enter a cell, which is usually the case with virus 
infections. Still, the IS can recognize intracellular 
infections by means of pathogen-derived antigens, 
which are presented on the surface of infected cells 
in the context of class I major histocompatibility 
complexes (MHC I). Therefore, peptides that are 
generated by protein degradation in the proteasome 
are actively translocated to the endoplasmatic 
reticulum (ER) by the transporter associated with 
antigen- presentation (TAP). Once in the ER, the 
correct loading of peptides to MHC I is mediated by 
tapasin and the chaperones calreticulin and Erp57. 
Loaded MHC I molecules then migrate via the Golgi 
network to the cell surface to present the peptides. 
Circulating CD8+ T cells scan these molecules for a 
putative match with their respective T cell receptor 
(TCR). As mentioned above, immune effectors are 
selected for their specificity to recognize non-self 
Figure 1.2: Infected cells present foreign 
antigen on MHCI and are eliminated by T 
cells. See text for details. ER, endoplasmatic 
reticulum; MHC major histocompatibility 
complex; TCR, T cell receptor. 
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structures. Hence, if a TCR matches a presented peptide, it is in general of foreign origin and 
indicates the infection of the cell. The TCR match activates effector mechanisms, which in 
case of cytotoxic CD8+ T cells lead to elimination of the infected cell via cytolytic effector 
functions (Germain, 1994).  
 
1.3 MHC: determining histocompatibilty  
T cell recognition of infected cells is not only dependent on the presented peptide but also 
on the presenting MHC molecule. A T cell’s co-receptor assist in antigen recognition: CD8 
binds to MHC I, which can be found on nearly every nucleated cell. CD4 binds to MHC II, 
which is present on APCs only. But the TCR itself also has to match the MHC molecule and 
is positively selected for this property during thymic maturation. 
In humans, the MHC is also termed human leukocyte antigen (HLA). Whereas MHC I 
heavy chains are encoded by the HLA-A, B and C genes, MHC II chains are encoded by 
HLA- DP, DQ and DR, all of them located on chromosome 6. Most of these genes have more 
than ten alleles, some of them have even more than 100. Thus, the HLA genes show a high 
degree of variation between individuals, far more than other human genes. Each individual 
inherits a paternal and a maternal allele of each locus. Both alleles alleles of all HLA genes 
are co-dominantly expressed on the same cell and form the repertoires of MHC I (max. 6 
different molecules) and MHC II (max. 12 different molecules). The individual entity of 
MHC molecules defines the tissue as ‘self’ and T cells of this individual will only tolerate 
self-MHC. Correct recognition of infected cells is hence based on self-MHC loaded with 
foreign peptide, whereas foreign MHC will lead to immunologic rejection by T cells 
recognizing ‘non-self’ structures. MHC incompatibility is a major obstacle in transplantation. 
Thus, there is a requirement for at least partly matching HLA in donor and recipient (Murphy, 
1999). 
 
1.4 Natural killer cells control for irregular MHC I surface levels 
Natural killer (NK) cells represent another type of potent cellular effectors of the immune 
system. They are characterized by the expression of the cell adhesion molecule CD56 and the 
Fc-γ receptor III (CD16) and account for 5-25% in PBMCs. NK cells belong to the arm of 
innate immunity, as they rely on conserved, invariant receptors. Regarding their evolution, 
NK cells are considered as the link between innate and adaptive immunity, as the relation to 
cytotoxic T cells is obvious and even a subset of NK cells with an invariant TCR has been 
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described (termed NKT cells) (Fowlkes et al., 1987; Godfrey et al., 2004).  
Most importantly, NK cells recognize pathogen induced MHC I downregulation on 
infected cells and eliminate them by deploying cytolytic function. To decide on activity, NK 
cells integrate activating and inhibitory signals, which they perceive by a variety of receptors 
scanning the surface of other cells. Dominant signals are usually derived from killing 
inhibitory receptors (KIRs) or CD94:NKG2 receptor dimers, which bind to MHC I molecules 
and minor-histocompatibility complexes, respectively. These signals dominate any potentially 
activating signals from cell contact sensing receptors. In case NK cells scan cell surfaces with 
low or absent MHC I molecules and simultaneously receive signals from activating receptors, 
the signal balance is shifted towards activation and causes the directed release of cytotoxic 
components like perforin and granzyme. Through their immediate presence and their unique 
potential to sense downregulated antigen presentation, NK cells are highly important for the 
restriction of viral infections (Vivier et al., 2011).  
 
1.5 Recognition through CD4+ T cells  
CD4+ cells recognize their targets similarly to CD8+ T cells, the difference being that 
their TCR in combination with the co-stimulatory CD4 molecule specifically binds to 
MHC II. MHC II is found exclusively on professional antigen presenting cells (APC) 
comprising dendritic cells, activated B cells and macrophages. These cells are able to engulf 
recognized pathogens or apoptotic cells for endocytosis. The load is processed by 
acidification and protease activation in endosomes, leading to the generation of peptides. 
Other vesicles with ready-to-load MHC II molecules fuse, however these MHC II still carry a 
placeholder (CLIP) in the peptide-binding groove. HLA-DM molecules mediate the 
replacement of CLIP with processed peptides and the then loaded MHC II molecules finally 
migrate to the cell surface (Pieters, 2000). In analogy to CD8+ recognition, scanning T cells 
are activated when their TCR matches the epitope and CD4 binds to MHC II. CD4+ T cells 
exhibit a so-called helper function by releasing cytokines that modulate the presenting cell's 
properties, thereby initiating the differentiation of B cells into antibody secreting plasma cells 
and memory cells, for instance (London et al., 2000). 
 
 
 
INTRODUCTION  1. The immune system 
 17 
1.6 Cytokine signaling 
The fate and behavior of cells of the immune system depend on signals derived not only 
from direct contact with other cells, but also on the presence of soluble signaling molecules, 
called cytokines. These include chemokines, which are important in chemoattraction of 
immune cells to a focus of inflammation, for example, and interleukins (ILs), initially named 
for their function of mediating communication between leukocytes. The major source of 
cytokines are CD4+ T cells, also termed T helper (Th) cells. Depending on their 
differentiation, they promote either cellular immune responses (Th1) or humoral immune 
reponses (Th2) (Romagnani, 1999; O'Garra and Arai, 2000). These distinct functions are 
associated with the secretion of characteristic cytokines: Th1 cytokines like IL-2, Ifn-γ, IL-12 
and TNF-β boost T and NK cell responses, while Th2 cytokines like IL-4, IL-5, IL-6, IL-10 
and IL-13 induce B cell differentiation and proliferation. However, these cytokines are also 
produced by other cell types, among them CD8+ T cells, monocytes, NK cells, B cells and 
mast cells.  
Cytokines form a complex network of communication that orchestrates the different IS 
compartments to respond in an appropriate manner. As such, certain cytokines act mutually 
antagonistic and the kind of immune response within a certain phase of an infection is 
determined by the predominant subset of cytokines: Ifn-γ, for example, hampers cytokine 
secretion of Th2 cells, whereas Th2 cytokines, such as IL-10 can suppress Th1 production and 
function (Fiorentino et al., 1989; Modlin and Nutman, 1993; Spellberg and Edwards, 2001).  
Table 1.1 represents the most important sources and functions of the cytokines analyzed in 
this study. 
 
1.6.1 Interferons 
Interferons (Ifn) represent the subgroup of cytokines which is predominantly associated 
with antiviral defense (Biron, 1994) and hence is of special interest in this work.  So far, three 
different types of interferon have been defined depending upon their receptor affinity: type I 
consisting of the subgroups Ifn-α and β, type II represented by Ifn-γ and type III represented 
by Ifn-λ. Although type III Ifn form an individual subfamily due to structural and genetic 
characteristics, their way of induction and function highly resemble those of type I Ifn 
(Kotenko et al., 2003; Sheppard et al., 2003). 
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 Cytokine Sources Major effects 
Ifn-γ  Activated NK and T cells 
(major source: Th1 cells), 
enforced secretion by IL-2 
signaling 
Inhibits the proliferation of infected cells and induces an 
“antiviral“ state, promotes cellular immune response and 
proliferation of NK an T cells 
TNF-α/β Activated T cells and other 
leukocytes, induced by Ifn 
and IL-2 signaling 
Induction of apoptosis or cytostasis in none-immune 
cells, induces chemoattractants, enhances proliferation 
of T cells, the spectrum of TNF-α and -β is similar, but 
TNF-α is more potent  
IL-1 Maturating monocytes, 
neutrophils, fibroblasts, 
lymphocytes (low level) 
Stimulation of IL-2 secretion in T helper cells, activation 
of T, NK and also B cells 
IL-2 Activated Th1 cells but also 
other T cells 
Induction of Ifn-γ, drives T cells into cell cycle and 
promotes clonal expansion, induces the secretion of IL-1 
and TNF-α/β 
Th
1 
cy
to
ki
ne
s 
IL-12 Induced peripheral 
lymphocytes, mainly T cells  
Contributes to the proliferation of lymphoblasts during 
clonal expansion, activates NK cells in combination with 
TNF-α, induces IL-2, Ifn-γ and TNF-α in Th1 cells 
    
IL-4 Activated Th2 cells Proliferation and differentiation of activated B cells, 
increases antigen presentation on MHC II, inhibits IL-6 
synthesis 
IL-5 Activated Th2 T cells Stimulation of B cell growth and immunoglobulin 
secretion 
IL-6 All stimulated leukocytes Pleiotropic promotion of inflammatory responses, 
inhibits TNF-α/β production 
Th
2 
cy
to
ki
ne
s 
IL-10 Regulatory T cells and 
activated B cells, also 
monocytes 
Pleiotropic anti-inflammatory cytokine, strong inhibitor 
of Th1 cytokine produciton and also of IL-6 synthesis, 
limits immune responses, promotes B cell growth 
 
 
 
Table 1.1: Th1 and Th2 cytokine sources and functions. The most important source cells and functions are 
listed (Thomson and Lotze, 2003). 
Figure 1.3: Scheme of Th1 and Th2 cytokine function and interaction. 
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Interferon alpha and beta 
In humans, Ifn-α comprises 14 different subtypes, which are mainly secreted by 
leukocytes (Hardy et al., 2004). Ongoing research is trying to elucidate the biological 
characteristics of the various family members and their respective sources. Ifn-α secretion is 
induced by downstream signaling of TLR-3 and RIG-I that both recognize the PAMP of 
double-stranded RNA (Meylan and Tschopp, 2006). Ifn-α exhibits antiviral effects that 
manifest in inhibition of proliferation and the expression of interferon-stimulated response 
factors. As a consequence, activated immune effectors are recruited and triggered to eliminate 
infected cells. Ifn-β is similar to Ifn-α with regards to structure and function but is 
predominantly produced by fibroblasts and epithelial cells (Theofilopoulos et al., 2005).  
 
Interferon gamma 
The major sources of Ifn-γ are activated Th1 cells, cytotoxic T cells and NK cells that 
encounter infections. Ifn-γ inhibits the growth of surrounding cells and increases antigen 
presentation. Therein, it shows the most pronounced effect of all known interferons. Ifn-γ 
represents the prototypic Th1 cytokine and its immune modulating properties promote a 
cellular immune response (Schroder et al., 2004; Schoenborn and Wilson, 2007). In vitro, 
secreted IFN-γ is often used as an indicator for T cell activity (Sitkovsky, 1988). 
 
1.6.2 IL-10  
IL-10 is a very remarkable member of the interleukin familiy. It was first discovered as 
cytokine synthesis inhibitory factor (CSIF) produced by Th2 cells (Fiorentino et al., 1989). 
Later, it was shown that regulatory T cells, B cells and NK cells are also significant sources 
for IL-10 (Groux et al., 1997; Bouaziz et al., 2008; Vivier and Ugolini, 2009). Whereas most 
cytokines display growth-promoting or response-boosting activities, IL-10 in contrast has 
turned out to be a key player in inhibiting inflammation and terminating an immune response 
(Moore et al., 2001). Many studies revealed inhibitory functions of  
IL-10, including the decrease of cytotoxic effector molecules and reduced antigen 
presentation through decreased MHC I and MHC II surface levels (de Waal Malefyt et al., 
1991a; Gazzinelli et al., 1992; Ralph et al., 1992). However, stimulatory effects on the 
proliferation and humoral activity of B cells have also been described (Go et al., 1990; 
Rousset et al., 1992a). They are in line with IL-10 as the canonical Th2 cytokine and its 
strong potential to attenuate cell-mediated immune reactions in favor of a humoral response 
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(Fiorentino et al., 1991). IL-10 deficient mice suffer from chronic inflammatory Bowel 
disease and exaggerated inflammatory responses in general (Kuhn et al., 1993; Berg et al., 
1995). Thus, the major function of IL-10 is obviously the containment and eventual 
termination of immune responses to prevent immunopathology. Therapeutic applications of 
IL-10 in humans suffering from autoimmune or inflammatory conditions were analyzed in 
several clinical studies, but always faced the risk of opportunistic infections due to the 
systemic immune suppressive effects of IL-10 (Opal et al., 1998). 
Taken together, IL-10 is a highly pleiotropic cytokine. The functional outcome of IL-10 
signaling appears to be highly dependent on its own concentration and that of concomitantly 
present cytokines as well as on the type and state of the target cell. 
  
2. Epstein Barr virus 
Epstein Barr virus (EBV) is an enveloped virus with a large double-stranded DNA 
genome (172kb) and an approximate particle size of 200nm. It belongs to the family of herpes 
viruses and the official nomenclature terms it human herpes virus 4 (HHV-4). EBV is one of 
the most widespread human pathogens and more than 90% of the worldwide population is 
infected (Epstein and Achong, 1979). EBV establishes a latent infection in B cells and only a 
minute number of viral proteins are expressed, thus preventing recognition by the IS. 
Sporadic reactivation from this reservoir is sufficient for eventual spread to other hosts and to 
enable life-long persistence of EBV in an infected individual. This strategy and tropism 
qualifies EBV as a classical lymphocryptovirus or γ1-herpes virus (Rickinson and Kieff, 
2007).  
2.1 Infection and tropism 
EBV enters its host via the epithelial cells of the oral mucosa from where it spreads to the 
B-cell compartment. Infection of B cells occurs through binding of the viral envelope 
glycoprotein 350 (gp350) to the cellular complement receptor 2 (CR2, i.e. CD21) and 
additional interaction of viral gp42 with cellular MHC II (Nemerow et al., 1987; Wang and 
Hutt-Fletcher, 1998). This interaction leads to the endocytosis of the particle, which in turn 
triggers the viral mechanism for membrane fusion, mediated by viral gHgL and viral gB, and 
finally releases the particle content including the viral capsid into the cytoplasm. The capsid is 
then transported to the nucleus where it discharges the linear viral genome, which forms a 
circle, replicates to several copies and is finally tethered to peri-chromatic regions of the 
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cellular genome (Kanda et al., 2001; Deutsch et al., 2010). Once established, the viral DNA 
replicates in synchrony with the cellular genome and is maintained as extrachromosomal viral 
plasmid, termed episome. In vitro, infection of B cells generates continuously proliferating 
lymphoblastoid cell lines (LCLs), which provide a reliable surrogate system to study many 
aspects of the interaction between the virus and its target cells.  
EBV is also able to infect epithelial cells. Their infection occurs by the same gp350/CD21 
interaction, however fusion is rather inefficient in vitro – presumably due to the lack of 
MHC II molecules and thus the lack of a gp42 interaction partner (Wang et al., 1998; 
Shannon-Lowe et al., 2009).  
2.2 From infection to latency 
In vivo, EBV preferentially infects naïve and memory B cells, both showing a resting 
phenotype (Joseph et al., 2000). The initial, virally triggered signaling events reactivate the 
cells. Upon infection, an immediate lytic phase is initiated that intriguingly does not give rise 
to progeny virus. This early lytic phase is presumably induced by the spontaneous expression 
of the two viral transcription factors Zta and Rta, encoded by the immediate-early genes 
BZLF1 and BRLF1, respectively. Together they drive infected cells from G0/G1 to S phase 
(Guo et al., 2010; Kalla et al., 2010). These viral transactivators also induce numerous early 
lytic transcripts that contribute to the transient activation of the target cell. The early lytic 
phase eventually subsides and infected cells enter latency. Based on this strategy, the virus 
persists in its host with rare episodes of reactivation to spread to other cells and to ensure an 
infection of the host organism for life. In vivo, an efficient immune control counteracts the 
growth transforming potential of EBV. EBV associated diseases are usually linked to immune 
deficiency or secondary infections that trigger lymphomagenesis (see also chapter 4.2). In 
vitro, growth-limiting effectors are absent and infection of B cells with EBV leads to growth 
transformation and continuously proliferating lymphoblastoid cell lines.  
Latently infected cells differ with respect to the number of expressed viral genes, which 
led to their classification in four different subtypes (see table 1.2). 
 
Latency expressed EBV genes associated cells 
 EBERs EBNA-1 LMP1 LMP2A EBNA-2,-3,-LP  / malignancy 
0 + n.d. - - - peripheral B cells* 
I + + - - - BL, PEL 
II + + + + - HL, NPC 
III + + + + + IM, PTLD, LCL 
 
 
Table 1.2: Latency programs are defined by the gene expression pattern and associated with distinct 
cellular phenotypes and malignancies. BL, Burkitt lymphoma; PEL, primary effusion lymphoma; HL, 
Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; IM, infectious mononucleosis; PTLD, post-transplant 
lymphoproliferative disorder; n.d., not determined; *: resting phenotype; (see also Kuppers, 2003) 
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2.3 Certain herpes viruses transfer RNA to their target cells. 
The discovery of packaged transcripts in virions of human cytomegalovirus (hCMV) 
added a new aspect to the field of herpes virus biology (Bresnahan and Shenk, 2000). 
Concomitant to the fusion of virus particles with the target cell, the RNA molecules are 
transferred and translated immediately. Initial synthesis of viral protein is hence independent 
of de novo transcription from the viral DNA genome and presumably contributes to the 
success of hCMV infection. 
Similar reports exist for Herpes simplex virus I (HSVI). Here, a tegument protein binds 
viral transcripts and thus mediates the incorporation of RNA into HSVI virions and their 
transfer to recipient cells (Sciortino et al., 2001; Sciortino et al., 2002). This finding suggests 
an intentional mechanism for directed RNA transfer by HSVI virions to fulfill a role in the 
immediate-early steps of viral infection.  
Virions of Kaposi sarcoma herpes virus (KSHV) have also been identified to contain RNA 
(Bechtel et al., 2005). This finding is of special interest as KSHV and EBV are highly related 
in terms of genomic structure and viral mechanisms. The establishment of a KSHV infection 
is also characterized by an initial lytic phase, for instance. Intriguingly, all of the transcripts 
that are contained in KSHV virions are also found during the initial lytic phase. Their transfer 
might thus represent the necessary trigger to engage the lytic phase, however functional 
correlations are still missing. With the given homology to KSHV and the similar 
transcriptional program during the first few days after infection, EBV might follow a similar 
strategy.  
The findings described above have reshaped the dogma of the strict dependency on DNA 
genomes in herpes virus biology (Roizman, 2000). RNAs could give the virus a head start by 
counteracting cellular defense mechanisms and shaping a supportive intracellular 
environment for a successful infection. Thus, packaged EBV RNAs might event promote the 
establishment of latency.  
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3. The immune evasion strategies of EBV 
The epidemiological success of EBV is owed in large extent to its potential to escape from 
immune responses of the host. In addition to the strategy of hiding in latency, EBV has 
acquired sophisticated active immune evasion strategies that are of major importance during 
the lytic phase. These strategies range from global reduction of transcription by a host shutoff 
factor to specific interference with antigen presentation (Rowe et al., 2007; Ressing et al., 
2008; Long et al., 2011). Interference with the inflammatory response of immune cells and 
the decrease of antigen presentation provide the virus with additional potent features to 
ascertain its persistence within the host. In this context, two immune evasins of EBV are of 
special interest: BNLF2a, encoding a unique inhibitor of epitope loading on MHC I molecules 
and BCRF1, encoding the viral homologue of human IL-10.  
3.1 BNLF2a: a unique factor that interferes with MHC I-loading 
Pudney and colleagues reported a steady decrease of antigen-presentation in EBV-infected 
cells with the onset of the lytic cycle that is not observed in other herpes viruses to this extent 
(Pudney et al., 2005). This observation drove the idea to screen for unique immune evasins of 
EBV that led to the identification of BNLF2a to act in an immune evasive manner (Hislop et 
al., 2007). Functional analyses revealed that BNLF2a blocks the binding of both ATP and 
peptides to TAP1. This impairs the function of TAP to translocate peptides to the ER and 
thereby diminishes the load of antigen to MHC class I molecules (Horst et al., 2009). Ectopic 
expression of high levels of BNLF2a even leads to decreased MHC I surface levels. In the 
context of EBV infection, BNLF2a supports the immune escape of established LCLs that 
undergo the lytic phase (Croft et al., 2009).  
No information about the impact of BNLF2a on the success of the initial infection is 
available. During these early days of virus infection, cells support the expression of lytic 
genes (Kalla et al., 2010), which leads to high antigen loads. This requires an efficient 
strategy to counteract the risk of recognition in an immune host, with the presumably 
important participation of BNLF2a. 
3.2 BCRF1, the viral homologue of cellular IL-10 
Considering the functions ascribed to IL-10, it can be rated as immune dampening, but 
also as a pro-viral factor. Indeed, several viruses have included a variant of the IL-10 gene in 
their genomes. So far, orthologues have been found in Epstein Barr virus (EBV), equine 
herpes virus type 2 (EHV2), poxvirus Orf, and human cytomegalovirus (hCMV) (Hsu et al., 
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1990; Moore et al., 1990; Vieira et al., 1991; Rode et al., 1993; Fleming et al., 1997; Kotenko 
et al., 2000). The EBV variant of IL-10 is encoded in the BCRF1 open reading frame and 
shows 84% homology to human IL-10 on the protein level, with most of the differences 
located in the N-terminal 20 amino acids. Additionally, a single amino acid exchange at 
position 87 was identified and crystal structures revealed this amino acid to be decisive for 
folding and dimerization, which is essential for receptor binding. Compared to human IL-10, 
this modification results in a drastically reduced affinity of viral IL-10 (vIL-10) to the IL-10 
receptor (Liu et al., 1997; Ding et al., 2000; Yoon et al., 2005). 
Assumingly, the viral IL-10 derivative still supports proliferation of B cells and decreases 
antigen presentation, but does not activate T cells (MacNeil et al., 1990; de Waal Malefyt et 
al., 1991b; Rousset et al., 1992b; Suzuki et al., 1995). This evolutionary adaption renders vIL-
10 even more favorable for the virus’ purposes and its value is reflected in its high 
conservation (Kanai et al., 2007). Moreover, previous work points to a specific contribution 
of vIL-10 to EBV’s immune evasion strategy (Zeidler et al., 1997). 
 
 
Figure 1.4: vIL-10 and h-IL-10 show strong amino acid homology, but bind differently to the IL-
10R1. A. Amino acid sequence alignment, differences are shown in bold letters, helix forming stretches are 
indicated. B. Ribbon diagram of a vIL-10 monomer, helices and changed amino acids are indicated 
(compare to A), box: the change of isoleucin 87 to alanin is responsible for different angles in C.  
C. Interdomain angles in vIL-10 (left) and hIL-10 (right) dimers and their orientation upon binding to the 
soluble IL-10 receptor 1 chain. Adapted from Yoon et al., 2005. 
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4. Immune responses to EBV: immune control and fatal failure 
4.1 Containment of EBV infection in immunocompetent hosts 
Virus-infected cells are usually recognized and eliminated by CD8+ T cells and NK cells 
that represent the effectors of the anti-viral compartment of the immune system. CD4+ T cells 
contribute to the elimination by provision of secondary signals that are essential for CD8+ 
cytotoxicity. EBV infection is usually asymptomatic during early childhood, but primary 
infection in adolescents or adults often manifests as infectious mononucleosis (IM) caused by 
antiviral immune responses. During acute IM, high numbers of T and NK cells as well as 
infected proliferating B cells are present (Young and Rickinson, 2004). It is their dramatic 
increase in number that causes the characteristic strong swelling of oropharyngeal lymph 
nodes. Analyses of the TCR repertoire revealed an oligoclonal character of the T cell 
population due to the expansion of EBV-specific T cells upon encounter of virus-infected 
cells (Callan et al., 1996).  
The exact contribution of NK cells to EBV control is largely unknown. Tonsillar NK cells 
can be primed by co-resident dendritic cells in vitro to produce Ifn-γ in amounts sufficient to 
inhibit B cell proliferation (Strowig et al., 2008) and kill EBV infected B cells in vitro 
(Wilson and Morgan, 2002). Moreover, EBV-encoded microRNA miR-BART2-5’ has been 
shown to reduce the expression of MICB, an NK-activating ligand (Nachmani et al., 2009). 
Of note, T and NK cell-mediated immunity efficiently limits virus spread, mainly by 
eradication of infected cells that show a transformed phenotype (latency III) or are in the lytic 
phase. Cells in latency 0 are spared in this process and represent the virus reservoir and their 
eventual reactivation ensures the life-long persistence of the infection in the host.  
4.2 EBV causes proliferative disorders and cancer 
EBV has also been aetiologically linked to several malignant diseases, including Burkitt 
lymphoma (BL), Hodgkin Lymphoma (HL) and post-transplant lymphoproliferative disorder 
(PTLD). Whereas BL and HL are associated with EBV infection but arise due to secondary 
events (such as c-MYC translocation in BL), PTLD exclusively occurs in 
immunocompromised individuals (Gottschalk et al., 2005b). More than 90% of all PTLDs 
occur due to missing immune surveillance of EBV infected B cells (Snow and Martinez, 
2007). In contrast to the prevalent state of latency 0 in B cells of healthy individuals, the 
immunological imbalance in PTLD permits for the continuous growth of B cells with a 
latency III expression pattern, which expand in these individuals and thus display a similar 
phenotype as LCLs in vitro. Three different conditions predominantly foster the development 
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of PTLDs: (i) EBV-positive solid organ recipients when their own EBV infected B cells 
reactivate after transplantation, (ii) EBV-negative recipients are transplanted with an organ 
from an EBV-positive donor containing EBV-infected B cells, and (iii) bone marrow 
transplants from EBV-positive donors with a high percentage of EBV infected B cells that 
cannot be controlled under immunosupression. Standard treatment of acute PTLD includes 
the reduction of immunosupression and the use of anti-CD20 antibodies that target B cells 
(Meijer and Cornelissen, 2008). Clinical trials with the adoptive transfer of autologous or 
HLA-matched EBV-specific T cell clones show a certain success of treatment in patients, but 
problems with preparation of cells in sufficient amounts in the given time are difficult to 
overcome (Papadopoulos et al., 1994; Rooney et al., 1998; Gottschalk et al., 2005a; 
Moosmann et al., 2010). Vaccination would provide the most adequate solution to reduce the 
risk of EBV-associated diseases, as immune hosts would eliminate infected cells before the 
virus could establish a latent infection. Promising results were obtained in our group with an 
attenuated vaccine of replication-incompetent EBV-like particles that induced immunity in 
humanized mice (Ruiss et al., 2011).  
5. Experimental strategies to unravel processes of EBV infection 
5.1 EBV-specific T cell clones as experimental tool 
EBV-specific T cell clones can be raised from PBMCs of EBV-positive donors by specific 
stimulation over several weeks (Bollard et al., 2008; Moosmann et al., 2010). Besides their 
intended use in therapy, they are also of great use in basic EBV research. T cells are highly 
sensitive tools to detect EBV infection of B cells and allow for the characterization of epitope 
presentation patterns during the different phases of infection. To this end, infected B cells of 
matching HLA are incubated with clonal CD8+ T cells of known epitope specificity for 
several hours. Shedding of Ifn-γ correlates with CD8+ T cell activation and indicates antigen 
recognition. Ifn-γ levels in the supernatant can be assessed by ELISA and allow to deduce 
whether B cells presented the cognate T cell epitope and thus expressed the viral protein. This 
approach requires only a few cells and is far more sensitive than protein detection by Western 
immunoblotting, for instance. The combination of this immunological assay with genetically 
modified recombinant EBV can furthermore provide information on the physiological impact 
of defined viral factors with regards to viral immune escape abilities, for example (see next 
chapter). 
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5.2 Genetically modified recombinant EBVs and their potential to unravel viral 
strategies 
The functions of BNLF2a and vIL-10 were identified in studies that expressed the proteins 
ectopically or in assays that used high doses of exogenous vIL-10 (Zeidler et al., 1997; Hislop 
et al., 2007). These results were sufficient to support the conclusions but did not measure the 
precise contribution of either BNLF2a or vIL-10 in the context of a virally infected cell.  
Loss-of-function situations are usually more specific and thus appropriate to unravel the 
physiological impact of proteins. This strategy has become available for EBV since  
Hammerschmidt and colleagues generated a recombinant EBV genome and established an 
inducible virus producer cell line (Delecluse et al., 1998). In brief, the complete EBV genome 
of the laboratory strain B95.8 was engineered onto an F-factor plasmid to yield a so-called 
bacterial artificial chromosome (BAC). A hygromycin resistance gene and an eGFP 
expression cassette were included, both constitutively expressed from heterologous 
promoters. The successful transduction of the BAC could thus be visualized by GFP 
fluorescence and stable clones could be selected. Out of several cell lines tested, HEK293 
cells were found to be permissive for virus production when transfected with an expression 
plasmid encoding the viral transcription factor BZLF1, both sufficient and essential for the 
induction of EBV’s lytic cycle. This seminal work enabled detailed studies on distinct 
features of single genes of EBV. The technology also allowed for the generation of the first 
EBV packaging cell line. The deletion of the terminal repeats (TR) that serve as genome-
packaging signals during virus egress provided a helper genome that cannot be encapsidated. 
Producer cells carrying these genomes exclusively give rise to genome-free virus like 
particles (TR– VLP) upon induction of the viral lytic phase (Delecluse et al., 1999). These 
particles served as vehicles for EBV-based gene vectors (Hettich et al., 2006), and have 
demonstrated their potential as vaccine candidates recently (Ruiss et al., 2011). 
A new strategy for BAC modifications through induced recombination sustainably 
facilitated the generation of new EBV variants (Warming et al., 2005). The approach enables 
straightforward gene replacement as well as traceless mutagenesis of single nucleotides in the 
context of the BAC of 180kb in size. I made use of this strategy, which is described in detail 
in the ‘Material and Methods’ section. 
The option to apply reverse genetics to this recombinant EBV genome has already 
contributed many details to the understanding of very different viral mechanisms. The 
facilitated and efficient method of BAC engineering will give rise to many other studies in the 
near future.  
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6. Aim of this study 
Given an infection rate of more than 90% of the worldwide population, Epstein Barr virus 
can be considered an extremely successful virus. This success is largely owed to EBV’s 
ability to persist in latently infected cells that are not recognized by the host’s immune 
system. Primary infection, however, is characterized by an initial lytic phase that promotes the 
successful infection of quiescent B cells and the establishment of latency (Kalla et al., 2010). 
This phase is characterized by the transcription of many different viral genes and concomitant 
antigen presentation, resulting in an increased probability for infected cells to be eliminated 
by immune effectors. Several sophisticated strategies to evade the immune response of the 
host have been associated with distinct gene functions of EBV (Ressing et al., 2008), but 
knowledge on their impact during the early lytic phase is still missing.  
In the early lytic phase of EBV infection the viral transactivators BZLF1 and BRLF1 are 
expressed which presumably induce the subsequent expression of additional viral genes. The 
initial trigger for the expression of both BZLF1 and BRLF1 is enigmatic and needs to be 
determined. 
This study intends to expand the understanding of events during the first few days of 
infection and their contribution to the successful establishment of the virus in infected B cells. 
To this end, this work is divided into two parts: 
 
1. Analysis of active immune evasion by EBV during the first days of infection with 
focus on BCRF1 and BNLF2a 
Previous work done by our group and others indicated that BCRF1, encoding the viral IL-
10 homologue (vIL-10), and BNLF2a, an immune evasin unique to EBV, account for a 
reduced antigen presentation by interference with MHC I loading (Zeidler et al., 1997; 
Hislop et al., 2007). A general decrease of MHC I surface levels on EBV infected cells 
has been described and overexpression experiments have suggested that both factors 
contribute to this effect. In this work, I addressed the physiological roles of BCRF1 and 
BNLF2a expression by generating recombinant EBV deletion mutants. I assessed the 
responses of EBV-specific CD8+ T cell clones and NK/NKT cells to B cells infected 
with these mutants to investigate the impact of vIL-10 and BNLF2a on specific cellular 
immunity. It is not exactly known to which extent vIL-10 reflects the capacities of 
cellular IL-10 to modulate the expression of other cytokines. I investigated the influence 
of BCRF1/vIL-10 deficiency on cytokine responses of PBMCs to infected B cells and 
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also analyzed BNLF2a effects in this regard. Finally, the importance of BCRF1 and 
BNLF2a expression for the success of virus infection in presence of immune effectors 
was evaluated in regression assays. 
 
2. Investigation on RNA transfer by EBV virions and their role as a trigger of initial 
events in EBV infection  
In the last few years, it became evident that several members of the Herpes virus family 
incorporate RNA into their virions in addition to their DNA genomes (Bresnahan and 
Shenk, 2000; Sciortino et al., 2001; Bechtel et al., 2005). During infection, RNAs are 
transferred to target cells and immediately translated. The contribution of these RNAs for 
the success of infection is still unclear. So far, RNA transfer has not been reported for 
EBV but could present a plausible explanation for the lytic program following infection. I 
intended to assess the presence of RNA in EBV particles and their putative transfer 
during infection. I evaluated the function of selected transcripts during early infection 
with the help of recombinant EBV mutants. The importance of immediate transcript 
presence with regards to the success of an infection was analyzed by the impact of virion 
RNA on viral transformation rates.  
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 RESULTS I 
- The contribution of BCRF1 and BNLF2a to the immune evasion of EBV - 
 
1. Generation of BCRF1- and BNLF2a-deficient EBV 
The contribution of BCRF1 and BNLF2a to the immune evasion of EBV was analyzed in 
a straightforward approach by generating viruses that are deficient for one or both of these 
two genes. The seminal work of Hammerschmidt and colleagues made reverse genetics 
available for EBV. They succeeded in cloning a recombinant EBV genome (p2089) in E.coli 
as a bacterial artificial chromosome (BAC), termed ‘maxi EBV’, and established the means to 
reconstitute infectious virus in HEK293 producer cells (Delecluse et al., 1998). Viruses based 
on the cloned EBV genome p2089 carry the genome of the B95.8 EBV strain together with 
the phenotypic markers of hygromycin resistance and GFP fluorescence. The availability of 
the viral genome as a BAC enables modifications by standard molecular cloning procedures.  
1.1 Selection of appropriate knock-out strategies 
To generate BCRF1-deficient EBV, I replaced the BCRF1 open reading frame (ORF) in 
the recombinant wildtype EBV genome (p2089) with a prokaryotic kanamycin resistance 
expression cassette. This strategy seemed appropriate, because BCRF1 does not overlap with 
other genes or cis-acting elements, which renders off-target effects unlikely (figure 2.1).  
Figure 2.1: 
Insertional mutagenesis 
or single nucleotide ex-
change was the knock out 
strategy of choice, de-
pending on the genomic 
situation. The BCRF1 
gene in the recombinant 
wildtype EBV-BAC 
(p2089) was replaced by a 
prokaryotic expression 
cassette for kanamycin 
resistance by homologous 
recombination. By traceless 
mutagenesis of 5 nucleo-
tides, the Methionine1-
codon of BNLF2a was 
replaced by a STOP-Codon 
and an additional SpeI site 
was introduced (see Mate-
rials and Methods for de-
tails). Numbers indicate the 
genetic position in kbp in 
the recombinant EBV ge-
nome (p2089). 
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The more complex genomic situation of BNLF2a necessitated a different cloning strategy, 
as the gene shares the transcript with BNLF2b and is situated in the first intron of LMP2A. 
Moreover, the area contains the 3’ untranslated region of BNLF1 encoding the latent 
membrane protein 1 (LMP1). Hence, the first codon of BNLF2a was mutated to a STOP-
codon in combination with the insertion of an additional SpeI site for diagnostic purposes. 
This minimal invasive exchange of four nucleotides only reduced the risk of unintended and 
adverse interference with expression or regulation of neighboring genes (Figure 1B). 
Three EBV mutants were constructed. Two single mutants were null for BCRF1 and 
BNLF2a and one double mutant combined both disabled alleles. Table 2.1 lists the used maxi 
EBVs and their genotypes. 
 
 
Explicit name in 
this study 
Genotype clone # 
(AGV 
database) 
recombinant 
wildtype 
(rec.wt.) 
B95.8 genome (Baer et al., 1984) on an F-factor BAC, contains CMV 
promoter-driven expression cassettes for hygromycin resistance and 
GFP (Delecluse et al., 1998) 
p2089 
ΔBCRF1 derived from p2089, a prokaryotic kanamycin resistance expression 
cassette (1.5kb) replaces the BCRF1 ORF (nt 9670-10200 in p2089)  
p3912 
ΔBNLF2a derived from p2089, mutation of 5’-AGATGG-3’ to 
 5’-ACTAGT-3’ (negative strand, nt 177322-177317 in p2089)  
results in a functional BNLF2a knock-out 
p4030 
double knock-
out (double k.o.) 
derived from p4030, combines both ΔBCRF1 and ΔBNLF2a  p4031 
 
1.2 Confirmation of genetic mutations and virus titrations 
I established virus producers from stably transfected HEK293 cells by selecting for 
hygromycin resistant single cell clones and testing for virus production-permissive cells. The 
genotypes were confirmed by Southern blot hybridization (figure 2.2A) and the titers of 
infectious virus in the supernatants were calculated from the percentage of GFP-positive Raji 
cells after infection, denoted as “green Raji units” (GRU). In subsequent steps of “back-
titrations”, I repeatedly performed these infection experiments to precisely adjust the 
calculated titers of the different recombinant viruses (figure 2.2B, see also Material and 
Methods). Infected B cells were routinely genotyped by PCR to confirm infection with the 
correct virus mutant (figure 2C), including a virus strain-specific multiplex PCR to exclude 
contamination with the B95.8 laboratory strain or EBV field strain-infected B cells from 
EBV-positive blood donors. 
Table 2.1: Genotypes of used recombinant EBVs. 
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Figure 2.2: Genotypes of EBV mutants were confirmed and 
virus supernatants were titrated for equal infection rates. 
A. Southern Blot was performed with digested genomic DNA 
of virus producer clones using probes complemetary to 
BNLF2b and oriP, respectively. Genomic DNA of parental 293 
cells was included as negative control (right lane) B. After 
titration of virus-containing supernatants on Raji cells and 
calculation of contained green Raji units (GRU), equal titers of 
infectious virus were confirmed on Raji cells and FACS 
analysis of GFP+ cells three days after infection. C. LCLs that 
had been generated by infecting primary B cells with the 
recombinant viruses were routinely genotyped by PCR for 
BCRF1 and BNLF2a. PCR analyses also certified the identity 
of the EBV backbone to exclude infection with field or 
laboratory virus such as MABA or B95.8, respectively (bottom 
panel). 
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2. Phenotypes of BCRF1- and BNLF2a-mutant EBV 
2.1 Expression analyses of BCRF1 and BNLF2a and their influence on TAP levels 
BCRF1 expression becomes detectable as early as a few hours after infection of B cells 
(Miyazaki et al., 1993). This finding has been interpreted in a way that BCRF1 acts prior to 
the cellular expression of human IL-10, which is induced later on in EBV infected B cells. 
Strong expression of BNLF2a was observed in lytic cells and was described to be directly 
driven by BZLF1 (Yuan et al., 2006; Bergbauer et al., 2010). An initial lytic phase was 
observed during the first few days after infection (Kalla et al., 2010), which might also 
include expression of BNLF2a to prevent the early recognition of virus infected cells.  
It was of principal interest to evaluate the kinetics of BCRF1 and BNLF2a expression, 
specifically with regards to the timing of immunological assays. Additionally, I intended to 
verify the antagonistic effect of vIL-10 (encoded by BCRF1) on TAP2 transcript levels that 
had been causally linked to decreased MHC-I levels (Zeidler et al., 1997). 
To this end, I analyzed the transcript levels of BNLF2a, BCRF1, hIL-10, TAP1 and TAP2 
in primary B cells at different time points post infection. Primary B cells were infected with a 
multiplicity of infection (MoI) of 0.1 GRU per B cell, uninfected cells were included as 
controls. I observed BNLF2a expression already two hours post infection (hpi). The transcript 
Figure 2.3: Following infection, BNLF2a and BCRF1 transcripts are present early and expression is 
maintained throughout infection. Quantitative PCR (qPCR) analyses were perfomed on cDNA from 
adenoid B cells that had been infected with recombinant wildtype EBV (2089) at an MoI of 0.1 GRU/cell. 
Uninfected adenoid B cells were included as negative control. Transcript levels were related to expression 
levels of glucuronidase beta (GUSB) that served as housekeeping gene. 
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level stayed stable until an induction of expression occurred at 8 hpi and reached a level that 
was approximately maintained during the period of analysis (30 days) (figure 2.3, squares). 
The two-tiered characteristics in combination with the immediate presence of stable levels as 
early as 2 hpi came as a surprise, and are the topic of investigation in the section “Results II”. 
BCRF1 expression was not detectable until around 6hpi (figure 2.3, filled triangles), 
confirming the semi-quantitative data on BCRF1 expression (Miyazaki et al., 1993). However 
contrasting that publication, the present analysis also shows constantly high levels of cellular 
IL-10 expression in uninfected B cells prepared from adenoids (Figure 2.3, empty triangles). 
This observation was confirmed with EBV-infected peripheral B cells (not shown).  
BCRF1 expression did not affect TAP2 transcript levels and thus did not contribute to a 
detectable extent to the postulated antagonistic effects of IL-10 on TAP2 transcripts (Zeidler 
et al., 1997). But my analysis could confirm the general inverse correlation of TAP2 and IL-
10 transcript levels, as raising hIL-10 expression starting 3 days post infection (dpi) was 
accompanied by a decrease of TAP2 expression (figure 2.3, triangles and rhombuses), but 
TAP1 expression remained unaffected (circles). In general, the observed physiological impact 
of both forms of IL-10 did not reflect observations from a study with exogenously 
administered IL-10 (Zeidler et al., 1997). 
 
2.2 MHC surface levels of cells infected with BCRF1- and BNLF2a-deficient virus 
mutants 
Both vIL-10 and BNLF2a reduce MHC I surface levels (Zeidler et al., 1997; Hislop et al., 
2007). B cells show high surface levels of MHC I and, due to their function as professional 
antigen presenting cells (APC), also carry MHC II on their surface.  
I analyzed B cells that had been infected with recombinant wildtype, ΔBCRF1, ΔBNLF2a, 
or double k.o. EBV for MHC surface levels by FACS analysis one, three, six and nine dpi. 
Primary B cells showed a dramatic increase of MHC I levels at day 3 post infection.  Data in 
figure 2.4A indicate that MHC I surface levels are not affected by physiological expression of 
BCRF1 and BNLF2a or that differences are too weak to be resolved by FACS analysis. 
The analysis of MHC II levels revealed slightly increased surface levels in cells infected 
with BCRF1-deficient EBVs (figure 2.4B). Despite the general low BCRF1 transcript 
abundance (figure 2.3), expression was obviously sufficient to influence MHC II levels.  
IL-10 has already been described to decrease MHC-II levels on macrophages and 
dendritic cells (de Waal Malefyt et al., 1991b; Steinbrink et al., 1997). Whether the detected 
minute differences are sufficient to alter CD4+ T cell activation remains to be clarified.  
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Figure 2.4: MHC surface levels on B cells are not significantly altered upon infection with mutant 
EBV. Adenoid B cells were infected with different virus constructs and surface levels of MHC I (A) and 
MHC II (B) were assessed by FACS (independent experiments). Diagrams show mean fluorescence 
intensities (MFI) of MHC signals at the indicated day after infection. Examples of FACS data at 3dpi are 
shown on the right. 
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2.3 EBV-specific CD8+ T cell clones recognize BNLF2a-deficient EBV-infected cells 
significantly better 
EBV specific CD8+ T cell clones constitute a valuable tool to assess immune evasive 
capacities of EBV in infected cells. T cell clones are generated by selective enrichment of 
EBV-specific T cells from PBMCs of EBV-positive donors followed by the subcloning of 
single T cells. Clonal cells share the same TCR and thus are specific for a single EBV epitope 
and the associated MHC I allele. Clonality is confirmed in FACS analyses by the use of 
fluorescent tags that mimic a specific EBV epitope/MHC complex (tetra- and pentameres) 
that bind to the matching TCR. A homogenously positive staining indicates unique TCR 
specificity as hallmark of a clonal T cell population. Upon recognition of a matching epitope, 
T cells are activated and secrete Ifn-γ, which is quantified in ELISA assays and serves as a 
measure for T cell activity. 
I intended to gain insight into the kinetics of epitope presentation as well as differences 
between cells infected with recombinant wildtype and mutant EBVs. Therefore, I performed 
time course experiments on T cell recognition of B cells that had been infected with 
recombinant wildtype, ΔBCRF1, ΔBNLF2a or double k.o. viruses. Starting on day one after 
infection, T cells of defined specificity were co-incubated overnight with HLA-matched, 
infected B cells in a constant effector/target ratio of 1:2 . The supernatants were subsequently 
assessed for Ifn-γ levels. 
A first analysis was performed with T cells specific for the “RAK” epitope of BZLF1 
(Bogedain et al., 1995). HLA-matched B cells that were infected with the BNLF2a-deficient 
EBV variants led to a significantly stronger Ifn-γ secretion of the RAK-specific CD8+ T cell 
clone (figure 2.5A). Furthermore, these T cells recognized ΔBNLF2a-infected B cells already 
1dpi, which was not the case with infected cells that could express BNLF2a (figure 2.5B). 
The difference in RAK recognition peaked at day 4 (figure 2.5C), was detectable during the 
first ten days of infection, but finally disappeared 30dpi with the establishment of latency. 
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Figure 2.6: BNLF2a reduces the presentation of 
TAP-dependent epitopes during the early phase of 
infection. 
Ifn-γ levels after overnight co-culture of specific T cells 
and HLA matched infected B cells were assessed by 
ELISA as indicated. The CD8+ T cell clones were 
specific for (A) the ‘QAK’ epitope of EBNA3a, (B) the 
TAP-dependent epitope ‘IED’ of LMP2 and (C) the 
TAP-independent epitope ‘CLG’ of LMP2. Values were 
normalized as described in figure 2.5. 
Figure 2.5: Lack of BNLF2a expression leads to earlier and stronger Ifn-γ  
signals of a T cell clone specific for EBV’s BZLF1 protein. 
A. Constant ratios of T cells specific for the ‘RAK’ epitope of BZLF1 protein 
and HLA-matched B cells infected with the different EBV mutants were 
incubated overnight at the indicated day post infection. Ifn-γ concentrations in the 
culture supernatant were assessed by ELISA. Values were normalized to the 
recognition of a wildtype EBV infected, established LCL to correct for variable 
activities of the T cell clone on the respective day. Data from day 1 and day 4 are 
plotted as a bar chart in B an C, respectively. Error bars indicate the standard 
deviation of three biological replicates, significance of differences was calculated 
by two way Anova analysis, ** p<0.01 *** p<0.001.  
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I obtained comparable results with T cell clones that recognized the epitopes “QAK” 
(Burrows et al., 1994) and “IED” (Burrows et al., 1994; Lee et al., 1996) native to the EBV-
proteins EBNA3a and LMP2, respectively (figure 2.6A and B). These epitopes were 
recognized later than the “RAK” epitope, indicating different epitope-specific presentation 
kinetics in this early phase of infection that were also observed in another study (Iskra et al., 
in preparation). In contrast to all other epitopes tested, the T cell response to the CLG epitope 
of LMP2 protein (Lee et al., 1993) proved to be independent of BNLF2a effects (figure 2.6C). 
This epitope is known to be loaded TAP-independently onto MHC I molecules, because its 
high hydrophobicity enables passive diffusion through the ER membrane (Lautscham et al., 
2001). As BNLF2a was found to reduce antigen presentation through impairment of TAP 
function (Hislop et al., 2007; Horst et al., 2009), the postulated mechanism was confirmed by 
these results. 
I could find that physiologic expression of BNLF2a was sufficient to inhibit epitope 
loading on MHC I although MHC I surface levels on infected B cells were not altered (figure 
2.4A). Cells that were infected with BNLF2a-negative virus experienced a stronger and earlier 
recognition through specific CD8+ T cells. These findings were in line with previous reports 
that described strong inhibitory effects of BNLF2a on TAP-dependent epitope loading to 
MHC class I (Hislop et al., 2007; Croft et al., 2009; Horst et al., 2009). My results extend the 
importance of BNLF2a to the early lytic phase of EBV, as effects were observed already 
during the early days of infection. 
Viral IL-10 did not influence the outcome of these targeted T cell recognition 
experiments: ΔBCRF1 virus-infected cells were identical to recombinant wildtype virus 
whereas the double k.o. virus simply reflected the phenotype of ΔBNLF2a virus (figures 2.5 
and 2.6). 
 
2.4 BCRF1 affects the peripheral cytokine response 
The T cell assays described above did not reveal an immunological phenotype of vIL-10. 
Nevertheless, its conservation during evolution (Kanai et al., 2007) and the strong immune 
modulatory capacity of its cellular homologue both suggest a beneficial role of vIL-10 in 
EBV infection. 
Human IL-10 plays an important role in the orchestration of cytokine secretion and affects 
a broad range of immune effector cells (Moore et al., 2001). Because Th1/Th2 cytokines are 
to some extent indicative for the systemic immune response, I compared their levels in the 
supernatant of PBMC cultures infected with the different virus mutants. I prepared PBMCs of 
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an EBV positive donor and infected them at a MoI of 0.1 GRU/B cell. Cells were kept in 
dense cultures (5x106 cells/ml) and aliquots of the supernatants were sampled every three 
days for multiplex ELISA analysis.  
Elevated levels of the Th1 cytokines Ifn-γ, IL-2 and TNF-β were observed in both 
ΔBCRF1 and double k.o. infected cultures and levels of the Th2 cytokine IL-10 were also 
found to be increased in these samples. These differences were detectable starting from day 3 
after infection and peaked at day 9 (figure 2.7). Similar results were obtained with different 
donors in independent experiments. My findings indicate that BCRF1 expression early after 
infection influences the peripheral cytokine release. CD4+ T cells usually constitute more 
than 50% to PBMCs and are the major source of Th1 and Th2 cytokines. Hence, a direct 
effect of BCRF1 expression and vIL-10 secretion on the cytokine response of CD4+ cells 
seemed likely. 
Figure 2.7: ΔΒCRF1 infected cultures of PBMCs show elevated levels of cytokines that regulate 
inflammation.  
PBMCs were infected with different viruses (MoI = 0.1 GRU/ B cell) and kept in dense culture 
(5x106cells/ml). On day 9 post infection, supernatants were analyzed by multiplex-ELISA for Th1/Th2 
cytokines. Error bars indicate the coefficient of variance of the analyte. Statistical significance of difference 
to cytokine level in recombinant wildtype samples was calculated by a two-way Anova using the Bonferroni-
Post-Test, * p<0.05, ** p<0.01. Percentage of cytokine levels in relation to those in wildtype infected 
PBMCs are plotted in the bar chart. Results represent one out of five independent experiments (5 different 
donors) with comparable results. 
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The loads of the cytokines Ifn-γ, IL-2 and TNF-β in double k.o.-infected PBMCs were 
consistently higher than in cultures infected with ΔBCRF1 EBV. Presumably, the stronger 
activation of EBV specific CD8+ T cells in absence of BNLF2a accounted for this synergistic 
effect. High hIL-10 concentrations in those cultures that had been infected with ΔBCRF1 
EBV suggested a secondary induction of hIL-10 expression as a dampening response to the 
elevated immune stimulatory signals (Ifn-γ, IL-2, TNFβ). As IL-10 antagonizes IL-6 
expression, the slightly lower levels of IL-6 might have resulted from high hIL-10 
concentrations.  
  
2.5 BCRF1 impairs NK cell-mediated killing of EBV infected cells  
In vivo, the frequency of EBV-specific CD8+ T cells is usually low and reactivation and 
clonal expansion takes several days. This delay of the adaptive response to viral infections 
causes a gap in defense, which has to be contained by so-called “first line effectors” of the 
innate IS (Janeway, 2005). With regards to viral infections, NK and NKT cells represent the 
most important innate effectors and were shown to be efficient in the killing of EBV-infected 
cells (Blazar et al., 1980; Pappworth et al., 2007). The early expression of BCRF1 and 
BNLF2a (figure 2.3) suggested that their gene products influence first line effectors as well. 
Therefore, I decided to investigate the impact of BNLF2a and BCRF1 expression on NK cell-
mediated killing of B cells infected with the different EBV mutants.  
For this purpose, B cells were isolated from peripheral blood and infected with the four 
different viruses. After three days, autologous CD56+ cells (i.e. NK and NKT cells, about 10-
20% of PBMCs) were added and specific lysis of B cells was assessed after 3 hours of co-
incubation (for details see “killing assay”, chapter 2.4.5 in section “Materials and Methods”). 
B cells infected with ΔBCRF1 virus were lysed preferentially. In contrast, only a faint 
reduction of lysis was observed for B cells infected with the ΔBNLF2a virus. B cells infected 
with the double-k.o. virus were lysed to an intermediate level which could be interpreted as 
the net sum of both effects (figure 2.8, mid panel).  
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2.6 CD4+ T cells stimulate NK cell-mediated killing  
CD4+ T cells represent an important source for many cytokines and their presence could 
provide a supporting microenvironment for NK/NKT cells. I was interested to see if 
autologous CD4+ T cells would influence effector functions. Therefore, I included them in 
one set of experiments to assess their contribution to NK cell-mediated killing of EBV-
infected cells. Indeed, NK/NKT cells elicited stronger cytotoxic activity in the presence of 
CD4+ T cells (figure 2.8B, right panel). In the samples that were infected with BCRF1-
negative EBVs, this difference was markedly strong (30% increase of killing), but absent in B 
cells infected with recombinant wildtype and ΔBNLF2a virus. Subpopulations of CD4+ T 
cells can show cytotoxic activity (Martorelli et al., 2010), but lysis did not exceed background 
levels when exclusively CD4+ T cells were added in absence of NK/NKT cells (figure 2.8B, 
left panel).  
Figure 2.8:  
A. BCRF1 prevents the NK/NKT cell-mediated lysis of virus infected 
B cells. Peripheral B cells were infected with indicated EBV variants. 
After 3 days, these B cells were labeled with calcein. Autologous CD56+ 
were isolated, added at the indicated ratio to the infected and labeled B 
cells and incubated for three hours. The percentage of lysed targets was 
calculated by measuring calcein fluorescence in the supernatant.  
B. The presence of CD4+ T cells improves NK/NKT killing when 
infected cells do not express BCRF1. The assay was performed in 
parallel to A but additionally included autologous CD4+ T cells. 
C. The beneficial effect of CD4+ T cells on NK/NKT cell-mediated 
killing is most prominent at low effector/target ratios. Identical settings 
and cells as in A and B were used, but lysis was assessed for different 
ratios of effectors, helpers and targets.   
 
One unit represents 1000 cells. Error bars indicate standard deviations of 
three biological replicates, significance of differences was calculated by a 
two-way Anova test, **p<0.01, ***p<0.001;  
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An even more prominent picture of the beneficial effects of CD4+ T cells on NK/NKT 
cell mediated killing was obtained at lower effector/target ratios, however only when BCRF1 
deficient virus was used for infection (figure 2.8C).  
Exogenous administration of viral and human IL-10 hardly affected NK/NKT cell-
mediated killing at effector/target rates of 10:1 nor did it completely rescue the ΔBCRF1 
phenotype (figure 2.9A).  
In contrast, exogenous IL-10 abrogated the supportive effects of CD4+ T cells on 
NK/NKT cell-mediated killing. These findings show that CD4+ T cells stimulate NK/NKT 
cell-mediated killing of EBV infected B cells (figure 2.9B). In wildtype EBV infected cells, 
vIL-10 counteracts CD4+ T cell help and prevents NK/NKT-mediated killing.  
 
Figure 2.9: NK mediated killing is partly rescued, CD4 effects are fully reverted by exogenous 
administration of IL-10. Killing assays were performed with an effector:target ratio of 10:1 (A) and CD4+ 
assisted killing assays were performed with an effector:helper:target ratio of 2:1:1 (B). His-tag purified viral or 
human IL-10 was administered at 1000pg/ml where indicated. 
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3. Effects on long-term immune control 
The previous experiments revealed that BNLF2a promotes the escape from the CD8+ T 
cell response and BCRF1 impairs NK/NKT cell-mediated killing and Th1 cytokine shedding. 
I could find that both factors are active already during the early days of EBV infection and 
wondered whether these early effects exert any impact on virus establishment in the presence 
of immune control. 
In vitro, such effects can be assayed in so-called regression assays (Wilson and May, 
2001), i.e. serial dilutions of EBV-infected PBMCs that are plated in statistically sufficient 
number of replicates and cultured for six weeks. During this time, infected B cells are either 
eliminated in case of sufficient numbers of effectors (dense cultures), grow out because the 
numbers of effectors are too low (medium dense cultures) or simply do not grow because the 
initial numbers of B cells are too low to support proliferation of EBV infected B cells at all 
(low density cultures). The number of wells with proliferating cells correlates with initial 
numbers of cells per well. This correlation follows a Gaussian distribution (figure 2.10A). A 
prerequisite for regression assays are both identical virus titers and identical transformation 
capacities of the viruses allowing for comparison of the results obtained with different 
viruses. Limiting dilutions of virus stocks revealed that the viruses used in this study showed 
similar characteristics of growth transformation of B cells (figure 2.10B).  
 
Figure 2.10:  
A. Regression assays follow a Gaussian distribution. PBMCs of a seropositive donor were EBV infected 
and plated at serial dilutions with 24 replicates. After 6 weeks of culture, the number of wells with 
proliferating cells was assessed, following a bell-shaped distribution. Solid line: approximated logarithmic 
Gaussian distribution. 
B. Limiting dilution of the viruses showed comparable transformation characteristics. After overnight 
infection with indicated dilutions of the virus stocks, primary B cells were seed on 96-well flat bottom plates 
with 1x105 cells/well and 48 replicates per virus dilution. After six weeks of culture, the number of wells 
with proliferating cells was assessed and plotted against the number of green Raji units (GRU) per well.  
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The results of the regression assays demonstrated that only the growth of B-cells infected 
with double k.o. virus was significantly impaired, whereas ΔBCRF1- and ΔBNLF2a- infected 
cells escaped from immune control as efficiently as wildtype virus (figure 2.11A). 
Subsequent analyses with PBMCs that had been depleted of CD4+ cells indicated that T 
cell help is critical for efficient immune control (figure 2.11B), as expected (Janssen et al., 
2003; Shedlock and Shen, 2003; Janeway, 2005). I observed a weak impairment of growth in 
samples with ΔBCRF1- and double k.o.-infected B cells in the CD4 depleted assay, 
presumably reflecting increased NK/NKT cell-mediated killing in case of BCRF1-deficiency 
(see chapter 2.5). Depletion of CD56+ cells from PBMCs affected the outcome of the 
regression assays only to a minor extent. Again, ΔBCRF1 and double k.o. infections resulted 
in slightly impaired outgrowth, but here CD4+ T cell activity was presumably increased and 
resulted in a stronger immune response. This might reflect a consequence of stronger Th1 
activity in case of BCRF1-deficiency (figure 2.11C). However, the effects on CD56+ and 
CD4+ cells are weak and thus are not detected in regression assays with complete PBMCs 
(compare figure 2.11A). 
Figure 2.11: In vitro, only 
double deficiency of 
BNLF2a and BCRF1 
leads to improved long-
term immune control. 
Complete PBMCs (A), 
CD4+ cell depleted (B) and 
CD56+ cell depleted 
PBMCs (C) were infected 
with the different virus 
mutants and cultured for 6 
weeks. Percentage of wells 
with proliferating cells is 
plotted against the log2 of 
the initial amount of plated 
cells/well. Logarithmic 
Gaussian distributions are 
fitted to the data sets in (A) 
(R2>0.95). 
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 RESULTS II 
- Packaged virion RNAs trigger initial events in EBV infection - 
 
1. The origin of early transcripts in EBV-infected B cells  
It has been described previously that EBV transcripts are detectable in infected B cells 
very early after infection and drive the initial lytic phase (Cheung et al., 1993; Miyazaki et al., 
1993; Kalla et al., 2010). The expression analysis performed in the first part of this work 
revealed the presence of BNLF2a transcripts in infected B cells as soon as 2 hpi (figure 2.3). 
Initially, the transcript levels of BNLF2a stayed constant for six to eight hours and increased 
subsequently.  
Interestingly, certain Herpes viruses incorporate RNA into their virions, among them the 
closely EBV related Kaposi sarcoma Herpes virus (KSHV) (Bresnahan and Shenk, 2000; 
Sciortino et al., 2001; Bechtel et al., 2005). I wondered if EBV virions also contain packaged 
RNAs and if they drive detectable functions in the target cell immediately after infection.  
1.1 Several EBV transcripts are present in B cells immediately upon infection 
I wanted to address the question whether transcripts other than BNLF2a were also present 
in B cells early after infection. In order to cover transcripts from different functional 
subfamilies, I established qPCRs for viral transcripts that represent the following classes of 
viral genes:  
a. Immediate early (IE) and early (E) transcripts of the lytic cycle,  
BZLF1 and BRLF1 encode transcription factors that are essential for the switch to the 
lytic cycle (Countryman et al., 1987; Ragoczy et al., 1998), BMRF1 encodes a DNA 
polymerase processivity factor with essential function during genomic DNA replication 
and early induction in the lytic cycle (Bayliss and Wolf, 1981; Neuhierl and Delecluse, 
2006; Nakayama et al., 2009). 
b. Immune evasins 
BNLF2a inhibits TAP function (shown in this study and in Hislop et al., 2007), BCRF1 
interferes with NK effector functions and the Th1 cytokine response (shown in this 
study), and BGLF5, a host shutoff factor (Rowe et al., 2007). 
c. Apoptosis antagonists 
BHRF1 and BALF1 are redundant genes, which encode homologues to Bcl-2 and are 
important for the initial survival of infected B cells (Altmann and Hammerschmidt, 
2005) 
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d. Latent genes 
LMP1 and LMP2A/B, which trigger CD40-like and BCR-like signals in infected B 
cells, respectively (Busch and Bishop, 1999; Mancao et al., 2005), EBNA2 encodes a 
transcriptional regulator which is critical for cell-cycle regulation and essential for 
EBV-mediated growth-transformation (Hammerschmidt and Sugden, 1989; Pan et al., 
2009).  
e. non-coding RNAs 
EBER 1 and 2 were shown to induce TLR3 and RIG-I signaling and contribute to B cell 
transformation (Iwakiri and Takada, 2010; Samanta and Takada, 2010). 
 
I infected B cells from adenoids with recombinant wildtype EBV (p2089), prepared total 
RNA 2 hours post infection (hpi) and assessed the presence of viral transcripts by quantitative 
PCR (qPCR). Similar to BNLF2a, a number of these transcripts could be detected as early as 
2hpi (figure 3.1). BMRF1 and EBER1 showed the highest prevalence and only BALF1 RNA 
was not reliably detectable. All data were reproducible with peripheral B cells as well as B 
cells from adenoids of different donors (not shown). 
Figure 3.1: EBV transcripts are detectable in B cells as early as two hours post infection. 
RNA was prepared from EBV-infected adenoid B cells two hours post infection, 1µg RNA was reversely 
transcribed into cDNA and analyzed by qPCR for various EBV transcripts. Reactions were run in triplicates 
and error bars represent the obtained standard deviations. PCR was additionally performed with controls that 
had not been reversely transcribed (noRT) and signals were not detected (n.d.) or shown as striped bars. Cp, 
crossing point (equivalent to the second derivative maximum of the sigmoid function of fluorescence 
intensity in qPCR); IE, immediate early; E, early. 
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The analysis of later time points provided the kinetics of single transcripts. The level of 
most genes rapidly inclined within 2-4 hours following infection (figure 3.2, lower and mid 
panel). The strongest induction was observed for transcripts of EBNA2, one of the essential 
factors for EBV-mediated transformation of B cells (Hammerschmidt and Sugden, 1989). In 
contrast, the transcripts of BNLF2a, LMP1, LMP2AB and EBER1 were stable during the first 
8 hours of infection and increased steadily thereafter (figure 3.2 upper panel). 
The biphasic kinetics of several transcripts (BNLF2a, LMP1, LMP2AB, EBER1, and less 
pronounced also BZLF1 and BRLF1) appeared interesting. The transcripts were detectable at 
stable levels for about 6 to 8hpi, followed by a substantial increase over time. The biphasic 
nature suggests that virion-delivered transcripts are responsible for the initial phase, which is 
followed by a second phase of active transcription from the viral genome. Moreover, it might 
be virion-delivered messenger of BZLF1 and BRLF1 that triggers the early lytic phase.  
2. EBV particles contain RNAs 
Figure 3.2: Several transcripts are immediately detectable and remain stable in the first hours of 
infection. RNA was prepared from EBV-infected adenoid B cells at the indicated time points after infection 
and 1µg was reversely transcribed into cDNA. qPCR was performed, the values were corrected for the  PCR 
efficiency of the given primer pair and put into relation to GUSB signals (housekeeper). The ratios were set 
to one at the first time point (2 hpi). Unpaired, two-tailed Student’s T tests were performed to analyze the 
significances of differences. ***/**/*: p<0.001/0.01/0.05, n.s.: not significant. 
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EBV virion-incorporated RNA might become transferred to recipient cells and could 
account for the observed transcript presence in cells immediately after infection. This 
assumption seemed promising because similar observations have already been made for other 
members of the herpes virus family (Bresnahan and Shenk, 2000; Greijer et al., 2000; 
Sciortino et al., 2001; Bechtel et al., 2005). Thus, I sought to determine whether viral RNAs 
are packaged within EBV virions. 
2.1 Preparation and validation of RNA from viral particles 
The analysis of packaged RNAs is challenging because these RNAs might be unstable, 
scarce and contaminating viral DNA genomes could be the source of false positive signals. 
EBV is particularly difficult to study as only a very limited number of cell lines are known, 
which release infectious particles. Besides, the EBV-titers released from these cell lines are 
far lower than those of other herpes viruses. To cope with these difficulties, I established a 
protocol as detailed in the section “Material and Methods”, chapter 2.3.8f, which uses 
concentrated virions from the supernatant of B95.8 cultures. In brief, EBV virions were 
concentrated, enzymatically treated to eliminate free RNA and DNA, pelleted by 
ultracentrifugation and subjected to standard RNA preparation. Based on this protocol, I could 
successfully isolate up to 2µg virion RNA from virion particles present in one liter of B95.8 
cell culture supernatant.  
Reverse transcription and subsequent qPCR analyses were performed on the RNA 
samples to detect BNLF2a as exemplary viral transcript. In parallel, quality controls were 
included at different steps of the preparation to verify the elimination of contaminating free 
RNAs or viral DNA genomes. Figure 3.3 displays the preparative workflow after the first step 
of superantant concentration and the qPCR results obtained with samples from the different 
preparative steps. RNA samples were either subjected to reverse transcription (RT), or left 
untreated (noRT). Strong qPCR signals for the viral transcripts of BNLF2a were obtained in 
reversely transcribed samples, whereas noRT samples did not show any signals above 
background level. Hence, signals were derived from RNA and indicated that EBV virions 
contained BNLF2a transcripts protected from initial RNAse-treatment (figure 3.3). Strong 
signals were observed whenever DNAse treatment was omitted (panels B and C). The particle 
preparations were spiked with RNA from the human EBV negative cell line BJAB 
representing the only source of PCR signals for human glucuronidase beta (GUSB). The 
B95.8 cell line is of marmoset origin and primers did not amplify marmoset GUSB. External 
DNAse and RNAse treatment did not affect the detection of viral transcripts, but eliminated 
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human GUSB RNA efficiently that had previously been spiked in (panels A and B) indicating 
the successful degradation of any free RNA. 
The applied protocol proved appropriate for the analysis of packaged RNAs because it 
efficiently removed contaminating DNA or RNA. The following set of experiments is based 
on this method of preparation.  
 
 
 
Figure 3.3: Viral transcripts are located inside EBV particles. EBV particles were enriched by sequential 
centrifugation steps from B95.8 cell culture supernatant. Human RNA was spiked into the preparation and 
represented the exclusive source of PCR signals for human GUSB (primers did not amplify GUSB from the 
marmoset cell line B95.8). Successful RNAse and DNase treatment eliminated human GUSB signals 
(panels A and B). Genomic EBV DNA was removed in a second step of DNAse treatment after capsid lysis. 
RT samples showed strong signals for BNLF2a (panel A), indicating that RNA was contained in viral 
particles and was protected from RNAse treatment. n.d., not detected. 
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2.2 Assessment of different transcript categories in viral particles 
Following the established protocol, I prepared EBV particles from two liters of B95.8 
supernatant and analyzed selected viral transcripts in virions by qPCR after cDNA synthesis. I 
obtained clear signals for all RNAs analyzed (figure 3.4A). Again, the highest levels were 
obtained for BMRF1 and EBER1 transcripts, but in contrast to B cells infected B95.8 virus 
stocks, BNLF2a, BHRF1 and LMP1 transcripts were also readily detectable.  
In the next step, I addressed the question whether EBV particles might also contain viral 
microRNAs. I prepared B95.8 particles as described above and applied a protocol for 
microRNA preparation. In EBV B95.8 infected cells, 13 mature microRNAs have been 
identified so far. They are derived from 9 pre-microRNAs that are encoded in the BART and 
BHRF1 transcripts. Three stem-loop structures are part of the BHRF1 transcript and are 
processed to pre-microRNAs (miR-BHRF1-1, miR-BHRF1-2, miR-BHRF1-3). BART 
microRNAs are organized in a cluster comprising 4 pre-microRNAs (miR-BART 3, 4, 1 and 
15) and the single, more distally located miR BART-2 (Pfeffer et al., 2004; Grundhoff et al., 
2006). Each pre-microRNA stem-loop is processed to mature microRNAs that can arise from 
the 5’ or 3’ end of the stem structure or both. Based on a protocol as detailed in Material and 
Methods I prepared cDNA from selected mature microRNAs from all loci but miR BART4, 
which could not be efficiently amplified by PCR. All microRNAs could be detected at high 
levels (figure 3.4B).  
With the help of the TR– 2/293 packaging cell line (Delecluse et al., 1999) it is possible to 
generate non-infectious virus-like particles (VLPs), termed TR– VLP in this study. TR– VLPs 
do not contain viral DNA, are not transforming but still fuse with B cells – a process termed 
pseudo-infection in this study. I analyzed VLP preparations for the presence of incorporated 
viral RNAs. I prepared RNA from one liter of supernatant from TR– 2/293 cells, which had 
been induced for particle production. In analogy to B95.8 virion preparations, TR– VLPs 
contained detectable amounts of viral RNAs (figure 3.4C) and microRNAs (figure 3.4D). 
BZLF1 transcripts were present in TR– VLPs at much higher concentrations than in B95.8 
virions, presumably because BZLF1 is expressed at very high levels in TR– 2/293 cells after 
transient transfection of a BZLF1 expression plasmid to induce VLP production. My findings 
indicate that VLP are a useful tool to investigate the function of transferred RNA in the 
absence of virion DNA in infected B cells.  
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2.3 Levels of selected transcripts differ between virus producers and viral particles 
Levels of virion-incorporated RNA can reflect those of their source cells suggesting a 
random integration (hCMV, Terhune et al., 2004), or are enriched in virus particles as in the 
case of HSVI (Sciortino et al., 2002). To analyze the situation with EBV, I compared the 
transcript levels in B95.8 cells and viral particles that these cells release.  
EBV producing cells express the viral glycoprotein gp350 on their surface (Flamand et al., 
1993; Yuan et al., 2006). The fraction of gp350+ cells in the B95.8 cell line depends on 
culture conditions and ranges between 1-10%. I enriched the gp350+ fraction of B95.8 cells 
by FACS-sorting and obtained an almost pure population (figure 3.5A) that was subjected to 
RNA preparation and reverse transcription for subsequent qPCR analysis.  
Transcript levels in two different samples can be compared by normalization to a 
housekeeping transcript that is expressed at equal levels in both samples. This requirement 
could not be assured in my approach addressing producer cells and viral particles. I chose the 
BMRF1 transcript as reference, which showed high abundance in both B95.8 cells and B95.8 
virus particles. Relative levels of several transcripts in sorted gp350+ cells and viral particles 
were calculated and plotted as shown in figure 3.5B.  
Based on this calculation, none of the transcripts showed equal levels in lytic cells and 
particles. The ratio between gp350+ B95.8 cells and viral particles shown in figure 3.5C 
suggested that most transcripts were contained in lower relative amounts in viral particles 
than in gp350+ cells, with exception of LMP1, LMP2AB and EBER transcripts. This finding 
might reflect their preferential packaging together with transcripts of the BMRF1 gene 
pointing to a preferential incorporation of certain transcripts.  
Whether the observed differences resulted from a selective packaging of BMRF1, LMP1, 
LMP2AB and EBER transcripts to virions is currently unclear. It will be essential to verify a 
reliable reference transcript for relative transcript comparisons. Analyses on the basis of 
absolute transcript levels remain error-prone because of a different compositions of cellular 
and particle RNAs, as 1µg of cellular RNA contains more than 90% of ribosomal and transfer 
RNA that is unlikely to be present to the same extent in viral particles. 
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 Figure 3.5: 
Viral particles and producer cells differ in their transcript levels.  
A. The fraction of spontaneously virus-producing B95.8 cells was assessed by FACS analysis. 
Gp350+ and gp350- cells were separated by FACS sorting B. Levels of different transcripts were 
normalized to BMRF1 and compared for viral particles and gp350+ cells. C. The ratio of the tran-
script levels was calculated from data in B. 
 
RESULTS II  2. EBV particles contain RNAs 
 54 
2.4 The RNA shuttle-protein EB2 of EBV is present in virions 
The BMLF1/BSLF1-encoded EBV protein EB2 is a candidate for the selective packaging 
of RNAs into viral particles. This hypothesis builds on previous analyses of capsid assembly 
and particle function (Gruffat et al., 2002; Batisse et al., 2005), and the in vitro interaction of 
EB2 with RNA (Hiriart et al., 2003a). EB2 has been shown to be essential for the formation 
of progeny virus in producer cells and mediates the export of non-spliced transcripts during 
the lytic phase. If EB2 is a mediator of the selective packaging of RNAs, it might become 
incorporated and be itself part of virions. I addressed the presence of EB2 in virions in the 
recombinant system for EBV production. Because an EB2 antibody is not available, I took 
use of a FLAG-tagged wildtype EB2 (wtEB2-FLAG) and FLAG-tagged mutant EB2 
(mutEB2-FLAG), with mutEB2 being incapable of RNA binding (Hiriart et al., 2003b). 
Expression plasmids for these constructs were transfected into the EBV producer cells 
293/2089 (rec.wt.) (Delecluse et al., 1998) together with an expression plasmid for BZLF1, 
which induces the lytic phase and the synthesis of progeny virus. The supernatants were 
harvested and parts of them used to infect Raji cells. The number of infected GFP+ Raji cells 
was assessed by FACS on day three after infection. The virus titers in the supernatants 
generated with the FLAG-tagged wildtype EB2 or mutant EB2 were comparable (figure 
3.6A).  
Figure 3.6: EB2 protein is packaged into virions.  
Wildtype recombinant EBV producer cells (293/2089) were induced for virus production by transfecting a 
BZLF1 expression plasmid. WtEB2-FLAG or mutEB2-FLAG expression vectors were co-transfected. 
A. Raji cells were infected with the respective supernatant. Equal percentages of GFP+ Raji cells in FACS 
analyses 3dpi confirmed equal virus production for both samples. B. Lysates from producer cells (left) and 
produced particles (right) were assessed by Western blot for FLAG-tagged EB2 proteins, BZLF1 and 
BRLF1. Actin signals served as loading control.  
RESULTS II  3. Virion-transferred transcripts are translated in recipient cells 
 55 
 
Lysates from the producer cells were analyzed by Western blot immunodetection and 
confirmed successful transfection of wtEB2-FLAG, mutEB2-FLAG as well as BZLF1. 
BRLF1, a viral gene downstream of BZLF1 was also readily induced and indicated the 
initiation of the lytic cycle in the cells (Amon et al., 2004; Yuan et al., 2006). Viral particles 
were purified and the protein lysates analyzed for the presence of wtEB2-FLAG and 
mutEB2-FLAG protein by Western blot immunodetection. Distinct signals for wtEB2-
FLAG, but not EB2mut, indicated that EB2 is contained within EBV particles suggesting that 
it might mediate RNA incorporation. The binding motif must be essential for incorporation, 
ARM-motif deleted “mutEB2” protein could not be detected in viral particles (figure 3.6B).  
In analogy to findings with HSV1 (Sciortino et al., 2002), the incorporation of EB2 into 
viral particles points to its role as a mediator of transcript selection serving as a transfer 
matrix. The general presence of EB2 in particles gives room to speculate on its role as a 
mediator of directed transcript incorporation into particles. 
3. Virion-transferred transcripts are translated in recipient cells 
3.1 Virion-incorporated transcripts are translated immediately in infected cells 
Two publications claim that mRNAs packaged into viral particles are translated in 
infected cells directly after virus entry (Bresnahan and Shenk, 2000; Bechtel et al., 2005). To 
address the translation of incorporated RNA in virus particles of EBV, I used EBV-negative 
Daudi cells (Nanbo et al., 2002) as indicators because Daudi cells are highly susceptible to 
EBV infection (own observations). In order to analyze the translation of virion-transferred 
RNAs, it is mandatory to discriminate this class of RNAs from those that are de novo 
transcribed in infected cells. Treatment of cells with ActinomycinD (ActD) efficiently inhibits 
transcription (Sobell, 1985) and copes with this issue. Additionally, a transfer of virion-borne 
protein also had to be considered. Control samples were treated with cycloheximide (CHX) 
prior to infection to block translation (Siegel and Sisler, 1963) evaluating the contribution of 
direct protein delivery by viral particles. ActD-treated and CHX-treated samples then 
provided the necessary controls in this experiment.  
First, I confirmed that ActD completely blocked transcription - the decrease of short-lived 
c-MYC mRNA (Marcu et al., 1992) served to measure inhibition. The concentration of 5µg 
ActD per ml medium entirely blocked de novo transcription in Daudi cells because c-MYC 
mRNA levels declined rapidly within 240 min (figure 3.7A).  
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Figure 3.7: Particle transcripts are translated in newly infected cells. 
A. Daudi cells were treated with indicated doses of ActinomycinD and transcript levels of c-MYC mRNA 
were measured in relation to GUSB by qPCR at indicated timepoints.  
B. Cycloheximide (CHX) at a concentration of 25 µg/ml inhibited translation of c-MYC at the indicated 
timepoints (upper panels). Actinomycin D (ActD) inhibited transcription and indirectly prevented de novo 
synthesis of c-MYC protein in a delayed manner (lower panels). 
C. 1x108 Daudi cells were treated with inhibitors as indicated and infected with concentrated B95.8 virions  
or left uninfected. Two hours post infection, cells were lysed, BRLF1 protein was immunoprecipitated and 
analyzed by Western Blot immunodetection. 1% of the input lysate was included to control for BRLF1 
enrichment and successful inhibitor treatment. Infection of the respective samples was verified by dot blot 
analysis of 5µl input lysate with a gp350-specific antibody. Actin signals served as loading control. Total 
cell lysates of BRLF1 transfected 293 cells served as positive control for BRLF1 signals (arrow), signals for 
the heavy chain of the IP-antibody indicate equal treatment during immunoprecipitation (arrowhead). 
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Translation was efficiently blocked in Daudi cells at a concentration of 25µg CHX per ml 
because c-MYC protein decreased with the reported half-life of about 15min (Luscher and 
Eisenman, 1988) and became undetectable after 60min of treatment (figure 3.7B). 
Next, virus particles were prepared from two liters of cell-free B95.8 supernatant and 
concentrated approximately 100-fold as described in Material and Methods. Daudi cells were 
pre-treated with ActD or CHX or left untreated and then incubated with concentrated B95.8 
particles for 2 hours at 37°C. Whole cell lysates were prepared and subjected to 
immunoprecipitation with an antibody specific for the viral BRLF1 protein. The precipitates 
were separated on SDS PAGE and the same anti-BRLF1 antibody was used to detect the 
protein. A clear signal of the expected size (105kD) was present in lysates from infected cells 
that had been pre-treated with ActD or left untreated. Moreover, untreated and ActD-treated 
cells displayed similar levels of BRLF1 protein, indicating that delivered mRNAs constitute 
the predominant source for BRLF1 protein within the first hours following infection. No 
signal could be detected in CHX-treated cells, hence BRLF1 protein levels in infected Daudi 
cells originated from de novo translation (figure 2.5C). The control experiments excluded the 
simple transfer of BRLF1 protein through viral particles.  
My experiments clearly demonstrated that EBV virions transfer RNAs that are translated 
in recipient cells immediately after infection.  
3.2 The translation of transferred RNAs leads to antigen presentation 
EBV antigen-specific CD8+ T cell clones constitute an alternative sensitive tool for the 
detection of viral proteins in infected cells because endogenously translated proteins are 
degraded in the proteasome and subsequently presented in association with MHC I molecules 
(Janeway, 2005). 
My experiments suggested that viral proteins could be translated from virion-packaged 
mRNAs. It appeared as a likely consequence that viral peptides are presented to antigen-
specific CD8+ T cells after RNA transfer. I used CD8+ T-cell clones specific for the 
immediate early EBV proteins BZLF1 (epitope RAK) and BRLF1 (epitope YVL), for the 
early protein BMLF1 (epitope GLC) and the latent protein EBNA3a (epitope QAK). These T 
cells were co-incubated with HLA-matched B cells that had been pseudo-infected with TR– 
VLP, which contain viral RNAs (figure 3.4) but are devoid of EBV DNA genomes. As a 
negative control, a fraction of the B cells had been pre-treated with CHX to block translation 
and also uninfected, untreated B cells were included. After 18 hours of co-culture, I assessed 
Ifn-γ levels in the supernatants released by antigen-activated effector T cells.  
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The results in figure 3.8 clearly indicate that T cells recognized MHC I associated 
epitopes on primary B cells that had been pseudo-infected with TR– VLPs. The levels of Ifn-γ 
were much lower than those obtained with LCLs as positive control, but differences between 
not infected and TR– VLP pseudo-infected cells were evident. CD8+ T cells specific for the 
lytic epitopes YVL of BRLF1, RAK of BZLF1 and GLC of BMLF1 released Ifn-γ, but T 
cells specific for the epitope QAK of EBNA3a did not. EBNA3a is a latent gene and its 
transcriptional activity is very low suggesting that EBNA3a RNA molecules are not 
incorporated into virions or translated at a level that is below detection in this assay. 
This experiment revealed that TR– VLP-transferred RNA is translated in the recipient 
cells, resulting in antigen presentation that is sufficient to trigger CD8+ T cell activity. This 
effect was clearly dependent on functional translation in the infected cells.   
Figure 3.8: CD8 T cell clones specific for lytic EBV epitopes recognize TR– VLP infected B cells. 
Peripheral B cells of matching HLA allotype were infected overnight with concentrated TR– virus like 
particles (VLP) and treated with cycloheximide (CHX) as indicated. Cells were washed, counted and 
incubated for 18h with T cells specific for the indicated epitope at an effector target ratio of 1:2. Ifn γ levels 
in the supernatant of the co-culture were assessed by low-range ELISA. Error bars indicate standard 
deviations of three biological replicates, significance was analyzed by Student’s T test,  
*/**/***: p≤0.05/0.01/0.001; n.s., not significant. 
 
RESULTS II  4. Virion-transferred RNAs modulate the immune response 
 59 
4. Virion-transferred RNAs modulate the immune response  
4.1 Packaged BNLF2a-RNA decreases the recognition of infected B cells by CD8+ T 
cells 
BNLF2a is an important immune evasin that inhibits TAP-dependent antigen presentation 
and exerts important function within the first days of infection, as described in the first part of 
this work. Transcripts of BNLF2a were detected in viral particles as well as in freshly infected 
cells (figures 3.1 and 3.4).  
I addressed the immediate impact of transferred BNLF2a-RNA on T cell recognition. To 
this end, I infected primary B cells with either recombinant wildtype EBV (Delecluse et al., 
1998) or the BNLF2a-deficient EBV mutant that was generated in the first part of this work 
(ΔBNLF2a, section “Results I”, chapter 1). Both are infectious viruses and induce de novo 
transcription upon infection. This was prevented in Actinomycin D (ActD) treated samples, 
delineating remaining effects to transferred RNA. The inhibition of translation in 
Figure 3.9: The transfer of BNLF2a transcripts impairs immune recognition of infected cells 
immediately after infection. Untreated, ActD-treated or CHX-treated B cells were infected overnight with 
recombinant wildtype (rec. wt) virus or ΔBNLF2a virus. The cells were co-incubated with EBV-specific 
clonal CD8+ T cells at an effector:target ratio of 1:2 for the following 18hrs. Ifn-γ levels in the supernatants 
of the co-culture were assessed by low-range ELISA. Error bars indicate standard deviations of three 
biological replicates, significance was analyzed by Student’s T test, */**/***: p≤0.05/0.01/0.001;  
n.s., not significant. 
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Cycloheximide (CHX) treated control samples resolved the putative contribution of virion-
mediated protein transfer to functional differences.  
As expected, RAK-epitope specific T cells recognized primary B cells infected with the 
ΔBNLF2a mutant EBV better than cells infected with recombinant wild-type EBV one day 
after infection. However, ActinomycinD treated B cells were also recognized by T cells and 
the difference in recognition of wild-type and ΔBNLF2a infected B cells samples remained 
significant. Cycloheximide treated cells did not present the epitope (figure 3.9, upper left 
panel). Similar observations were obtained for the GLC epitope of BMLF1, reflecting 
however an overall weaker recognition (figure 3.9, upper right panel).  
Thus, transfer of BNLF2a transcripts but not BNLF2a protein contributed to impaired 
recognition of newly infected B cells. Besides, these results expanded the findings from the 
previous chapter: Also upon infection with functional virus transferred RNA is translated, 
which leads to the presentation of viral peptides on MHC I.  
Rather strong T cell responses were also obtained with the YVL-epitope (derived from 
the viral BRLF1 protein), but BNLF2a did not show any effect here (figure 3.9, lower left 
panel). This resulted from TAP-independent loading of the hydrophobic YVL peptide to 
MHC I (Lautscham et al., 2003) that is not affected by BNLF2a-mediated interference with 
antigen presentation (BNLF2a inhibits TAP, Horst et al., 2009). The equal T cell response to 
this epitope in samples with and without ActD however showed that ActD treatment did not 
affect antigen presentation. The QAK epitope was not recognized one day after infection and 
reflected previous findings with TR– VLP pseudo-infections (figure 3.9., lower right panel). 
This experiment assigned a first functional advantage to virion-mediated RNA transfer, as 
EBV uses this strategy to immediately impair epitope presentation by the transfer of BNLF2a 
RNA that is translated to act as an immune evasin. 
 
4.2  Packaged EBERs induce Ifn-α  production in infected cells 
The non-coding RNAs EBER-1 and -2 of EBV are among the most abundant viral 
transcripts in infected cells. EBERs form secondary structures with double-strand character 
that bind to cellular PAMP recognition receptors (PRR), including retinoic acid-inducible 
gene (RIG)-I (Samanta et al., 2006) and toll-like receptor (TLR)-3 (Iwakiri et al., 2009). 
Binding activates their downstream signaling cascade (Kawai and Akira, 2008; Iwakiri and 
Takada, 2010). As EBER-1 and -2 transcripts are abundantly present in EBV particles (figure 
3.4), I asked whether they might function immediately upon infection. The most prominent 
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effect ascribed to EBERs is the induction of type I interferons in EBV infected cells upon 
binding to RIG-I or TLR-3 (Samanta and Takada, 2010).  
For this analysis I generated two EBV mutants that lack the genes for both EBER-1 and    
-2. The first mutant, termed ΔEBER, is derived from the recombinant wildtype EBV genome 
p2089 (Delecluse et al., 1998). The second mutant, termed ΔEBER TR–, is derived from the 
recombinant EBV genome that lacks the terminal repeats (p2114, “TR–”, (Delecluse et al., 
1999). Accordingly, ΔEBER virions contain viral genomes and viral RNAs, whereas ΔEBER 
TR– virus-like particles (VLP) are devoid of viral genomes, but still contain viral RNAs. Both 
efficiently transduce the co-packaged RNAs to target cells, however only the infection with 
genome-containing virions stably establishes the virus in the cell. 
I infected primary B cells from adenoids with (i) recombinant wildtype virus, (ii) ΔEBER 
virus, (iii) TR– VLPs or (iv) ΔEBER TR– VLPs and measured Ifn-α synthesis. In order to 
exclude free EBERs in the supernatant, which are sufficient to induce Ifn-α (Iwakiri et al., 
2009), one subset of EBER containing virus supernatants was additionally treated with 
RNAse prior to infection. Ifn-α levels in the supernatant were assessed by ELISA three days 
after infection.  
 
 
Figure 3.10: The virus particle-mediated transfer of EBERs induces Ifn-α synthesis in infected B cells.  
B cells were infected with recombinant wild-type EBV (rec.wt.), EBER-deficient recombinant EBV (ΔEBER), 
TR– VLP or EBER-deficient TR– VLP (TR– ΔEBER). To control for effects of free EBERs, an RNAse treated 
sample was included. A. Ifn-α levels in the supernatant were determined by ELISA, errors bars indicate the 
standard deviation of three biological replicates. B. Equal infection rates of VLP-infected samples were 
confirmed by FACS analysis, numbers in histograms indicate the mean GFP-fluorescence intensity of the 
samples. The same control was applied for virus-infected samples (not shown). 
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As shown in Figure 3.10, recombinant wild-type infected B cells produced high levels of 
Ifn-α within the first three days of infection as did B cells pseudo-infected with TR– VLPs. In 
sharp contrast, cells incubated with ΔEBER virus or ΔEBER TR– VLPs released significantly 
less Ifn-α. Treatment of the supernatants with RNAse reduced the Ifn-α production only 
slightly. These results indicate that EBER transfer through virus particles is already sufficient 
to trigger RIG-I signaling. Moreover, free EBERs in the supernatant contribute only little to 
Ifn-α induction, but the majority of EBERs is obviously contained in particles and during 
infection.  
These data demonstrate that packaged EBERs are functional in infected cells as they are 
sufficient to induce the synthesis of Ifn-α.  
 
4.3 Virion-transferred microRNAs decrease MICB surface levels on infected B cells 
Since their discovery, a large number of miRNAs have been described and many of them 
deploy important regulatory function. miRNAs have by now been proven to be potential 
regulators in nearly every aspect of cellular biology (He and Hannon, 2004). So far, also 235 
miRNA-encoding stem-loops have been discovered in viruses, which of 146 are encoded by 
Herpes viruses. EBV field strains encode 25 miRNA stem-loops whereas the laboratory strain 
B95.8 has only 13 miRNAs stem-loops left due to a 10.5kb deletion in its genome (Grundhoff 
et al., 2006; Swaminathan, 2008). So far, two B95.8 miRNAs are known to target cellular 
transcripts: miR BHRF1-3 decreases messenger levels of CXCL11, a chemoattractant for B 
cells, and miR BART2-5’ targets transcripts of MICB, a NK cell activating surface ligand 
(Xia et al., 2008; Nachmani et al., 2009). Hence, both miRNAs are immune modulatory and 
support EBVs immune escape. 
As viral particles contain relatively high levels of miR BART2-5’ (figure 3.3), I evaluated 
whether a downregulation of MICB surface levels is detectable on B cells and associated with 
the virion-mediated transfer of miR BART2-5’.  
To address this question, I infected primary B cells from adenoids with either 
recombinant wildtype EBV, or an EBV mutant deficient for all known miRNAs (ΔmiRall, 
Seto et al., 2010), or TR– VLPs. Three days after infection, I assessed MICB surface levels of 
GFP+ infected cells by FACS analysis. 
The infection with ΔmiRall virus led to a 50% increase in MICB surface expression on 
infected cells 3dpi, compared to infection with recombinant wildtype EBV. Infection of B 
cells with virus-like particles (VLP) also reduced the surface levels of MICB, indicating that 
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miRNAs are transferred and target messenger RNAs immediately after infection and delivery 
(figure 3.11). Additionally, these data provide first evidence that miR BART2-5’ targets 
MICB also in B cells. The early timing and magnitude of this effect suggests a high 
importance of this molecule for the immune escape of EBV-infected primary B cells.  
 
 
Figure 3.11: Within the first days of infection, TR– VLP pseudo-infection results in comparable MICB 
surface levels as on wildtype infected-B cells, indicating functional microRNA transduction. 
B cells were infected with recombinant wildtype EBV or microRNA deficient recombinant EBV (ΔmiRNA) 
or pseudo-infected with TR– VLP, cultured for three days and analyzed by FACS for MICB surface levels. 
A. Dot blots of FACS analyses. Virion-infected cells are GFP+, TR– VLP pseudo-infected cells are GFP 
shifted, mean fluorescence intensities (MFI) of the MICB signal are shown in gates. B. Bar chart of MICB 
MFI and Isotype MFI of GFP+ cells, numbers indicate APC-MFIs (compare to A). 
ΔmiRall 
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4.4 Packaged RNAs enhance EBV's capacity to transform B cells 
Growth transformation of human B-cells in vitro is a hallmark of EBV. Following an 
initial lytic transcription program, EBV eventually establishes a latent infection in B cells. 
The latency-associated expression of viral genes is the reason for growth-transformation of 
EBV infected cells in vitro (Rickinson and Kieff, 2007). EBV-transformed B cells start to 
proliferate in culture and give rise to permanently proliferating lymphoblastoid cell lines 
(LCL). The transformation capacity of EBV preparations can be quantified in limiting 
dilution assays that are analyzed for the amount of proliferating cells several weeks after 
infection (Wilson and May, 2001). I used a modified limiting dilution assay to analyze 
whether the particle-associated transfer of RNAs enhance EBV’s transforming capacities.  
I compared the transformation capacity of B95.8 particles either alone, in combination 
with TR– VLPs, or in combination with gp350+/GFP+ exosomes derived from transiently 
transfected HEK293 cells. Gp350+/GFP+ exosomes were included as a control because the 
binding of gp350 to CD21 might result in a stimulus sufficient to reactivate B cells (Bouillie 
et al., 1995) and also promote successful infection. I plated primary B-cells on 96-well cluster 
plates at a density of 10.000 cells/well and infected them with serial dilutions (5 - 0.1 µl/well) 
of B95.8 virus stocks, including 24 replicates per dilution step. In a preliminary experiment, 
5µl/well of the B95.8 virus stock caused the outgrowth of infected cells in approximately 50% 
of the cultures. Three sets of plates were prepared and cells were infected with B95.8 virus. 
One of these plates was additionally pseudo-infected with TR– VLPs, the second one treated 
with gp350+/GFP+ exosomes and the third one left as it was. Cells on additional sets of plates 
were only pseudo-infected with TR– VLP or treated with gp350+/GFP exosomes and 
controlled for direct effects of these particles on B cell outgrowth without addition of B95.8 
virus. The infection of the donor with field-strain EBV can be sufficient to lead to outgrowth 
of B cells.  An additional plate with untreated cells controlled for this putative spontaneous 
outgrowth. Six weeks post infection, I assessed the number of wells with proliferating cells by 
an MTT-assay. 
TR– VLPs, but not gp350+/GFP exosomes, significantly fostered the outgrowth of B95.8-
infected cells. At limiting doses of B95.8 virus (0.5µl/well), the additional infection with TR– 
VLP boosted the outgrowth most prominently (figure 3.12A). Control plates did not show any 
proliferating cells after 6 weeks of culture. The supportive effect of TR– VLPs at low 
concentrations of B95.8 particles considerably illustrated the relevance of packaged RNAs for 
the establishment of latency. The particle concentration of TR– VLP and gp350+/GFP+ 
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exosome preparations were adjusted by infection of Raji cells and FACS analysis of GFP 
fluorescence (figure 3.12B). 
Taken together, this assay provided evidence that particle-mediated transfer of viral 
RNAs to target cells significantly increased EBV’s capacity to transform primary B-cells. 
These findings support the hypothesis that transcription-independent translation of viral 
proteins enhances the success of EBV to infect primary B cells and to establish a latent 
infection.  
 
 
Figure 3.12: Co-infection of primary B cells with EBV and TR– VLP enhances the transformation 
potential of B95.8 virus stocks. 
A. Limiting dilution assays were performed with B95.8 supernatant. Either TR– VLPs (TR–), gp350+GFP+ 
exosomes (Exo) or no additives (w/o) were included to the infection. After six weeks of culture, the number 
of wells with proliferating cells was determined by an MTT assay. Significances of differences were 
calculated by Fisher’s exact test, n.s.: not significant (p>0.05). 
 B. The particle concentration of TR– VLP and gp350+/GFP+ exosome preparations were adjusted by 
infection of Raji cells and FACS analysis of GFP fluorescence 1dpi. 
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 DISCUSSION 
1. EBV balances immune evasion to prevent counter-mechanisms 
1.1 Unraveling viral immune evasin mechanisms by reverse genetics 
Extensive investigations led to detailed knowledge on the latent and the lytic phase of 
EBV. A variety of sophisticated viral mechanisms have been unraveled including principles 
of virus-mediated growth transformation of B cells, different types of latency and efficient 
immune evasion strategies (Cohen, 1999; Ressing et al., 2008). However, much of this 
knowledge results from model systems, which rely on ectopic expression of single viral genes 
at high levels. These studies revealed dedicated protein functions, but the models did not 
reflect viral function during the process of infection. In a seminal work, Hammerschmidt and 
colleagues (Delecluse et al., 1998) established a recombinant system to produce infectious 
EBV from an engineered viral BAC genome, which made the virus amenable to reverse 
genetics. Based on this work and further optimization of BAC modifications (Warming et al., 
2005), straight-forward investigations can now be performed on loss-of-function situations. 
This option provides the possibility to study the contribution of single viral factors during 
infection of primary human B cells (Delecluse et al., 2008).  
I applied reverse genetics to study BNLF2a and its contribution to the evasion of CD8+ T 
cell recognition. In general, my observations are in line with data from previous 
overexpression experiments (Hislop et al., 2007; Horst et al., 2009), but my data additionally 
show that BNLF2a is of high importance during the initial phase of infection. It became 
evident that no other viral gene complements BNLF2a’s function. Its deletion causes strongly 
increased immunogenicity of EBV-infected cells, which is most apparent early after infection. 
In contrast to previous publications (Zeidler et al., 1997), my experiments with BCRF1-
negative EBV indicated that the endogenous expression level of BCRF1 hardly influences 
TAP levels and antigen presentation on MHC I molecules. After viral infection of primary B 
cells the amounts of vIL-10 are insufficient to decrease TAP2 levels, but I observed systemic 
effects on cytokine orchestration and impaired NK cell function. My findings rank vIL-10 as 
an important immune evasin, addressing however a different compartment of immune 
effectors than BNLF2a. 
These data emphasize the importance of loss-of-function approaches to interpret gene 
functions. The outcome of loss of endogenous gene expression can be significantly different 
from overexpression or artificial administration, as shown here for BCRF1.  
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However, loss-of-function analyses can also be misleading when gene deletions interfere 
with the expression of neighboring genes or cis-acting promoter elements. Depending on the 
genomic structure, modifications of the EBV genome were thus realized by different 
approaches of mutagenesis in this study.  
BCRF1 was replaced by a prokaryotic selection marker. The open reading frame (ORF) of 
BCRF1 did not overlap with adjacent genes or promoters and thus allowed for complete 
replacement. A similar strategy could be applied for the replacement of the EBER genes in the 
second part of this work. 
The BNLF2a ORF shares the transcript with BNLF2b. Therefore, I mutated the 
methionine1-codon to prevent translation. No information is available on the regulation of 
translation for BNLF2b, but considering other bicistronic transcripts, a collateral effect of 
increased BNLF2b translation in case of mutated BNLF2a could not be ruled out. The 
observed BNLF2a phenotype could theoretically also result from upregulated BNLF2b 
translation. However, such effects seem unlikely because overexpression of monocistronic 
cDNA of BNLF2a (Hislop et al., 2007) led to a complementary phenotype to that observed 
with loss of BNLF2a function in my experiments.  
 
1.2 BNLF2a – a dedicated antagonist of antigen presentation 
BNLF2a has important function for the evasion of infected B cells from CD8+ T cell 
responses, in particular during the early phase of infection. Deletion of BNLF2a increased 
TAP-dependent antigen presentation starting as early as one day after infection. However, 
neither MHC I surface levels nor NK cell-mediated killing were altered by the loss of 
BNLF2a.  
1.2.1 The early phase of infection reveals phenotypes of early lytic genes 
The increased CD8+ T cell response to B cells that were infected with BNLF2a mutant 
EBV was expected from previous studies (Hislop et al., 2007; Croft et al., 2009; Horst et al., 
2009). These reports, however, dealt with results from artificial expression or induced and 
spontaneously lytic cells. The very early manifestation of a BNLF2a phenotype in the present 
study illustrates its relevance during the establishment of infection for the first time. The 
physiological expression levels of BNLF2a during the initial phase of infection are obviously 
sufficient to exert strong function. These findings are in line with reports of an incomplete 
lytic phase following EBV infection and BNLF2a as an early lytic gene (Yuan et al., 2006). 
My results suggest that this early phase of infection is suitable to reveal phenotypes of early 
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lytic genes. Simultaneous infection of nearly all cells triggers the synchronized initiation of 
the initial lytic phase. This circumvents the need for separate considerations of lytic and latent 
subfractions of an infected LCL culture or even the artificial induction of the lytic phase to 
obtain enough lytic cells for analyses. Additionally, investigations on the initial phase of 
infection provide insights into events that are of importance for the success of the virus, but 
are still only poorly understood. But, comparisons of samples immediately after infection 
depend on the premise of equal infection and transformation rates. To this end, thorough 
evaluation of recombinant virus supernatants represent a mandatory requirement. 
1.2.2 TAP-dependent antigen presentation represents a vulnerable bottleneck 
The observed BNLF2a effects were limited to TAP-dependent epitopes and thus in line 
with the postulated molecular mechanism of BNLF2a-mediated interference with antigen 
presentation: BNLF2a binds to the ATP-binding pocket of TAP1 and also blocks interaction 
of TAP1 with peptides, inhibiting their translocation to the ER (Hislop et al., 2007; Horst et 
al., 2009).  
In analogy, interference strategies of other viruses also aim at the bottleneck of TAP-
dependent peptide translocation. Many of them prevent ATP- and peptide-binding to TAP 
similar to BNLF2a (US6 of hCMV, UL49.5 of HHVX, ICP47 of HSVI), but certain viruses 
also prevent TAP expression (UL 41 in pseudorabies) or target TAP for degradation (MK3 in 
mHV68)(Hill et al., 1995; Ambagala et al., 2003; Boname et al., 2004). Hence, TAP 
interference represents a highly exploited strategy to diminish the presentation of antigens. 
The advantage for the virus is evident: One viral factor is sufficient to inhibit the presentation 
of the majority of viral epitopes.  
Highly hydrophobic peptides do not rely on TAP translocation but presumably diffuse 
passively to the ER, where they are loaded onto MHC I molecules (Lautscham et al., 2003). 
BNLF2a does not affect this mechanism. For EBV, eight TAP-independent epitopes have 
been characterized so far (Lautscham et al., 2003). Their contribution to the elimination of 
infected cells is difficult to judge, as the prevalence of these epitopes is variable as well as the 
frequency of HLA alleles that enable their presentation. The TAP-independent pathway 
enables antigen presentation although infecting pathogens interfere with TAP-dependent 
epitope presentation. Hence, interference with TAP severely reduces antigen presentation, but 
never prevents it completely. 
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1.2.3 Endogenous BNLF2a expression leaves MHC I levels unaffected 
The interference with MHC I antigen presentation usually results in decreased MHC I 
surface levels, as only epitope loaded MHC I molecules show sufficient stability to dissociate 
from chaperones and migrate to the cell surface (Purcell and Elliott, 2008). Reduced MHC I 
surface levels can result from impaired epitope loading, as observed with BNLF2a 
overexpression (Hislop et al., 2007). In turn, extremely low surface levels of MHC I 
molecules are recognized as a signal of infection and trigger NK cell cytotoxicity (Long, 
1999). 
In my experiments, BNLF2a did neither decrease MHC I surface levels nor increased NK 
cell-mediated killing of EBV-infected cells (figures 2.4 and 2.8). BNLF2a expression levels 
are obviously tightly balanced to achieve impaired antigen presentation without altering the 
MHC I surface levels that would evoke NK cell activation. This equilibrium points to a 
perfect adaptation of immune evasin levels to the host’s counter-acting defense mechanisms.  
Still, the complete lack of influence of BNLF2a on MHC I surface levels comes to a 
surprise. Besides the assumed balanced expression of BNLF2a, other viral factors could also 
be responsible for steady levels of MHC I despite impaired antigen presentation. For hCMV, 
UL18 and UL142 were identified to mimic MHC I molecules and both were shown to inhibit 
NK cell-mediated lysis (Beck and Barrell, 1988; Wills et al., 2005; Wagner et al., 2008). 
Homologous proteins have not been described for EBV, however a similar mechanism might 
have evolved independently, as observed for the development of various analogous TAP 
inhibitors in different virus species (Hansen and Bouvier, 2009; Griffin et al., 2010). If such 
molecules were indeed present on EBV infected cells, they would share at least those domains 
with human MHC-I molecules that interact with NK cells and that are bound by the MHC-I 
specific antibody used in FACS analyses (Figure 2.4A, pan-specific HLA-A/B/C antibody). 
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1.3 BCRF1/vIL10 – a secreted immune evasin with differences to hIL-10 
The performed experiments on the immune evasive functions of BCRF1/vIL-10 pointed to 
an involvement in cytokine orchestration and the prevention of NK cell-mediated killing of 
infected cells. The elimination of ΔBCRF1- or double k.o.-infected B cells by NK cells was 
found to be enhanced. At low effector/target rates CD4+ T cells improved NK cell-mediated 
killing in ΔBCRF1-infected samples. BCRF1 deficiency was associated with a more 
pronounced Th1 cytokine response that presumably accounted for the boost of NK cell 
activity when CD4+ T cells were present.  
1.3.1 Endogenous BCRF1 expression does not influence specific T cell recognition in vitro 
The observation that BCRF1 deficiency did not influence MHC I levels or T cell activity 
(figures 2.4A, 2.5 and 2.6) contrasted with experiments on vIL-10 effects of previous studies 
(Zeidler et al., 1997; Bejarano and Masucci, 1998; Salek-Ardakani et al., 2002). Presumably, 
levels of vIL-10 differed significantly between these studies. Levels of different cytokines, 
and those of IL-10 in particular, are known to be critical for function (Moore et al., 2001). 
Inappropriate timing and dosage may even evoke opposing effects (Mocellin et al., 2004).  
In general, the ad-hoc recognition of targets by activated T cells is independent of 
secondary signals in case of a strong TCR trigger (Akdis and Blaser, 2001). The conditions to 
generate and raise T cell clones enrich exactly those T cells with high TCR affinity to EBV 
targets (Rickinson and Moss, 1997). This experimental setting might have simply masked the 
direct impact of secreted vIL-10 on T cells. Nevertheless, physiological vIL-10 levels 
apparently did not affect MHC-I levels and antigen presentation.  
1.3.2 vIL-10 and Th1 cytokines  
In experiments with PBMC derived effector cells ex vivo, BCRF1 deletion resulted in an 
immune phenotype. One of the assays revealed a dampening effect of vIL-10 on the Th1 
cytokine response. This observation is in line with the known feature of IL-10 to promote Th2 
responses and to impair Th1 cytokine secretion (Moore et al., 2001). Interestingly, production 
of human IL-10 did not complement BCRF1 deficiency and did not rescue the phenotype. In 
contrast, IL-10 reached highest levels when cells had been infected with virus that lacked 
BCRF1, but still did not prevent high Th1 levels (figure 2.7). Apparently, vIL-10 impairs Th1 
cytokine production with a higher specificity than human IL-10, which at first glance 
contrasts the described low affinity of vIL-10 to the IL-10R (Liu et al., 1997). However, a 
number of reports have associated high IL-10 levels with effector activation (Mocellin et al., 
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2004). The suboptimal binding of vIL-10 probably induces an intermediate signaling of that 
might rather induce anergy and prevent Th1 cytokine shedding.  
CD4+ T cells represent the major source of Th1 and Th2 cytokines, but other cells can 
also secrete these factors. Dedicated effects of BCRF1 on CD4+ T cells were however 
observed in experiments that investigated the supportive role of CD4+ T cells in NK cell 
mediated killing of infected B cells. This observation strongly contributed to the model that 
vIL-10 indirectly hampers the induction of cellular immune responses via the inhibition of 
Th1 cytokine synthesis by CD4+ T cells. 
Taken together, vIL-10 appears to be of defined inhibitory function for Th1 cytokine 
responses and might fulfill this task to a larger extent than human IL-10. Hypothetically, the 
IL10-R induces a weak signaling cascade in case of low affinity binding of viral IL-10 and a 
strong signal upon high affinity binding of human IL-10. Whether this is indeed the case and 
why CD4+ T cells react on vIL-10 in a particularly sensitive way remains to be elucidated. 
1.3.3 vIL-10 impairs NK cells 
NK cells can be a source of IL-10 and have regulatory potential on dendritic cells (Vivier 
and Ugolini, 2009). However, I observed that NK cells can also be inhibited themselves by 
vIL-10, representing a remarkable advantage for EBV and presumably also for other IL-10 
encoding viruses (Rode et al., 1993; Fleming et al., 1997; Kotenko et al., 2000). For human 
IL-10 in contrast, several publications postulate stimulating effects on NK cell activity 
(Petersson et al., 1998; Lauw et al., 2000; Parato et al., 2002). The reason that NK cells react 
differently to hIL-10 and vIL-10 remains elusive and mechanistic reasons are unclear. 
Generally speaking, the artificial administration of high concentrations of IL-10 probably 
leads to different outcomes than cellular secretion.  
Interestingly, CD8+ T cells were shown to recruit cytokine receptors to the immunological 
synapse upon target recognition, which was shown by fluorescent labeling and time lapse 
analysis (Maldonado et al., 2004; Maldonado et al., 2009). Hence, sensitivity to cytokines can 
be regulated by the recipient cell and might also be realized by NK cells. The visualization of 
such processes at the immunological synapse is technically demanding, but would probably 
bear interesting insight on the general behavior of NK cells during target recognition. 
Patients with X-linked lymphoproliferative disease (XLD), a rare disease with abrogated 
NK and NKT cell development (Hislop et al., 2010), suffer from symptoms highly similar to 
infectious mononucleosis in case of EBV infection. This observation represents the link that 
NK cells importantly contribute to the control of an EBV infection in vivo. The EBV 
microRNA BART2-5’ targets the NK cell activating ligand MICB which implies NK cell 
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mediated immunity (Nachmani et al., 2009). My experiments could contribute the aspect that 
synthesis of EBV-encoded vIL-10 reduces NK cell killing of infected B cells in vitro. To 
which extent this observation differs for NK cell subsets that are comprised in CD56+ cells 
(Cooper et al., 2001; Godfrey et al., 2004) could not be derived from this data, but remains to 
be addressed in future investigations. 
1.3.4 vIL-10 and hIL-10 – homologues with different posttranscriptional regulation 
Viral IL-10 has apparently acquired distinct features that distinguish it from human IL-10. 
In addition, expression analyses revealed different transcript levels: Human IL-10 messengers 
are abundant in primary B cells and not affected by EBV infection. BCRF1 transcripts, in 
contrast, were barely detectable and relative levels per se suggested a minor contribution 
compared to hIL-10. 
Regulation of human IL-10 has been intensively studied and occurs on both transcriptional 
and post-transcriptional level (Mosser and Zhang, 2008). No comprehensive data exist for 
BCRF1. The prediction of promoter binding sites 800 bp upstream of the BCRF1 ORF by the 
PROMO algorithm identified binding sites for many of those transcription factors that also 
regulate hIL-10 expression (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi? 
dirDB=TF_8.3, Messeguer et al., 2002). Apparently, also the cis-acting promoter elements of 
hIL-10 have been integrated in the viral genome within gene uptake (figure 4.1A). The same 
regulatory elements can hence drive both hIL-10 and BCRF1 expression. Moreover, four 
BZLF1 binding sites were identified for hIL-10 and presumably also exist for BCRF1, despite 
they differ in relative distance to the start site of gene transcription (Mahot et al., 2003; 
Bergbauer et al., 2010). Thus, both genes appear to be also similarly regulated by the viral 
transactivator BZLF1. 
Nevertheless, significant differences in transcript prevalence were detected in this work. In 
general, cytokine transcripts are highly regulated also at the post-transcriptional level. 
Tristetraprolin (TTP) represents an important regulator of transcript half-life, as it targets 
messengers for accelerated decay by binding to an AU-rich element (ARE) (Carballo et al., 
1998; Blackshear, 2002). TTP also affects hIL-10 due to its six AUUUA pentamer motifs in 
the 3’ untranslated region (UTR) (Stoecklin et al., 2008). TTP is induced upon EBV-infection 
and is of presumable importance for this method of transcript regulation during infection 
(own observations). 
Human IL-10 mRNA is targeted by microRNA hsa-miR106a, which is expressed in all 
cells of lymphoid origin (Sharma et al., 2009). In total, the 5’UTR of 60bp and the 3’UTR of 
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1032bp flank the 537bp of coding sequence in the transcript of human IL-10, rendering it 
highly prone to additional post-transcriptional regulation mechanisms. 
In sharp contrast, EBV genes generally have short UTRs - presumably driven by the 
evolutionary pressure to reduce the risk of unintended cellular regulation to a minimum. 
Accordingly, BCRF1 transcripts comprise a 5’UTR of 44bp and a 3’UTR of just 73 bp. The 
entire transcript lacks both ARE motifs and a consensus sequence for hsa-miR106a.  
Hence, the post-transcriptional regulation of hIL-10 and BCRF1 differs fundamentally 
(figure 4.1B). The low abundance of BCRF1 transcripts might be compensated by a high 
transcript longevity resulting in levels of vIL-10 protein that are obviously sufficient to cause 
the distinct phenotypes.  
 
 
Figure 4.1: Transcriptional and post-transcriptional regulation of hIL-10 and BCRF1. A. Known 
promoter binding sites for hIL-10 (Mahot et al., 2003; Mosser and Zhang, 2008) and predicted binding sites 
for BCRF1 (symbols with dotted outlines, predicition by the PROMO algorithm, Messeguer et al., 2002, and 
Bergbauer et al., 2010). Black arrow: transcriptional start, red arrow: translational start, the scale indicates 
the approximate distance in nucleotides relative to the translational start.  
B. Transcript structure of hIL-10 and BCRF1, boxes indicate translated sequence with black bars 
representing exon-exon junctions. Known sites of posttranscriptional regulation are indicated (Stoecklin et 
al., 2008; Sharma et al., 2009). ARE, AU rich element. 
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1.4 EBV copes with innate and adaptive immunity 
The results of the first part of this study pointed to effective viral mechanisms to evade 
both the innate and adaptive immune response of NK cells and CD8+ T cells, respectively. In 
addition, EBV also impairs the Th1 cytokine secretion of CD4+ T cells. Hence, EBV encodes 
potential modulators of both major arms of the immune system.  
The long-term effects of the immune evasive genes BCRF1 and BNLF2a were analyzed in 
regression assays. This in vitro model revealed an impaired outgrowth of cells infected with 
the double k.o. mutant virus. The impact of deficiency in either BCRF1 or BNLF2a was to 
weak to lead to a detectable effect in vitro. Apparently, only the impairment of both the innate 
and the adaptive arm of the immune system at the same time led to a more efficient immune 
control in this in vitro setting. The immune control was completely lost when CD4+ T cells 
were depleted, but depletion of CD56+ NK cells had a minor effect, only. These findings 
emphasized the importance of CD4+ T cells for in anti-viral immune responses and confirmed 
the role of NK cells in containment of viral infections but minor contribution to the effective 
elimination.  
Both BCRF1 and BNLF2a are classified as early lytic genes (Yuan et al., 2006). In vitro, 
their pronounced effects during the early lytic phase after infection are sufficient to influence 
the overall success of LCL outgrowth in the presence of immune effectors. This observation 
emphasizes the importance of immune evasion during the early lytic phase, which is crucial 
for the establishment of an EBV infection and for the persistence in sero-positive hosts.  
The artificial milieu and technical detection limits of regression experiments in vitro might 
mask additional effects. The obtained results will therefore readily reveal strong effects, but 
not necessarily reflect the same characteristics that regression in vivo would have. Thus, 
regression assays point out a tendency but hardly ever reflect a complete picture. 
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1.5 Concluding remarks 
With a reverse genetics approach, I was able to discover the physiological impact of 
BNLF2a and BCRF1 expression on the immune evasion of EBV during the establishment of 
an infection. I found that BNLF2a is of high importance for infected cells in the early lytic 
phase to evade the CD8+ T cell response. Viral IL-10 was assigned to impair Th1 cytokine 
secretion by CD4+ T cells and to prevent NK cells from eliminating EBV infected B cells, 
contributing a new aspect to the involvement of NK cells to the immune control of EBV 
infection. Furthermore, effects of viral IL-10 could be analogous in other IL-10 encoding 
viruses.  
With regard to BCRF1, obtained data shed new light on the function of this viral cytokine, 
but the mechanism of transcriptional regulation and its perception by effectors demand further 
investigation. The functional redundancy of vIL-10 and hIL-10 could only be partially 
confirmed. How different conformations of vIL-10 and hIL-10 lead to different function 
remains an interesting topic for future investigations.  
Fig. 4.2: Scheme of BNLF2a and BCRF1 mediated immune evasion. BNLF2a impairs epitope loading 
onto MHC I, preventing CD8+ T cell-activity. vIL-10 impairs NK cell- and Th1 CD4+ T cell-activity, 
presumably by attenuated IL10R signaling. TCR, T cell receptor; KIR, killing inhibitory receptor; NK, 
natural killer cell; IL10R, IL-10 receptor; 21, CD21. 
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2. Viron packaged RNAs trigger early events in EBV infection 
The second part of this work focused on events that occur concomitantly to infection but 
influence longterm viral establishment. I could show that EBV particles contain viral RNAs 
and transfer them to their target cells. During the first few hours of infection, this transfer 
renderes the virus independent from de novo transcription. In addition, I could demonstrate 
the functionality of transferred viral RNAs in different experiments and their contribution to 
successful establishment of latent infections of B cells. 
2.1 Which events trigger the initial lytic phase of EBV? 
The classical view of EBV’s life cycle in B cells consisted of the primary establishment of 
latency and eventual reactivation of the lytic phase to give rise to progeny virus. Both phases 
are associated with distinct expression patterns of viral gene subsets. This biphasic life cycle 
has recently been revised, as an initial lytic phase was discovered that follows infection and 
precedes the establishment of latency. In contrast to productively lytic cells, this initial lytic 
phase does not give rise to progeny virus but enhances the establishment of EBV infection 
(Kalla et al., 2010).  
Kalla and colleagues observed the presence of lytic transcripts 1dpi, i.e. the earliest time 
point assessed. I expanded these findings and could demonstrate that these transcripts were 
already present in infected cells as early as 2hpi. Although the kinetics of intracellular capsid 
transport and DNA decapsidation are not known for EBV, it can be deduced from other 
herpes viruses that these RNAs are most likely co-transferred by the virion and do not require 
de novo transcription (Sodeik et al., 1997; Ojala et al., 2000). 
 
This observation led me to investigate EBV particles for the presence of viral RNAs. The 
first report on viral transcripts in Herpes viruses dates from Breshnahan and Shenk for human 
cytomegalovirus (hCMV), followed by similar observations for HSV (Bresnahan and Shenk, 
2000; Sciortino et al., 2001). These findings reshaped the established concept of the infection 
with these viruses, as RNA-transfer had so far not been considered (Roizman, 2000). I could 
find that RNA is also packaged in EBV virions and that it is transferred during the process of 
infection. 
An intial lytic phenotype comparable to that of EBV has also been described for Kaposi 
sarcoma associated Herpes virus (KSHV). Interestingly, also KSHV was found to carry RNAs 
in its virions. These virion transcripts correspond to transcripts that drive KSHV’s initial lytic 
cycle (Krishnan et al., 2004; Bechtel et al., 2005). This renders ransferred RNA a likely 
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trigger of the initial program in KSHV and identical conclusions can be drawn from the data I 
obtained for EBV in this study. The presence of transcripts for the transactivators of the lytic 
switch (BZLF1 and BRLF1) is fundamental in this context. Known to create positive 
feedback loops and to transactivate each other (Miller et al., 2007), the immediate translation 
of BZLF1 and BRLF1 represents the prerequisite to launch the lytic program. Although the 
subsequent onset of this phase during the first few days of infection relies on de novo 
transcription from the viral genome, the initiation likely arises from the translation of 
transferred transcripts of these factors.  
 
2.2 Translation of transferred RNA proves the concept 
The presence of messenger, non-coding and microRNA in EBV particles is a new aspect 
in EBV biology. An effective transfer of mRNA by virus particles however implies their 
translation within infected cells. Previous studies demonstrated the translation of virally 
transferred transcripts for selected examples. Along this line, I could immunoprecipitate 
BRLF1 protein from freshly infected, transcription-inhibited cells and provide first 
biochemical evidence for the translation of transferred RNAs after EBV infection (figure 3.7). 
Additionally, T cell responses constitute a very sensitive assay to detect cellular protein 
synthesis. Misfolding during translation and natural protein turnover leads to protein 
degradation. This process generates peptide fragments of any cellular protein and certain 
peptides from this pool are loaded onto MHC I molecules and presented to cytotoxic CD8+ T 
cells. A presentation of phagocytotically acquired material on MHC I, called “cross-
presentation”, is common for dendritic cells but does not occur in B cells (Rock and Shen, 
2005). Thus, the epitopes that were detected by clonal T cells in my experiments were derived 
from viral protein that had been translated endogenously within the presenting B cell. T cells 
also recognized epitopes from viral proteins on TR– VLP pseudo-infected B cells, which 
indirectly proved the translation of transferred RNA. Epitope presentation was omitted when 
translation was inhibited and further substantiates this interpretation.  
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2.3 Linking RNA transfer to function 
The translation of packaged mRNAs in the recipient cell raised the question whether the 
immediate presence of protein influences any process in the infected cell to a measurable 
extent. In this study, I could directly link the transferred virion RNAs to function and thus 
associate them with distinct effects for the first time. 
2.3.1 Counteracting RNA induced immunogenicity 
The immediate translation of viral RNA in newly infected B cells goes along with 
immediate presentation of foreign peptides. This puts newly infected B cells at risk to become 
eliminated by effector T cells. The presence of several transcripts that give rise to immune 
evasins however points to a viral strategy how to cope with this issue. Indeed, the transfer of 
BNLF2a transcripts led to a detectable impairment of CD8+ T cell responses. The differences 
reached statistical significant levels, though the recognition of infected, but transcription 
inhibited cells was of low. With regard to BNLF2a, the levels of transferred RNA are hence 
far from replacing de novo transcription one day post infection, but do exert function. 
However, faint effects might already be of importance during the first hours of infection – but 
this period cannot be precisely addressed with T cell recognition assays. As BNLF2a was 
among those transcripts that are not de novo transcribed until 8hpi (figure 3.2), the transfer of 
transcripts circumvents this gap and enables BNLF2a function immediately following 
infection.  
Experiments with TR– VLP pseudo-infected cells illustrated that immune responses were 
reduced by BNLF2a albeit not completely prevented. A certain immunological challenge due 
to immediate RNA translation is hence inevitable. To which extent this challenge results in 
the induction of an adaptive immune response and the elimination of freshly infected cells in 
vivo could not be delineated from these data. Apparently, the remaining risk to raise an 
immune response is largely compensated by benefits of RNA transfer for successful infection.  
 
2.4 Effects of non-coding RNA 
In functional analyses of transferred RNAs the experimental settings usually had to 
control for putative protein co-transfer by virions. Non-coding transcripts do not give rise to 
protein and represent the ideal target to analyze functional effects of transferred RNA. EBV 
encodes several forms of non-coding RNAs that include numerous microRNAs and two non-
coding EBV-encoded RNAs (EBER) (Swaminathan, 2008). 
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2.4.1 EBERs and their functions 
EBER1 and EBER2 are two non-coding RNAs of similar length (around 170 nt). They are 
transcribed by polymerase II and III, lack a poly-A tail and are abundantly expressed in all 
EBV infected cells.  
Their presence has been known for decades (Lerner et al., 1981; Rosa et al., 1981) but 
their function is still not fully understood. Several approaches to analyze their role with the 
help of EBER-negative EBV did not result in a defined phenotype and led to controversial 
results (Swaminathan et al., 1991; Komano et al., 1998; Ruf et al., 1999; Gregorovic et al., 
2011). 
However, EBERs induce defined signaling events in infected cells: EBERs form stem 
loop structures that bind to toll-like receptor 3 (TLR3) or retinoid acid inducible gene I  
(RIG-I) (Samanta et al., 2006; Iwakiri et al., 2009). Downstream signaling cascades induce 
IL-10, which promotes B cell survival, and type I Interferons (Ifn-α and Ifn-β). Many events 
can induce IL-10 (Moore et al., 2001) and do not necessarily correlate with EBV infection 
(own observations). In contrast, Ifn-α induction in B cells depends almost exclusively on 
induction by EBERs in the context of an EBV infection. EBERs themselves prevent autocrine 
Ifn-α effects by inhibiting RNA-activated protein kinase (PKR) activation that interrupts 
Ifn-α induced apoptosis signaling (McKenna et al., 2007).  
Hence, the secretion of Ifn-α provided a precise indicator for EBER-induced signaling. 
Accordingly, the generated EBER-deficient virus mutants showed strongly impaired Ifn-α 
induction. These effects were also observed in pseudo-infections with TR– VLP and proved 
that particle packaged EBERs function in the recipient cell. This observation provided strong 
evidence that RNA transfer of Herpes viruses is intended to immediately modulate the 
cellular phenotype. 
2.4.2 MicroRNA regulated immune escape 
Pfeffer and colleagues discovered that EBV encodes microRNAs (miRs)(Pfeffer et al., 
2004), which was followed by analyses on their expression patterns and putative viral and 
cellular targets (Grundhoff et al., 2006; Dolken et al., 2010). The viral transcripts of LMP1 
and BALF5 are targeted by miRs encoded in the BamH1A rightward transcript (BART) 
region (Lo et al., 2007; Barth et al., 2008). Also two cellular targets have been described, 
which interestingly belong to the class of immune stimulatory molecules: CXCL11, a T cell 
attractant, which is targeted by miR BHRF1-3 (Xia et al., 2008), and MICB, an NK cell 
activating membrane molecule, which is targeted by miR BART2-5’ (Nachmani et al., 2009). 
Whereas most investigations of MICB were performed in epithelial cells, I could show that 
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MICB is induced in B cells upon EBV infection (figure 3.11). The comparison of MICB 
levels on B cells that had been infected with recombinant wildtype EBV or microRNA 
deficient EBV showed notably higher levels when microRNAs were absent. This experiment 
illustrated that the described effects of EBV microRNAs in HeLa cells (Nachmani et al., 
2009) were detectable in EBV infected B cells. Furthermoe, this data confirmed functional 
transfer of microRNAs during the process of particle fusion with infected cells. The influence 
of virion incorporated microRNAs on immune responses of the infected cells is an important 
feature, but presumably represents only one aspect out of a multitude of potential effects. The 
observation that EBV miRNAs participate in the establishment of latency and counteract 
apoptosis is of special importance in this regard (Seto et al., 2010). The immediate 
counteraction of apoptosis might represent one of the major advantages that RNA transfer 
confers to the success of EBV infection.  
 
2.5 RNA in particles: a coincidence or a selective mechanism? 
The criteria for RNA packaging into virions can be difficult to analyze and the underlying 
mechanism may be different for each virus. Accordingly, Shenk and colleagues initially 
postulated selective packaging of RNA into CMV particles, but showed a few years later that 
particle transcript levels in virions mirror those of the virus-producing cells (Bresnahan and 
Shenk, 2000; Terhune et al., 2004). For HSV-I, an RNA-interacting protein was described 
that is a virion component and mediates RNA loading of particles and the transfer to the 
cytoplasm of the infected cell (Sciortino et al., 2002). In case of KSHV, exactly those 
transcripts were detected in viral particles that were subsequently responsible for the initiation 
of an early lytic phase comparable to EBV (Bechtel et al., 2005). 
The comparison of transcript levels in viral particles and producer cells in this study was 
based on gp350 as a surface marker for virus producing cells. Gp350 presence on cells gives 
evidence for the completion of the lytic cycle (Al Tabaa et al., 2009) and these cells 
presumably contribute to the highest extent to particles in the supernatant, rendering them the 
model of best fit for EBV producing cells.  
Assuming that viral particles contain a rather different RNA composition than cells, I 
consider comparisons of absolute transcript levels inappropriate as this technique relies on the 
use of equal amounts of RNA. The relative quantification of transcript levels require the 
identification of a housekeeper with stable levels in both particles and cells that could not be 
realized in this work.  
The given data in figure 3.5 are thus preliminary but point to the following model:  
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In lytic cells the high prevalence of viral transcripts causes coincidental packaging into 
particles. In addition, transcripts for certain factors that are crucial for transformation are 
selectively enriched (here detected for LMP1, LMP2AB and EBER1). Upon fusion with a 
target cell, all transcripts are delivered and immediately translated in the cytoplasm of the 
infected cells. Due to the high prevalence of coincidentally packaged transcripts, the 
translational state of the lytic cell of origin is transferred to the new host cell. Within 
translation all factors become functional, including the transcription factors of the lytic 
switch, BZLF1 and BRLF1. The presence of BZLF1 and BRLF1 triggers the early lytic phase 
that, once initiated, is self-sustaining but excludes the expression of late lytic genes. This 
would require a certain pattern of genome methylation, which is missing early after infection 
(Bergbauer et al., 2010). Eventually, the lytic cycle is aborted and the virus switches to 
latency. Thus, the principal intention of transcript transfer might be the immediate provision 
of latency factors that accelerate the establishment of the virus – and result in enhanced 
transformation in vitro. The additional transfer of lytic transcripts might be coincidental, but 
still advantageous. The early lytic phase reactivates the B cell, which is equally essential for 
successful infection. It is likely that the virus has evolved the virion-mediated transfer of 
mRNAs to its advantage, because the immediate mRNA presence confers a robust advantage 
for the establishment of the virus in the cell: The transcripts support cell survival, activate the 
cell, mediate evasion of immune recognition and help to establish a latent infection. 
Interestingly, the detected latent transcripts that are enriched in particles match those that 
are present at stable levels in the first hours of infection (LMP1, LMP2AB, EBER1; figures 
3.2 and 3.5). It remains to be elucidated in which aspect their function is important in the first 
hours of infection. In contrast, BNLF2a also showed stable levels in the first hours after 
infection, but the applied method did not indicate BNLF2a transcript enrichment in particles. 
Hence, how and why viral transcripts are enriched in particles remains a topic for future 
investigation.  
The involvement of the EBV protein EB2 (BMLF1/BSLF1) in the process of RNA 
selection is interesting. The interaction of EB2 with transcripts was allocated to an RNA 
binding “arginine rich motif” (ARM), that shuttles unspliced EBV transcripts from the 
nucleus to the cytoplasm. This function is not restricted to EBV transcripts (Hiriart et al., 
2003a). The mutation of this motif abrogates RNA binding and prevents the incorporation of 
the protein into particles. MutEB2 proteins are still able to shuttle between the nucleus and the 
cytoplasm and the reason why mutEB2 is not incorporated into particles remains obscure. The 
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analysis of EB2-shuttling between sites of virion assembly and the cytoplasm might provide 
new insights to this issue. 
If EB2 is present in spontaneously produced B95.8 virus particles and is indeed an 
important key player in RNA packaging to EBV virions, are challenging open questions for 
the future.  
 
2.6 RNA transfer increases the chances of virus establishment 
To investigate putative effects of RNA transfer on transformation, I applied a modified 
limiting dilution experiment. Doses of B95.8 virus stocks that barely led to transformation of 
primary B cells were supplemented with RNA-carrying, genome-free TR– VLPs. This 
increased the outgrowth rates significantly. Controls did not show this effect and included 
gp350+ exosomes instead of TR– VLP to assess B cell activation that occurs upon CD21 
stimulation (Rock and Shen, 2005). Co-stimulatory signals can increase transformation rates 
in EBV infection (Iskra et al., 2010) and these samples were reliable controls to assign effects 
to TR– VLP contents. As the exosome controls did not change outgrowth rates, TR– VLP-
transferred RNAs are the most likely reason for improved transformation. This improvement 
in successful infection provides the virus with an important advantage that obviously 
compensates for the concomitant hazard of potential immune responses. 
In general, virion assembly is always accompanied by the synthesis and release of virus-
like particles (VLP). VLPs may still be able to fuse with target cells, but lack a viral genome 
and do not establish the virus in the cell. So far considered as an inevitable bystander product 
during virus synthesis, they acquire a functional quality with the observation that VLPs 
contain RNA (here observed for TR– VLP). The virus probably benefits from their presence: 
co-infection of the same cell with virion and VLP increases initial transcript amounts and thus 
promote a faster establishment of infection.  
 
2.7 Concluding remarks 
My data represent the first report of RNA in EBV particles. The function of selected 
transcripts and one microRNA for the process of infection could be demonstrated, such as 
immediate immune evasion. Moreover, RNA transfer most likely represents the so-far 
unknown trigger for the initial lytic cycle in freshly infected B cells (Kalla et al., 2010). 
Despite the fact that EBV is a DNA virus, it also depends on RNA transfer during 
infection, which is surprising but in line with other members of this virus family (Bresnahan 
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and Shenk, 2000; Sciortino et al., 2001; Bechtel et al., 2005). Herpes viruses seem to use this 
strategy to their benefit.  
First experiments support the notion that several transcripts are selectively enriched in the 
virus particles. It remains a challenging task to analyze the underlying molecular mechanisms 
and purpose of this selection. 
Taken together, the presence of RNA in EBV particles sheds new light on the biology of 
the Epstein Barr virus and will probably influence future investigations on this topic. 
 
 
Figure 4.3: Immediate effects of transferred RNA provide a supportive environment for EBV 
establishment. (1) The virus binds to the B cell and is internalized. The acidic milieu of the endosome 
induces the fusion of the virion envelope with the vesicle membrane. (2) The virus capsid and the packaged 
RNAs are released to the cytosol. The immediate translation of messengers and function of non-coding 
RNAs prevent apoptosis, modulate the immune response of the infected cell and trigger cell activating 
signaling. (3) The capsid unloads the viral genome into the nucleus and immediately present viral factors 
initiate the early lytic phase. Effects of transferred RNAs shape an environment that promotes virus 
establishment independently of de novo transcription. Red: packaged viral RNA, green: viral proteins and 
effects. 
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 MATERIAL & METHODS 
1. Material 
1.1 General equipment 
Agarose gel chamber Peqlab, Erlangen 
Bacteria incubator Thermo Fisher, Wlatham, USA 
Blotting apparatus Trans-Blot SD, Bio-Rad, München 
Centrifuges Avanti J-26 XP, Beckman Coulter, Krefeld 
Multifuge 3L-R, Heraeus, Hanau 
5415R, Eppendorf AG, Hamburg 
Electroporation device GenePulser II, BioRad, München 
ELISA plate reader EL-800, BIO-TEK Instruments, Bad Friedrichshall 
FACS machine FACSCalibur, BD, Franklin-Lakes, USA 
FACS sorter FACSAria, BD, Franklin-Lakes, USA 
Film developing machine CP100, AGFA, Mortsel, Belgium 
Fluorescence plate reader Wallac Victor2 1420, PerkinElmer, Rodgau-Jügesheim 
Heating blocks Eppendorf AG, Hamburg 
Hybridization oven Kendro, Langenselbold 
Light Cycler LC480, Roche, Basel, Switzerland 
PCR Cycler Biometra, Göttingen 
pH meter WTW, Weilheim 
Pipets Gilson, Limburg-Offheim 
Brand, Wertheim 
Integra Biosciences, Zizers, Switzerland 
Quantification of nucleic acids nanodrop, PeqLab, Erlangen 
DanaQuant 200, Hoefer, Holliston, USA 
Rotors for ultracentrifuges 70Ti, TFT 75.13, SW28, SW30, TL-100,  
Beckman Coulter, Brea, USA 
SDS PAGE device Hoefer MightySmall, Amersham, Freiburg 
Ultracentrifuges Optima XL70, Beckman Coulter, Brea, USA 
TL-100, Beckman Coulter, Brea, USA 
UV-transilluminator Peqlab, Erlangen 
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1.2 General consumables 
Dialysis membrane Spectra/Por, Spectrumlabs, Breda, Netherlands 
ELISA plates Nunc, Wiesbaden 
Films (autoradiography) Hyperfilm ECL, GE Healthcare, Freiburg 
Hyperfilm MP, GE Healthcare, Freiburg 
NiNTA agarose and columns Qiagen, Hilden 
Nitrocellulose membrane Hybond ECL, GE Healthcare, Freiburg 
Nylon mebrane for nucleic acids Immobilon-NY+, Millipore, Zug, Switzerland 
PCR tubes ThermoStrips, Thermo Scientific 
Pipet tips Gilson, Limburg-Offheim 
Pipet tips with filter Greiner Bio-One, Kremsmünster, Austria 
Polystyrene tubes 15ml, 50ml BD Falcon, Heidelberg 
qPCR 96 well plates for LC480 Roche, Basel, Switzerland 
Reaction vials 1.5ml, 2ml Eppendorf AG, Hamburg 
Sephadex columns NICK columns G50, GE Healthcare, Freiburg 
Tubes for ultracentrifugation Microfuge Tubes 1.5ml, Beckman Coulter, Brea, USA 
Quickseal Tubes, Beckman Coulter, Brea, USA 
UZ PA 38.5, Kisker Biotech, Steinfurt 
 
1.3 Cell culture equipment 
Fluorescence microscope Axiovert200M, Carl Zeiss, Jena 
Incubator (5% CO2) UniEquip, Martinsried 
Irradiation unit Gammacell 40 (Cs137, t ½= 30y), calibration date 
15.06.1979, 125,8 R/min, 
Atomic Energy of Canada Ltd., Ottawa, Canada 
Laminar flow hood (S2) BDK, Sonnenbühl-Genkingen 
Microscope Axiovert25, Carl Zeiss, Jena 
Neubauer Counting chamber Paul-Marienfeld, Königshofen 
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1.4 Cell culture consumables 
96-well round bottom plates Nunc, Wiesbaden 
96-well V-bottom plates Hartenstein, Würzburg 
Cryo tubes Nunc, Wiesbaden 
Culture dishes (ø 10cm,14cm) BD Falcon, Heidelberg 
FACS tubes BD Falcon, Heidelberg 
Filter mesh for 50ml Tube BD Falcon, Heidelberg 
Filter units, 0.8µm pore size Schleicher&Schuell, Dassel 
Flat-bottom plates  
(6-/12-/24-/48-/96-well) 
BD Falcon, Heidelberg 
Needle for BAC extraction  
(CsCl gradient) 
2.1x38mm, Bovivet, Henry Schein Vet, Hamburg 
Roller bottles BD Falcon, Heidelberg 
Serological pipets Greiner, Kremsmünster, Austria 
Syringes, needles and butterflies Dispomed, Gelnhausen 
 
1.5 Media and solutions for cell culture 
Actinomycin D Merck, Darmstadt 
Calcein AM Invitrogen, Karlsruhe 
Cycloheximide Sigma-Aldrich, St.Louis, USA 
Defibrinated sheep blood Hemostat, Dixon, USA 
Fetal calf serum (FCS) Biochrom, Berlin 
Ficoll (“Biocoll”) Biochrom, Berlin 
HygromycinB Invitrogen, Karlsruhe 
IL-2 (Proleukin® S) Novartis, Basel, Switzerland 
MTT Invitrogen, Karlsruhe 
OptiMEM Invitrogen, Karlsruhe 
Polyethylenimine (PEI) (MW=25000) Sigma-Aldrich, St.Louis, USA 
Penicillin/streptomycin Invitrogen, Karlsruhe 
RPMI 1640 Invitrogen, Karlsruhe 
Trypsin/0.5% EDTA Invitrogen, Karlsruhe 
Türk’s solution Merck, Darmstadt 
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1.6 Enzymes for molecular biology 
Restriction enzymes and other DNA modifying enzymes that are not listed below were 
purchased from New England Biolabs, Ipswich, USA, or MBI Fermentas, St.Leon-Rot.  
All enzymes were used with buffers recommended by the supplier. 
DNAse I (bovine pancreas) Roche, Basel, Switzerland 
DNAse I, RNAse free (amp. 
grade) 
Invitrogen, Karlsruhe 
Klenow fragment MBI Fermentas, St. Leon-Rot 
Klenow fragment for radioactive 
labeling 
High Prime DNA Labeling Kit, Roche, Basel, 
Switzerland 
Lysozyme Sigma-Aldrich, St. Louis, USA 
Pfu PCR Stratagene, Amsterdam, Netherlands 
Proteinase K Carl Roth GmbH, Karlsruhe 
qPCR reaction Mix LightCycler® 480 SYBR Green Master I, Roche, Basel, 
Switzerland 
reverse transcriptase SuperScriptIII Kit, Invitrogen, Karlsruhe 
RNAse A Applichem, Darmstadt 
RNAsin Promega, Mannheim 
taq PCR goTaq, Promega, Mannheim 
 
 
1.7 Kits for molecular biology and biochemistry 
Purpose Product 
Determination of protein content BCA assay, ThermoScientific, Waltham, USA 
ELISA human Ifn-γ ELISA Kit, human IL-10 ELISA Kit,  
Mabtech, Nacka Strand, Sweden 
ELISA human Ifn-α lpha Kit (multi-subtype),  
PBL, Piscataway, USA 
Magnetic cell sorting human B cell isolation Kit II, CD56+ MicroBeads 
(human), CD4+ Microbeads (human),  
Miltneyi Biotec, Bergisch-Gladbach 
Multiplex ELISA 11plex Th1/Th2 FlowCytomix,  
BenderMed Systems, Wien, Austria 
Plasmid preparation  
(transfection grade) 
EndoFree Plasmid Maxi Kit, Qiagen, Hilden 
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Preparation of genomic DNA QIAamp DNA Blood Mini Kit, Qiagen, Hilden 
Preparation of microRNA mirVANA Kit, Ambion, Austin, USA 
Preparation of total RNA RNeasy Mini Kit, Qiagen, Hilden 
Purification of DNA NuceloSpin Extract II, Machery-Nagel, Düren 
 
1.8 Chemicals and reagents 
All chemicals and reagents that are not listed below were purchased from Carl Roth GmbH, 
Karlsruhe, or VWR, Darmstadt, or Sigma-Aldrich, St. Louis, USA.  
Agarose Biozym, Hess 
Select Agar Invitrogen, Karlsruhe 
Ethidium bromide Merck, Darmstadt 
γ-P32 dCTP, 3000Ci/mMol Hartmann Analytik, Braunschweig 
Cesium chloride Merck, Darmstadt 
dNTPs Fermentas, St.Leon-Roth 
Protease Inhibitor “completeMini” Roche, Basel, Switzerland 
BSA (crystalline) Applichem, Darmstadt 
MacConkey Agar Invitrogen, Karlsruhe 
HoechstDye 33258 Hoechst, Frankfurt 
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1.9 Media, solutions and buffers 
Alkaline lysis solution I 50mM Glucose, 25mM Tris-HCl pH 8.0, 10mM 
EDTA in H2O, store at RT, add RNAse A (100µg/ml) 
before use 
Alkaline lysis solution II 0.2M NaOH, 0.1% (w/v) SDS,  
do not store, prepare freshly 
Alkaline lysis solution III 3M KAc, 11.5% (v/v) glacial acetic acid in H2O, store 
at 4°C 
Blocking buffer (WB) 5% (w/w) milk powder, 0.1% Tween 20 in 1x TBS 
Church buffer 700ml 10% SDS, 89g Na2HPO4, 4ml H3PO4, 2ml 0.5M 
EDTA, 10g BSA (pre-dilute in 100ml H2O ), adjust pH 
to 7.2 with H3PO4, H2O ad 1000ml,  
heat and keep at 40°C 
DNA loading dye (5x) 50% glycerol, 0.1 M Tris-HCl pH 7.5, 0.1 M EDTA 
pH 8, 0.1% SDS, ca. 1% xylene cyanol, 5% 
bromphenol blue, in ddH2O  
DNA staining buffer (10x) 100mM Tris pH 7.4, 10mM EDTA, 1M NaCl 
ELISA AP substrate (5x) 5mg/ml p-Nitrophenylphosphate (p-NPP), 0.5mM 
MgCl2, 50% Diethanolamine, pH 9.5, store at -20°C 
Laureth broth (LB) 10g tryptone, 5 g yeast extract, 5 g NaCl, H2O ad 1000 
ml, adjusted to pH 7.5 with NaOH, autoclaved 
Lysis buffer “RIPA” 50 mM TrisHCl pH 7.4, 1% (v/v) NP-40, 0.5% DOC, 
0.1% SDS, 137.5mM NaCl, 1% glycerol, 0.5mM 
EDTA pH 8.0, add protease inhibitor, do not stock 
M63 agar (1 liter) 15g agar in 800mlH2O (autoclave), 200ml M63 salt 
solution, 1ml 1M MgSo4•7H2O, 10ml 20% (w/v) 
galactose or 20%DOG+20% glycerol, 5ml biotin 
(0.2mg/ml), 4.5ml L-leucine (10mg/ml), antibiotic as 
selection marker 
M63 salt solution (5x) 10g (NH4)2SO4, 68g KH2PO4, 2.5mg FeSO4•7H2O, 
adjust to pH 7.0 with KOH, add H2O ad 1000ml and 
autoclave 
M9 salt solution 6g Na2HPO4, 3g KH2PO4, 1g NH4Cl, 0.5g NaCl, H2O 
ad 1000ml, autoclave 
PBS 138 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 • 2 
H2O, 1.76 mM KH2PO4 in H2O, ph=7.4 
SDS PAGE running buffer 125mM Tris-HCl, 14.4% (w/v) glycine, 1% (w/v) SDS 
SDS PAGE sample buffer 
(Laemmli) 
62.5mM Tris/HCl (pH 7.4), 20% (v/v) glycerol, 2% 
(w/v) SDS, 5% β-mercaptoethanol, 0.0625% (w/v) 
bromphenol blue 
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SDS PAGE separating gel  
(12.5%, 4 mini-gels) 
8ml separating gel buffer (4x), 10.7ml H2O, 13.3ml 
30%Acrylamid/8%Bisacrylamid, 200µl APS, 30µl 
TEMED 
SDS PAGE stacking gel  
(5%, 4 mini-gels) 
3.75ml stacking gel buffer (4x), 8.75ml H2O, 2.5ml 
30%Acrylamid/8%Bisacrylamid, 100µl APS, 15µl 
TEMED 
Separating gel buffer (4x)  0.5M Tris-HCl (pH 6.8), 0.4% (w/v) SDS 
Special TE 50mM Tris-HCl pH 8.0, 20mM EDTA 
SSC (20x) 175.3g NaCl, 88.2g Sodium citrate dihydrate 
(M=294.1), 800ml 
H2O, adjust to pH 7.0, add H2O to 1000 ml 
Stacking gel buffer (4x)  1,5M Tris-HCl (pH 8,8), 0,4% (w/v) SDS 
Standard TE 10mM Tris-HCl pH 8.0, 0.1 mM EDTA 
TAE (50x) 242 g Tris, 100 ml 0.5M Na2EDTA pH 8.0,  
57.1 ml glacial acetic acid, H2O ad 1000 ml 
TBE (5x) 54 g Tris, 27.5 g H3BO3, 3.72 g Na2EDTA, H2O ad 
1000 ml 
TBS (10x) 24.2 g Tris, 80g NaCl, H2O ad 1000ml 
TfB I (competent bacteria) 30mM KAc, 100mM RbCl, 25mM CaCl2, 50mM 
MnCl2, 15% glycerol, adjust pH to 5.8 (Ac) before 
adding glycerol 
TfB II (competent bacteria) 25mM MOPS, 75mM CaCl2, 25mM RbCl, 15% 
glycerol, adjust to pH 6.5 (KOH) before adding 
glycerol 
Transfer buffer (semi-dry blotting) 39 mM glycine, 48 mM Tris, 0.0375% SDS, 20% 
MeOH 
Washing buffer (WB) 0.1% Tween20 in TBS 
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1.10 Antibodies 
1.10.1 Antibdies for FACS stainings 
Specificity Conjugate Clone Supplier Dilution 
CD3 PE.Cy5 HIT3a BD Pharmingen, Heidelberg 1:50 
CD4 PE RPA-T4 BD Pharmingen, Heidelberg 1:50 
CD8 APC RPA-T8 BioLegend, SanDiego, USA 1:100 
CD19 FITC HIB19 BD Pharmingen, Heidelberg 1:50 
CD56 PE B159 BD Pharmingen, Heidelberg 1:100 
MHC-I PerCP W6/32 BioLegend, SanDiego, USA 1:100 
MHC-II PerCP TÜ39 BD Pharmingen, Heidelberg 1:100 
MICB none* 236511 R&D Systems, Minneapolis, USA  0.5µg/µl 
gp350 none* 72A1 E.Kremmer, HelmholtzZentrum, München not diluted  
(hybridoma SN) 
mouse-Ig APC polyclonal Invitrogen, Karlsruhe 1:500 
* cells were counterstained by anti-mouse-Ig/APC  
 
1.10.2 Antibodies for immune biochemistry 
Specificity Source Clone Supplier Dilution 
(Western blot) 
Rta / BRLF1 mouse 8C12 E.Kremmer, HelmholtzZentrum,  
München 
1:100  
(hybridoma SN) 
Zta / BZLF1 mouse BZ1 E.Kremmer, HelmholtzZentrum,  
München 
1:50  
(hybridoma SN) 
gp350 mouse 72A1 E.Kremmer, HelmholtzZentrum,  
München 
1:5  
(hybridoma SN) 
FLAG® mouse M2 M2, Sigma-Aldrich,  
St.Louis, USA 1:2000 
c-MYC mouse 9E10 E.Kremmer, HelmholtzZentrum,  
München 
1:20  
(hybridoma SN) 
anti-mouse IgG,  
HRP coupled goat polyclonal 
Promega,  
Madison, USA 1:10000 
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1.11 Oligonucleotides 
Oligonucleotides were synthesized by Metabion GmbH, Martinsried.  
1.11.1 Primers for standard PCR: 
PCR Primer name Sequence (5’-3’) product 
size(bp) 
Annealing 
(°C) 
     
BCRF1 intern fw TGGAGCGAAGGTTAGTGGTCAC BCRF1 BCRF1 intern rev ATGGTCTTTGGCTTCAGGGTCC 300 58 
     
common BNLF2a fw GAGCAGGCATAAAAGTCCAA wtBNLF2a BNLF2a wt rev GCCTCACTCTCGAGATGG 188 58 
     
common BNLF2a fw GAGCAGGCATAAAAGTCCAA ΔBNLF2a 
(M1STOP) BNLF2a ko rev CTGTGCCTCACTCTCGACTAGT 192 58 
     
oriP fw GTCTTGGTCCCTGCCTGG oriP oriP rev GGTTAGTAAAAGGGTCCTAAGGAAC 528 53 
     
BNLF2b fw ACGATGGCGGAAACAACTC BNLF2b BNLF2b rev TCCAAAAGGTCAAAGAACAAGG 604 54 
     
common EBV fw ATCGACGTATCGCTGGAAAC  
wt/MABA EBV rev ATCCTGTTCAACGTGGTGGT 348 
B95.8 EBV rev CAGTCCTGATCGTCCTCCTC 489 
EBV 
genotype 
rec. EBV rev CTTGTATGGAGCAGCAGACG 742 
60 
     
     
1.11.2 Primers for maxiEBV cloning 
Replacement Primer name Sequence (5’-3’) 
   
BNLF2aGalK_fw 
177267CCGCAGGCAGAGGACTGCTGCTCTAGCAAAGCACGCTCCAGG
ACGTGTA177316CCTGTTGACAATTAATCATCGGCApGalK BNLF2aSTART 
à BNLF2aGalK 
BNLF2aGalK_rev 
177372TGTCCTTACTGTATAAAAGTCCACGAAAACAGCTGTGCCTCA
CTCTCGA177322TCAGCACTGTCCTGCTCCTT pGalK 
   
BNLF2aSTOP_fw 
177258GAAGAGCCGGGCAGGCCGCAGGCAGAGGACTGCTGCTCTAGC
AAAGCACGCTCCAGGACGTGTA177316ACTAG177322TCGAGAGTG BNLF2aGalk  
à BNLF2aSTOP 
BNLF2aSTOP_rev 
177385CTGGCCTTCTTTCCTTGTCCTTACTGTATAAAAGTCCACGAA
AACAGCTGTGCCTCACTCTCGA177322CTAGT177316TACACGTCCT 
   
EBERGalK_fw 
5930CATTAACCTCAACCACAAAATGGGGGTTGGAGAAAGTAACCAC
ATATACT5979CCTGTTGACAATTAATCATCGGCA pGalK EBER locus  
à GalK 
EBERGalK_rev 
7259GAACTAAGACTGGGTGTCCAGGAAACCCTGTCACAGAATTGAT
TGGCAAAAGG7207TCAGCACTGTCCTGCTCCTT pGalK 
   
bold letters: homology to the EBV genome; superscripted numbers: genomic position of homologous 
sequence in p2089; italic letters: matching sequence in PCR template; subscripted: template vector; 
underlined: complementary region of primer pair. 
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1.11.3 Primers for quantitative PCR 
Target 
(transcript) forward primer (5’-3’) reverse primer (5’-3’) 
product 
size(bp) 
BZLF1 CTGGTGTCCGGGGGATAAT TCCGCAGGTGGCTGCT 107 
BRLF1 CCTGTCTTGGACGAGACCAT AAGGCCTCCTAAGCTCCAAG 100 
BMRF1 CGTGCCAATCTTGAGGTTTT CGGAGGCGTGGTTAAATAAA 116 
BNLF2a TGCTGACGTCTGGGTCCT TGCTTTGCTAGAGCAGCAGT 98 
BCRF1 ACCTTAGGTATGGAGCGAAG GGGAAAATTGTCACATTGGT 110 
BGLF5 TTCGGCCGCTATTAGCTTAG GACGGGGGAATAATCAACCT 75 
BHRF1 CATCTGGAACGGCTTACCTC CCCTTGTTGAATAGGCCATC 82 
BALF1 ACCGCAAACACCACTGTGTA CGCAGTGTACAACGACCACT 75 
LMP1 AGGCTAGGAAGAAGGCCAAA CTGTTCATCTTCGGGTGCTT 109 
LMP2AB ATCGCTGGTGGCAGTATTTT GAGTATGCCAGCGACAATCA 105 
EBNA2 ACATGAACCGGAGTCCCATA TGCGGGGTCTATAGATGGAG 82 
EBER1 GACCTACGCTGCCCTAGAGGTTTTGC CCAGCTGGTACTTGACCGAAGACG 150 
EBER2 GGACAGCCGTTGCCCTAGTGG AGCGGACAAGCCGAATACCCTTC 166 
TAP1 CTCCCTCAGGGCTATGACAC ACACGGTTTCCGGATCAAT 105 
TAP2 AGCATATCGCCTCGACTCAC GATCTCCCGAAGCACTTCCT 105 
GUSB CGCCCTGCCTATCTGTATTC TCCCCACAGGGAGTGTGTAG 91 
 
 
1.11.4 Stem-loop primers and qPCR primers for microRNAs 
Common stem-loop primer start sequence (5’ terminus, 5’-3’):  
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACCTGTAC… 
 
Target 
(microRNA) 
Specific first strand  
primer terminus*(5’-3’) 
qPCR forward primer 
(5’-3’) 
product 
size(bp)** 
BHRF1-1 …CAACTCC AGAGTAACCTGATCAGCCCC 59 
BHRF1-2 3’ …CTCAATT GGCGTATCTTTTGCGGCAGA 59 
BHRF1-3 …CTGTGCT GGCGTAACGGGAAGTGTGTA 59 
BART1 5’ …CCACAGC CGGTCTTAGTGGAAGTGACGT 60 
BART2 5’ …CGCAAGG GCCGGTATTTTCTGCATTCGC 60 
BART3 5’ …CAGCACA GGCGGACCTAGTGTTAGTGT 59 
BART15 …CTCAAGG GGCGGGTCAGTGGTTTTGTTT 60 
 
Common miR-qPCR reverse primer (5’-3’): GTGCAGGGTCCGAGGT 
 
*  first strand synthesis was performed with miR specific stem-loop primers with a common part (5’ terminus) 
forming the stem-loop and a specific part (3’ terminus) annealing to the microRNA 
** product sizes are related to qPCR products generated with the combination of  
miR-specific forward primer (see row) and common qPCR reverse primer 
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1.12 Plasmids 
Plasmid No. 
(AGV database) 
Description 
p509 BZLF1 expression plasmid, lytic phase induction in recombinant producer 
cells  
p2670 BALF4 expression plasmid, used for increased virus synthesis in induced 
producer cells 
p2130 BRLF1 expression plasmid, overexpression in 293 cells (control lysates) 
p2242 gp350 expression plasmid, used for gp350+ exosomes synthesis 
p2104 GFP expression plasmid, used for GFP+ exosome synthesis 
pGalK GalK cassette encoding plasmid, PCR template for synthesis of 
recombination fragments 
p3964 BCRF1-6xHis expression plasmid, generation of recombinant vIL-10 
p3965 hIL-10-6xHis expression plasmid, generation of recombinant hIL-10 
pAACFLAG 
EB2 
EB2-FLAG, used for EB2 overexpression in virus producer cells  
(see also Hiriart et al., 2003a) 
pAACFLAG 
EB2mut 
EB2mutant-FLAG, used for EB2mut overexpression in virus producer 
cells (see also Hiriart et al., 2003a) 
p3866 Cloning vector for prokaryotic kanamycin resistance cassette flanked by 
BCRF1-neighboring homology arms 
1.13 maxiEBV BACs 
Plasmid No.  
(AGV database) 
Name Description 
p2089 recombinant 
wildytpe 
BAC encoding the EBV B95.8 genome, extended for CMV 
promoter driven expression of hygromycin resistance and 
GFP (Delecluse et al., 1998) 
p2114 TR– like p2089, but with deletion of the terminal repeats 
(Delecluse et al., 1999) 
p3912 ΔBCRF1 like p2089, but with the BCRF1-ORF replaced by a 
prokaryotic kanamycin resistance cassette 
p4030 ΔBNLF2a like p2089, but with transmutation of 5 nucleotides at the 
start of the BNLF2a-ORF to a STOP-codon 
p4031 double k.o. like p4030 with additional deletion of the BCRF1-ORF like 
in p3912 
p4661 ΔEBER like p2089 with replacement of both EBER genes by a 
prokaryotic GalK expression cassette 
p4662 TR– ΔEBER like p4661 with replacement of both EBER genes by a 
prokaryotic GalK expression cassette 
For details on cloning and generation of producer clones with maxiEBV-BACs see 
Methods, chapter 2.1.4. 
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1.14 Bacterial strains 
Escherichia coli DH5a F-, F80dlacZDM15, D(lacZYA-argF), U169, deoR, recA1, 
endA1, hsdR17(rk-,mk), supE44, λ-, thi-1, gyrA96, relA1 
Escherichia coli SW105 F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZ M15 ΔlacX74 
deoR recA1 endA1 araD139 Δ(ara, leu) 7649 galU ΔgalK 
rspL nupG [ λcI857 (cro-bioA) <> tet], (from Warming et al., 
2005) 
 
 
1.15 Eukaryotic cell lines 
B95.8 EBV B95.8 infected lymphoblastoid marmoset 
cell line 
(Miller et al., 1972; 
Miller and Lipman, 
1973) 
Raji EBV positive Burkitt lymphoma cell line (Pulvertaft, 1964) 
Daudi Burkitt lymphoma cell line 
subcloned for EBV-loss 
(Klein et al., 1968; 
Nanbo et al., 2002) 
HEK-293 human embryonal kidney cells (Graham et al., 1977) 
293/TR– 2 HEK-293 stably transfected with p2114, 
recombinant TR– VLP producer cell line 
(Delecluse et al., 1998) 
293/2089 HEK-293 stably transfected with p2089, 
recombinant wildtype EBV producer cell line 
(Delecluse et al., 1998) 
293/3912.27 HEK-293 stably transfected with p3912, 
recombinant ΔBCRF1 EBV producer cell line 
established in this study 
293/4030.J9F HEK-293 stably transfected with p4030, 
recombinant ΔBNLF2a EBV producer cell line 
established in this study 
293/4031.J2 HEK-293 stably transfected with p4031, 
recombinant ΔBCRF1ΔBNLF2a (double k.o.) 
EBV producer cell line 
established in this study 
293/4661.36 HEK-293 stably transfected with p4661, 
recombinant ΔEBER EBV producer cell line 
established in this study 
293/TR– 
4662.12 
HEK-293 stably transfected with p4662, 
recombinant TR– ΔEBER VLP producer cell line 
established in this study 
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1.16 EBV specific T cell clones 
EBV specific T cell clones had been raised from PBMCs of EBV positive donors 
according to standard protocols (Moosmann et al., 2010) and were a kind gift from A. 
Moosmann. The following clones and their described epitopes were used: 
short 
name 
clone name epitope  protein of 
epitope origin 
HLA 
restriction 
first identification 
RAK LSK-RAK#17 RAKFKQLL BZLF1 B*0801 (Bogedain et al., 1995) 
QAK LSK-QAK#21 QAKWRLQTL EBNA3a B*0801 (Burrows et al., 1994) 
IED JN-IED#16 IEDPPFNSL LMP2 B*4001 (Lee et al., 1996) 
CLG JG-CLG#18 CLGGLLTMV LMP2 A*0201 (Lee et al., 1993) 
GLC MA-GLC#14 GLCTLVAML BMLF1 A*0201 (Steven et al., 1996) 
YVL MA-YVL#1 YVLDHLIVV BRLF1 A*0201 (Saulquin et al., 2000) 
 
 
1.17 Primary cells 
 
1.17.1 PBMCs 
Peripheral blood mononuclear cells (PBMCs) of healthy donors were derived from 
voluntary blood donations of HLA-typed individuals in accordance to the Helsinki declaration 
of the World medical association on medical research with humans.  
 
1.17.2 Adenoid tissue 
Anonymized adenoid tissue samples from routine adenoidectomies were provided by the 
Department of Otorhinolaryngology, Klinikum Grosshadern, Ludwig-Maximilians-University 
of Munich. The institutional review board (Ethikkommission) of the Klinikum Grosshadern, 
approved of the study and did not require prior informed patient consent. 
 
MATERIAL  1.18 Software 
 97 
1.18 Software 
FACS data FlowJo 9, TreeStar, Ashland, USA 
DNA analysis and vector maps MacVector 10.0, MacVector Inc., Cary, USA 
ELISA analysis KC4, BioTek Inc., Winooski, USA 
FlowCytomixPro 2.3, BenderMedSystems, Wien, Austria 
Image editing Photoshop CS3, Adobe, San Jose, USA 
Illustrator CS3, Adobe, San Jose, USA 
Freehand MX, Macromedia, San Francisco, USA 
Spreadsheet programs and 
statistical analyses 
Excel 2008, Microsoft, Seattle, USA 
Prism 5, GraphPad Software, La Jolla, USA 
qPCR analyses LightCycler480 Software SP3, Roche, Basel, Switzerland 
Word processor Word 2008, Microsoft, Seattle, USA 
Bibliography EndNote X4, ThomsonReuters, San Francisco, USA 
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2. Methods 
2.1 Molecular biology 
2.1.1 Bacterial culture 
Suspension cultures of bacteria were grown in LB medium at 37°C under aerobe 
conditions (shaking with 200rpm). Single cell clones were raised on LB-agar plates. 
Bacteria were selected for resistance by addition of 100µg/ml ampicillin, 30µg/ml 
chloramphenicol or 100µg/ml kanamycin to the medium.  
For long-term storage of bacteria, 500µl of a dense liquid culture were mixed with 500µl of 
100% glycerol and stored at -80°C. 
2.1.2 Generation and transformation of chemically competent bacteria 
To generate stocks of chemically competent bacteria, 5ml of LB medium without 
antibiotics were inoculated with bacteria from a single clone and grown to a dense culture 
(o/n). This culture was expanded to two flasks with 400ml LB medium without antibiotics 
and grown at 30°C until the suspension reached an OD600 of ~0.6 . Bacteria were pelleted by 
centrifugation at 2000 g at 0°C for 10min and kept on ice. All following steps were performed 
on ice in the cold room and pre-chilled materials were used. The pellets were carefully 
resuspended in 80ml TfB I buffer, pooled and centrifuged at 2000 g at 0°C for 10min. The 
supernatant was accurately removed and the pellet was resuspended in 20ml TfBII buffer 
followed by 15min of incubation on ice in the cold room. The suspension was aliquoted, 
shock-frozen on dry-ice and stored at -80°C. The competence in uptake of DNA was 
evaluated by transformation of 50µl competent bacteria with 10pg of plasmid DNA, that 
usually resulted in 50-100 colonies.  
For transformation, competent bacteria were thawed on ice. For each sample, an aliquot of 
50 µl was transferred into pre-chilled Eppendorf tubes and mixed gently with either 10 µl of a 
ligation mixture or 1-10 ng of plasmid DNA. After incubation on ice for 15 min the 
transformation reaction was heat shocked for 45 seconds at 42°C and subsequently placed on 
ice for additional 2 min. Following, the reaction mix was plated on agar plates and incubated 
o/n at 37°C. 
2.1.3 Generation and electroporation of electro-competent bacteria 
Competent bacteria were prepared by pelleting 40ml of liquid bacteria culture  
(OD600 ≈ 0.6) at 2000 g for 10min at 0°C. The following steps were performed on ice and 
prechilled materials were used. Bacteria pellets were carfully resuspended in 1ml H2O by 
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swirling the tubes in an ice-water slurry. 9ml of H2O were added and the bacteria were 
pelleted again. This step was repeated once. After the final washing step, the supernatant was 
carefully removed by briefly inverting the tubes on a paper towel. The pellet was kept on ice 
and resuspended autonomously in the remaining supernatant.  
For electroporation, 25µl of the electro-competent bacteria were mixed with 
approximately 50ng of DNA (5µl of a strong PCR product eluated in 50µl) and transferred to 
a 0.1cm pre-chilled electroporation cuvette. Electroporation was performed at 25µF, 1.75kV 
and 200 Ω, the cuvette was briefly chilled on ice (2min) and bacteria were resuspended in 1ml 
LB medium without antibiotics and left to recover and to express antibiotic resistance factors 
for 1h at 32°C in a shaking incubator. Finally, the cultures were pelleted, resuspended in 50-
100µl and streaked on agar plates with appropriate selection. 
2.1.4 Engineering of recombinant EBV 
The use of recombinant EBV was established by Hammerschmidt and colleagues 
(Delecluse et al., 1998) and is based on an F-factor plasmid carrying the whole EBV genome 
of the B95.8 strain with additionally inserted CMV promoter driven expression cassettes for 
GFP and Hygromycin B phosphotransferase, providing phenotypic markers. A bacterial 
artificial chromosome (BAC) encoding an EBV genome that can give rise to progeny virus 
was termed “maxiEBV”. 
The applied strategies to replace the BCRF1 ORF and to prevent BNLF2a translation are 
depicted in figure 2.1. In analogy to BCRF1, the EBER genes do also not overlap with 
neighboring genes and allowed for a similar straight-forward gene replacement.  
Genomic engineering was carried out by homologous recombination, based on the E.coli 
strain SW105 (Warming et al., 2005). This strain is RecA deficient but carries a λ prophage, 
that encodes RecA under the control of a heat inducible promoter, enabling homologous 
recombination upon heat shock. Furthermore, these bacteria are incompetent to galactose 
metabolism due to the lack of the galK gene, which provides an option for positive and 
negative selection.  
The BCRF1 gene was replaced by a prokaryotic expression cassette of Neomycin 
phosphotransferase II, conferring kanamycin resistance, with flanking arms of 200bp 
homologous to the EBV sequence up- and downstream of the BCRF1 ORF. The whole 
construct of 1500 bp was cut out of the cloning vector p3866 and electroporated into 
recombination competent SW105 bacteria that contained the recombinant wildtype maxiEBV 
p2089. Successful recombination allowed for growth of resistant clones on kanamycin 
containing agar plates (100µg/ml).  
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The EBER genes represent a total fragment of 500bp and were replaced by a GalK 
expression cassette of 700 bp with an integrated BglII restriction site. This product was 
generated by Pfu PCR and the use of the primer pair EBERGalK_fw/rev. The used forward 
primer consisted of the identical sequence as the 50 (non-priming) bases upstream of the  
targeted region and the initial 20 (priming) nucleotides of the galK cassette. The reverse 
primer consisted of the complementary sequence to the 50 (non-priming) bases downstream 
the targeted region and the terminating 20 (priming) nucleotides of the galK cassette. The 
PCR product was electroporated to SW105 bacteria that carried the recombinant wildtype 
EBV genome (p2089) or the TR– genome (p2114) to generate EBV genomes that give rise to 
EBER-deficient EBV virions and EBER-deficient TR– VLPs, respectively. After recovery 
from electroporation, residual amounts of medium were washed three times with M9 salt 
solution and subsequently plated on M63 minimal agar that contained galactose as exclusive 
carbon source. Bacteria were incubated for 5 days at 32°C, five colonies were picked and 
streaked on MacConkey/galactose agar. One bright pink colony from each plate was 
subjected to further analysis.  
Due to a more complex genomic localization, the BNLF2a ORF was not replaced, but 
instead prevented from translation by mutation of 5 nucleotides. The methionine-1 codon was 
replaced with a STOP-codon and a diagnostic SpeI site was inserted (see figure 2.1). This was 
realized by a two-step recombination strategy. First, a Pfu PCR product was generated with 
with the primer pair BNLF2aGalK_fw/rev from the template vector pGalK. As described 
above, the PCR product was electroporated to SW105/p2089 bacteria. The five targeted 
nucleotides were replaced with the galK expression cassette by homologous recombination. 
Positive clones were selected on minimal media plates with galactose as the exclusive carbon 
source, subcloned on MacConkey Agar and analyzed by restriction digests. In a next step, a 
forward primer with the identical 50 homologous bases used before, the desired 5 mutated 
nucleotides and 15 complemetary bases to the reverse primer was used together with a similar 
reverse primer of opposing orientation. After annealing, these primers formed a 20bp double 
strand. 5’overhangs were blunted with Klenow polymerase (Fermentas), column purified 
(Nucleobond Kit, MacheryNagel) and quality checked on an agarose gel. The bacterial clone 
from the previous step was induced for recombination competence, the new fragment was 
electroporated and replaced the galK cassette by homologous recombination. Bacteria were in 
turn counter-selected for galactose metabolism by growth on minimal plates with 2-deoxy-
galactose (DOG, toxic when metabolized) and glycerol as carbon sources.  
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For all engineered maxiEBVs, a restriction digest that generated a knockout specific band 
pattern due to the integrated additional restriction site during gene replacement indicated 
successful gene replacement. Overall BAC integrity was confirmed by uniform band patterns 
upon digestion with restriction enzymes that were not specific for the mutation. Sequencing 
confirmed the generation of the desired sequence at the intended region. 
A detailed description on the procedure can be found in (Warming et al., 2005) and is 
available online at http://web.ncifcrf.gov/research/brb/recombineeringInformation.aspx.  
2.1.5 Isolation of plasmid DNA from bacteria 
Plasmid DNA for transfection was purified from bacteria by matrix-affinity kits (including 
endotoxin removal) in accordance to the manufacturers protocol (Qiagen). 
For enzymatic screening, plasmid DNA was prepared by alkaline lysis (Sambrook and 
Russell, 2001). In brief, bacteria from dense 2ml cultures were pelleted at 6000 g for 5min 
and resuspended in 200µl alkaline lysis solution I (including 50µg RNAse/ml). 200µl freshly 
prepared alkaline lysis solution II, containing 1% SDS and 0.1M NaOH, were added and 
induced lysis of bacteria. Samples were gently inverted several times and incubated for 5min 
at RT. The reaction was neutralized by addition of 200µl prechilled alkaline lysis solution III. 
Samples were shaken vigorously and incubated on ice for 20min. Cellular debris and 
chromosomal DNA were pelleted by centrifugation for 20min at 16000 g and 4°C. Plasmid 
DNA was precipitated from the supernatant by adding 500µl of isopropanol, shaking and 
10min of incubation at RT. DNA was pelleted by centrifugation for 10min at 16000 g, 
washed with EtOH and air-dryed for 10min at RT. The DNA was resuspended in H2O or TE 
and subjected to restriction digests. 
2.1.6 Phenol-chloroform precipitation of DNA 
The volume of the DNA containing solution was defined and 2.5 volumes of a phenol-
chloroform mix (ratio 3:1, Carl Roth GmbH) were added. Following 30 seconds of vortexing, 
aqueous and phenolic phases were separated by 15min of centrifugation at 20000 g. The 
upper phase was transferred into a new tube and the addition of an equal volume of ether 
precipitated residual amounts of phenol. Centrifugation at 16000 g for 5min separated phases 
again. This time, the upper phase was discarded and residual amounts of ether and phenol 
volatilized during incubation for 1min at RT with opened lid in the fume hood. The residual 
volume was determined again and 1/10 volume of 3 M potassium acetate was added. By 
further addition of 3 volumes of isopropanol and thorough mixing DNA began to precipitate. 
After 15min of incubation at RT, DNA was pelleted by centrifugation at 16000 g at 18°C for 
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15min. The supernatant was carefully removed and the pellet was washed with 70% Ethanol, 
centrifuged at 20000 g for 10min, the supernatant was removed and the obtained pellet was 
air-dried for 10min. The purified DNA was finally resuspended in H2O or TE. 
2.1.7 Preparation of high quality maxiEBV BAC DNA 
The establishment of stable virus producer cell lines by transfection of EBV genome-
encoding bacterial artificial chromosomes (maxiEBVs) to 293 cells required DNA of both 
high purity and high integrity. Therefore, a protocol for preparation of maxiEBVs from 
bacteria had been established previously that represents a modified form of alkaline lysis. A 
6ml pre-culture was inoculated with a maxiEBV carrying bacterial clone and incubated o/n. 
Six conical flasks with 400ml LB medium, 24ml 5M NaCl and an antibiotic for selection each 
were prepared and the pre-culture was equally distributed to them. In dependence of the 
bacteria strain, cultures were raised for 18-20h at 37°C or 24-30h at 32°C and bacteria were 
pelleted by centrifugation for 15min at 5000 g at 4°C and subsequently kept on ice. Each 
pellet of the six cultures was carefully resuspended in 10ml of prechilled alkaline lysis 
solution I, before the volume of each tube was adjusted to 45ml by further addition of alkaline 
lysis solution I. 10mg of lysoszyme were added per tube, followed by an incubation on ice for 
5-10min. The addition of 58ml alkaline lysis solution II induced lysis and brief and cautious 
turning without overhead rotation ensured equal distribution. After incubation for 5min on 
ice, lysis was stopped by addition of 70ml of alkaline lysis solution III to each tube. 
Suspensions were immediately homogenized by careful mixing, including overhead rotation. 
The tubes were again incubated on ice for 30min. Debris was pelleted by centrifugation for 
45min at 4°C and 9000 g. Passaging through gauze and a fluted filter further cleared the 
supernatant. The volume of the solution was determined and equally distributed to 4 new 
centrifugation tubes of 500ml capacity. The DNA was precipitated by addition of 0.75 
volumes of isopropanol followed by thorough shaking, 20min of incubation at RT and 
centrifugation at 9000rpm at 20°C for at least 20min. DNA pellets were washed with 200ml 
70% Ethanol, centrifuged as before and subsequently air-dried for 10min. Each pellet was 
carfully resuspended in 10ml Special-TE by slow agitation on a shaking device. All solutions 
were pooled in one tube and incubated at 37° for 15min after 400µg of RNAse had been 
added. Following, contaminating proteins were digested by treatment with 6mg proteinase K 
and incubation at 50°C for 45min.  
In the next step, nicked and supercoiled DNA were separated on a CsCl gradient. 
Therefore, the weight of the DNA solution was determined and 1g of CsCl was added per 
gram of solution. To avoid precipitation, the stepwise addition of CsCl was accompanied by 
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heating in a waterbath. The sample was distributed on two 35ml tubes suitable for 
ultracentrifugation, 1.5ml of a 1% ethidiumbromide (EtBr) solution was added to each tube 
and the residual volume in the vials was filled and balanced for centrifugation with an 
aqueous CsCl solution (ρ =1.55g/ml). The tubes were centrifuged at 100000 g (38000rpm in a 
70Ti rotor) at 20°C for 3 days. After this step, UV light illuminated nicked (upper band) and 
supercoiled (lower band) DNA that had separated due to difference in density. The lower 
band was extracted from the tube by a syringe and needle (bovivet) and transferred to an 
11.5ml tube for ultracentrifugation. 0.5ml EtBr were added and the residual tube volume was 
filled again with aqueous CsCl solution. After further centrifugation at 100000 g at 20°C for 3 
days, the lower band containing supercoiled DNA was extracted as before. DNA was 
precipitated by addition of 5ml (at least 1.5 volumes) CsCl saturated isopropanol and 
centrifugation (4000 g, 30min, RT), which was repeated several times to extract residual EtBr 
at the same time. Finally, the DNA pellet was washed with 75% ethanol and briefly air-dried 
(5min). Depending on the pellet size, 50-200µl of TE were added and left for resuspension for 
2 days at 4°C.  
2.1.8 Measurement of DNA concentration 
DNA concentration was measured by the ratio of light absorption at 260nm and 280nm 
using the nanodrop device and software (Peqlab). Do determine the precise amount of double 
stranded DNA, aliquots of the samples were diluted in DNA staining buffer (10x) and H2O to 
1ml and stained with HoechstDye 33258 (dilution 1:10000) that intercalated in DNA double 
strands and emitted fluorescence (450nm) upon excitation (350nm) measured in a fluorimeter 
(Dynaquant, Hoefer).  
2.1.9 Enzymatic treatment of DNA and agarose gel electrophoresis 
These methods were carried out exactly as previously described (Sambrook and Russell, 
2001). Besides, enzymatic treatment was performed in buffers recommended by the supplier.  
For control digestions of maxiEBVs, all DNA from one miniprep (2ml bacterial culture) 
was analyzed in one restriction digest, as BACs replicate only in low copy numbers. In order 
to distinctly resolve the number and size of fragments that result from restriction digests of 
BACs, gelelectrophoresis was carried out in gels of 25cm length containing 0.8% agarose and 
run overnight at 50V with continuous circulation of running buffer to avoid pH imbalance at 
the electrodes.  
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2.1.10 Southern blottting 
For southern blotting, genomic DNA from eukaryotic cells was extracted using the 
QIAamp DNA Blood MiniKit according to the manufacturers instructions for culture cells. 
3µg of genomic DNA were digested by standard procedures and resolved on a 25cm agarose 
gel in an overnight run to achieve best resolution. DNA ladder sizes were marked with dots of 
ink in the gel that were applied with a needle under UV transillumination. Subsequently, 
nucleic acids were depurinated by 20min of slowly agitated incubation of the gel in 0.75% 
HCl in H2O . This was followed by denaturation in a 1.5M NaCl/0.5M NaOH solution for 
additional 20min. These steps assured single strand conformation of the DNA and improved 
the transfer to the blotting membrane.  
Blotting of the DNA from the gel to a membrane was performed by capillary transfer. The 
agarose gel was placed upside down on impermeable film. A nylon membrane for transfer of 
nucleic acids (Millipore) was placed on the gel and potentially included air bubbles were 
removed. Two whatman filters were pre-wetted in the solution used for denaturation and 
placed on top of the membrane, again avoiding the inclusion of air-bubbles. Capillary transfer 
was induced by placing a 4cm layer of cellulose sheets on top of the filters, additionally 
carrying a uniformly distributed weight of approximately 1 kg. Cellulose was replaced 
whenever liquid reached the uppermost sheets of cellulose. After approximately 2 hours, any 
liquid had been soaked from the gel to the cellulose, indicated by the drastically reduced 
thickness of the gel. 
To mark DNA sizes also on the membrane, ink dots were applied again. The membrane 
was briefly washed in 2xSSC, transferred to a hybridization tube and pre-hybridized with 
10ml of Church buffer in an hybridization oven under rotation at 65°C for about 30min. 
In the meantime of blotting, a suitable DNA probe (preferentially of 300-800bp) was 
radioactively labeled. The template was briefly denatured at 95°C, followed by incubation on 
ice. 50ng of template sequence were resuspended in a total volume of 11µl H2O and incubated 
with 4µl of High Prime mix (Roche) and 5µl of γ-P32 labeled dCTP, corresponding to 50µCi. 
The mix was incubated for 1h at 37°C, before the labeled probe was purified by a Sephadex 
G-50 column (GE Healthcare). The column was equilibrated with 2ml of TE, the labeled 
probe mix was applied and free nucleic acids were washed away by application of 400µl of 
TE. Another 400µl of TE eluted the probe from the column matrix. The successful labeling of 
the probe was verified by measurement of radioactive decays per minute in the sample, which 
exceeded at least exceed 10 millions. Finally, the probe was denaturated again by incubation 
for 10min at 95°C. A hole in the lid of the tube prevented unsnapping during heating. The 
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labeled probe was added to 25ml of Church buffer that replaced the pre-hybridization 
solution. The membrane was then incubated o/n at 65°C under continuous rotation. On the 
next day, the labeling solution was discarded and the membrane was washed with 
0.2xSSC/0.1%SDS repeatedly for 10min at 60°C in a shaking water bath, until the membrane 
emitted less than 100 counts/second (Geiger counter). Finally, the membrane was wrapped 
into saran film and exposed to Hyperfilm MP (GE Healthcare) at -80°C with exposure time 
varying with signal intensity (1d-2weeks). 
2.1.11 RNA extraction 
Total RNA extraction was performed using the RNeasy MiniKit (Qiagen) according to the 
manufacturer’s instructions. In time course analyses, cells were harvested, washed in ice-cold 
PBS and lysed using the lysis buffer of the kit supplied with β-mercaptoethanol to inhibit 
RNAses. Lysates were stored at -80°C until further preparation of all samples of the time 
course. 
In infected samples, a final treatment with RNAse-free DNAse (Invitrogen) was 
mandatory to eliminate contaminations with genomic virus DNA. Thus, the yielded 30µl of 
RNA preparation were treated with 2.5µl of DNAse accompanied by addition of 4µl of 
DNAse buffer (10x, Invitrogen) and 1.5µl of RNAsin (Promega, inhibits RNAse activity) for 
30min at 37°C and subsequently inactivated by incubation at 65°C for 10min. 
MicroRNAs were extracted using the miRvana Kit (Ambion) in accordance to the 
manufacturer’s protocol. Also for microRNA preparations from infected samples a final 
DNAse digestion was mandatory and performed as described above. 
2.1.12 Reverse Transcription 
cDNA was prepared from RNA by SuperScriptIII reverse transcriptase and the 
accompanying kit (Invitrogen). Usually, 1µg of RNA was used for reverse transcription. 
Random hexamer oligonucleotides were used for priming, as EBERs do not carry a polyA-tail 
(polymerase III transcripts). With regards to other transcripts, efficiency of reverse 
transcription did not differ for oligo-dT and random-hexamer priming. 
Reverse transcription of microRNAs relied on stem-loop PCR priming as described 
elsewhere (Chen et al., 2005). In brief, specific RT-primers for each addressed EBV 
microRNA were included in the reverse transcription mix at concentrations of approximately 
1pmol per primer and sample. Each of these primers specifically annealed to 6 nucleotides of 
one mature EBV microRNA and primed reverse transcription. The primer itself formed a 
stem-loop structure, that comprised an identical sequence for all miRNA-primers and served 
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later on as annealing template during quantitative PCR (see also figure 5.1). By this means, 
quantitative PCR can be performed with sequence specificity for miRNAs, despite mature 
miRNA sequences are in principle too short to give rise to a PCR product.  
miRNA-first strand synthesis was also performed with SuperScriptIII, but used a mix of 
specific first-strand primers (max. 10) and followed the depicted PCR cycles: 
1. 16°C for 30min 
2. 30°C for 30sec 
3. 42°C for 30sec  
4. 50°C for 1sec 
5. 85°C for 5min 
 
 
 
 
 
2.1.13 quantitative PCR 
Transcript prevalence was determined by real-time quantitative PCR on 96-well plates in a 
LightCycler®480 (Roche). PCR products were detected by intercalation of SYBRGreen into 
doublestrand DNA and resulting fluorescence. Three technical replicates were included for 
each sample as well as for the negative control that was free of template. The total reaction 
volume was 10µl, containing 5pmol of each primer, 2µl of diluted cDNA template and 5µl of 
2x SYBRGreen Reaction Mix (Roche). Preceding use in qPCR, cDNA stocks had to be 
diluted at least 5-fold with H2O in order to prevent influence of reverse transcription buffers 
on PCR efficiencies. qPCR efficiencies were determined for each primer pair with dilution 
series of LCL cDNA. Relative quantification was calculated with respect to PCR efficiencies 
using LC480 Software Service Pack 3 (Roche). Glutathione synthetase B was used as 
reference transcript for normalization, as it shows steady expression levels in B cells and 
LCLs (de Brouwer et al., 2006). 
60 cycles of step 2 to 3  
Fig. 5.1: Quantitatve assessment 
of microRNAs. A. Reverse 
transcription of microRNAs is 
primed by stem-loop primers with 
specificity for 6 nucleotides of the 
microRNA. B. qPCR is performed 
with a microRNA specifc forward 
primer and a reverse primer that 
anneals to the common stem-loop 
sequence. 
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standard qPCR program:  
1. 95°C 10min  
2. 95°C 10sec 
3. 60°C 10sec, acquisition of fluorescence       
4. 72°C 10sec 
5. 95°C 5sec 
6. 65°C 1sec 
7. continuous heating to 95°C with acquisition of fluorescence (melting curve) 
 
To increase specificity of qPCR on miR cDNA, a touch-down program was applied: 
1. 95°C 10min 
2. 95°C 10sec 
3. touchdown annealing and combined elongation of 1min/cycle  
(including acquisition of fluorescence): 
initial 5 cycles at 70°C  
15 cycles with reduction of annealing temp. of 0.6°C/cycle 
25 cycles with annealing at 60°C 
4. 95°C 15sec 
5. 65°C 10sec 
6. continuous heating to 95°C with acquisition of fluorescence (melting curve) 
 
2.1.14 Standard PCR 
PCR was carried out using goTaq polymerase (Promega) with the supplied buffer. A 
standard mix comprised 20µl and contained 10-100ng template, 10pmol of each primer, 4µl 
goTaq buffer (5x), 0.5µl dNTPs (10mM, Fermentas) and 0.2 µl goTaq polymerase. Addition 
of 1µl DMSO prevented putative secondary structures in template or primers, H2O was added 
to reach 20µl reaction volume.  
A standard PCR program included initial denaturation at 95°C for 2min, annealing of 
primers at a primer-specific temperature for 20sec, product elongation at 72°C for a product-
size dependent time (taq polymerase elongates ~1000bp in 1min) and denaturation at 95°C for 
15sec. Restarting from the annealing step, up to 36 cycles were performed. A final step of 
3min at 72°C enabled completion of abortive elongation reactions of all strands. 
PCR for cloning purpose was performed using Pfu polymerase (Stratagene) that comprises 
a proof-reading feature and shows a drastically reduced error rate in sequence reproduction. 
45 cycles of 
step 2 to 3 
45 cycles of step 2 to 4  
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Pfu polymerase elongates approx. 500bp/min and requires extended elongation time in 
comparison to taq polymerase. Reaction conditions were similar but a special Pfu buffer had 
to be used (supplied by Stratagene). 
2.1.15 EBV genotyping PCR 
The generation of LCLs required the evaluation of the EBV genotype, as potentially also 
field-strain infected cells from EBV positive donors might give rise to growing cultures in 
vitro. To this end, a multiplex PCR was established, that generated PCR products of different 
sizes depending on the virus strain that was present in the cell. The assay included a common 
forward primer annealing in any EBV genome and strain-specific reverse primers. The PCR 
sample was prepared as follows: 
• template of genomic LCL DNA 10-200ng 
• Primer:  EBV common fw  2.5pmol 
  EBV wt/MABA rev 2.5pmol 
  EBV B95.8 rev  2.5pmol 
  EBV rec. rev  2.5pmol 
• dNTPs (10mM)   0.5µl 
• 5x goTaq Buffer   4µl 
• goTaq     0.2µl 
• MgCl2 (25mM)   1µl 
• DMSO     1µl 
• H2O      ad 20µl 
 
The PCR program included the following steps: 
1. 95°C 2min  
2. 60°C 45sec  
3. 72°C 1min 
4. 95°C 30sec 
5. 72°C  3min 
This led to products of 350bp in case of infection with field strain virus (e.g. MABA), of 
500bp in case of infection with the laboratory strain  B95.8 and of 750bp in case of infection 
with recombinant EBV (based on p2089). The assay takes use of the preferential formation of 
short products in PCR reactions to unravel contamination with wildtype-infected cells in 
predominantly recombinant EBV infected cultures.  
34 cycles of step 2 to 5  
Fig. 5.2: Band patterns of  
the EBV genotyping PCR. 
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2.2 Protein biochemistry 
2.2.1 Cell lysis 
Cells were washed in PBS and lysed by 20min of incubation on ice in RIPA buffer, 
containing a protease inhibitor (completeMini, Roche). Cellular debris was pelleted by 
centrifugationfor 20min at 4°C and 16000 g, the supernatant was transferred to a new tube 
and protein content was determined using the BCA protein assay (Pierce). Lysates were 
stored at -20°C or directly subjected to immunoprecipitation or SDS-PAGE. 
2.2.2 Immunoprecipitation of BRLF1 protein from infected cells 2hpi 
Coupling of antibody to beads 
250µl of SepharoseG bead slurry was centrifuged (1000 g, 1min) and liquid was 
discarded. Beads were washed with 1ml of PBS and subsequently incubated o/n with 5ml of 
anti-BRLF1 hybridoma supernatant (clone 8C12) on an orbital shaker at 4°C. Beads were 
pelleted by centrifugation, washed 5 times with PBS and finally resuspended in an equal 
volume of PBS, here 125µl.  
Immunoprecipitation 
2x108 EBV negative Daudi cells were used per sample. Cells were pelleted by 
centrifugation at 300 g for 5min and washed with PBS. Whole cell lysates were prepared in 
RIPA buffer as described, however containing 0.2% SDS to improve results for BRLF1 
protein precipitation and DNAse (Roche, 100 µg/ml final) was added to digest large amounts 
of chromosomal DNA. 30µl of bead slurry that had previously been coupled to BRLF1-
antibody were added to cleared lysates and incubated o/n at 4°C in an orbital shaker. Beads 
were settled by centrifugation and washed 3 times with RIPA Buffer. Finally, Laemmli 
sample buffer was diluted to 2x concentration with RIPA Buffer and 40µl were added to the 
beads. Boiling for 10min at 95°C eluted antibodies and precipitated protein from the beads, 
beads were settled again by centrifugation and the protein containing supernatant was 
subjected to SDS PAGE.  
2.2.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
In this study, electrophoretic separation of protein was performed under denaturating 
conditions by discontinuous SDS PAGE. For analysis, the protein content of all samples was 
adjusted to equal levels by addition of lysis buffer and Laemmli-sample buffer (4x). The 
intended denaturation of protein was achieved by the reducing conditions of the Laemmli 
buffer in combination with heating of the samples to 95°C for 10min.  
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Additionally, this led to homogenous coverage of proteins with SDS and provided a net 
negative charge in dependence of the protein’s size. Hence, separation was driven by electric 
forces, but proteins were effectively separated in order to their size in denatured state and not 
due to their native charges (they are covered by SDS). In this work, separating Hoefer mini 
gels were prepared and consisted of a 12.5% acrylamide containing separating gel and a 
overlaying 5% acrylamide containing stacking gel. Gels were run in a Hoefer Mighty Small 
unit at a current per gel of initial 10mA (stacking gel) and subsequent 25mA (separating gel). 
2.2.4 Immunoblotting 
Protein Transfer to Membranes 
For immunodetection of proteins that had been separated by SDS-PAGE, the proteins 
were transferred to nitrocellulose membranes by semi-dry blotting. Two sheets of whatman 
paper were soaked in blotting buffer and placed on the anode, the nitrocellulose membrane 
was also pre-wetted and placed onto the whatman papers. The gel was carefully positioned on 
top of the membrane and air bubbles were removed. Finally, two whatman papers were used 
to cover the gel and air bubbles were removed again. The  cathode was placed on top and 
protein transfer was performed at 18V for 40min. 
Immunodetection of Proteins on Membranes 
Following the transfer of proteins, the membrane was incubated washing buffer containing 
5% of milk powder for 1 h at RT under agitation. The blocking solution was removed and the 
membrane was rinsed with washing buffer. The blot was subsequently incubated with a 
primary antibody (diluted in washing buffer with 1% BSA and 0.01% azide) under gentle 
shaking for 3h at RT or o/n at 4°C. After washing 3 x 10min with washing buffer, the 
membrane was incubated with an idiotype-specific secondary antibody conjugated to 
horseradish peroxidase (diluted in washing buffer with 3% milkpowder) for 2h at RT. The 
membrane was washed 6 x 5min with washing buffer and incubated for 1min in 
chemiluminescence substrate (Roti®lumin, Carl Roth GmbH). Finally, the membrane was 
placed into a film cassette and bound secondary antibody was detectable by exposure to 
Hyperfilm ECL (GE Healthcare) due to chemiluminescence. 
2.2.5 Purification of His-tagged protein 
His-tagged human IL-10 and viral IL-10 were purified from serum free supernatants of 
transfected 293 cells by Ni-NTA agarose (Qiagen). Columns were loaded with 300µl Ni-NTA 
slurry and beads were allowed to settle down for 30min. Residual liquid was drained and the 
beads were equilibrated with 2ml of 10mM imidazole in RPMI. The supernatant was applied 
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in aliquots of 1ml, inducing a flow-through that supported efficient binding of His-tagged 
protein to the beads. The loaded columns were washed 3 times with 600µl (= two column 
volumes) 20mM imidazole in RPMI, followed by 2 elution steps with 600µl of 400mM 
imidazole in RPMI. Residual amounts of imidazole were removed by o/n dialysis of the 
eluate fractions against PBS through a membran of 10kD exclusion size (Spectrumlabs, 
Netherlands). Finally, protein contents were assessed by BCA assay (Pierce) and purity was 
evaluated by SDS PAGE with subsequent silver stain analysis according to standard protocols 
(Sambrook and Russell, 2001). The final acquisition of IL-10 concentrations was realized by 
pan-specific IL-10 ELISA (Mabtech). 
2.2.6 ELISA 
Kits with suitable antibodies for sandwich ELISA (enzyme-linked immunosorbent assay) 
were used in accordance to the manufacturer’s instructions (Mabtech, Sweden). In brief, 
protein adsorbing plates (Nunc) were coated overnight at 4°C with primary antibody and 
blocked for 1h at RT with 10% FCS in RPMI before culture supernatants were applied 
(100µl/well). Standard concentrations of the cytokine of interest were included in duplicates 
following a √10 dilution: 146,3µl of the starting concentration were applied to the first well 
and 46.3µl thereof were transferred to the next well that already contained 100µl of sample 
matrix liquid, here 10% FCS in RPMI, resulting in a series of 10000-3333-1000-333-100-33-
10-3.3-1 pg/ml. Samples and standards were incubated for 2h at RT, followed by 1h of 
incubation at RT with the second cytokine-specific antibody that was coupled to biotin. In a 
third step, streptavidin coupled alkaline phosphatase (AP) was bound to the biotin of the 
secondary antibody (45min at RT). Finally, the AP substrate p-Nitrophenylphosphate (p-NPP) 
was added and catalyzed to p-Nitrophenol. The intensity of the observed colorshift to yellow 
was photometrically assessed at 405nm wavelength by an ELISA-Reader and, based on the 
integrated standard, cytokine prevalences could be quantified. Between the incubation steps 
with antibody, the wells were washed with 0.05% Tween in PBS. 
Low range ELISA on Ifn-γ was performed in analogy, but comprised blocking for 2h and 
development at 4°C in the dark for 24-48h. The ELISA Kit for multi-subtype human Ifn-α 
included pre-coated plates and was performed as recommended by the manufacturer (PBL, 
USA).  
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2.3 Cell culture 
2.3.1 Culture of stable cell lines 
Cells were cultured in GIBCO®RPMI 1640 medium (Invitrogen), supplemented with 
10% FCS (PAA laboratories), penicillin (100U/ml) and streptomycin (100mg/ml) at 37°C in a 
5% incubator, unless otherwise indicated. 
Suspension cells were splitted by thorough resuspension and dilution with fresh medium. 
Adherent cells were splitted when plates reached confluency. Medium was soaked off and 
cells were washed with PBS. Trypsin was applied in amounts that were sufficient to form a 
covering liquid layer and incubated at 37°C for 5-10min to detach the cells. RPMI medium 
was added and repeated pipetting led to a single cells suspension, which of 1/10 was kept in 
culture and supplied with fresh medium.  
2.3.2 Culture for EBV-specific CD8+ T cell clones 
T cells clones had been generated from PBMCs of EBV positive donors as previously 
described (Moosmann et al., 2010) and were a kind gift of Dr. A. Moosmann. Cells were 
cultured on 96-well round-bottom plates (200µl/well) in medium supplied with IL-2 
(1000U/ml) and 0.2nM selenium. Every two weeks, T cells were stimulated with a mix of 
feeder cells. Therefore, LCLs of matching HLA and not specified PBMCs of three different 
donors were irradiated (50 Gy). A feeder mix consisting of 1x105 irradiated LCLs and 1x106 
irradiated PBMCs per ml medium (containing selenium and IL-2) was prepared, T cells were 
harvested, deprived of old medium and resuspended in the feeder mix. The suspensions were 
plated on 96-well plates. In parallel, the lack of growth of pure feeder mix cultures controlled 
for successful feeder inactivation.  
Depending on the T cell growth, cells were splitted at a 1:2 ratio (max.) and/or supplied 
with fresh medium. The clonal specificity of the culture was regularly assessed by multimer-
staining for the respective TCR and subsequent FACS analysis. 
2.3.3 Freezing and thawing of eukaryotic cells 
Cells were centrifuged for 5min at 300 g and resuspended in 500µl cold FCS (100%). 
During centrifugation, cryo-tubes (Nunc) were labeled and preloaded with 500µl of 20% 
DMSO in FCS (cold). The cells in FCS were mixed with the freezing solution in the tube, 
adjusting the final concentration of DMSO to 10%, the tubes were kept on ice and transferred 
to -80°C. For long-term storage, frozen cells were kept in the gaseous phase above liquid 
nitrogen (-192°C).  
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Cell stocks were thawed by brief incubation in a 37°C waterbath, followed by immediate 
transfer to 50ml of fresh medium or PBS. Cells were centrifuged at 300 g for 5min at RT, 
carefully resuspended in an appropriate amount of medium and plated in a suitable culture 
vial. 
2.3.4 Transfection of 293 cells 
For transfection, 293 cell cultures were cultured to ~70% density before medium was 
replaced with OptiMEM (Invitrogen). Polyethylenimine (PEI, MW=25000) diluted 1:1000 
(w/v) in sterile H2O was used for transfection. Depending on the culture size, the following 
parameters were applied:  
culture dish 6-well (ø 3.5 cm) 14 cm dish 
seeded cells 5x105 1x107 
volume of OptiMEM on cells 1 ml 13 ml 
amount of transfected DNA 1-1.5 µg 15-30 µg 
dilution of DNA 100 µl OptiMEM 1 ml OptiMEM 
amount of PEI (1:1000 dil.) 9 µl 120 µl 
resupension of PEI in 100 µl OptiMEM 1 ml OptiMEM 
incubation stir PEI/OptiMEM mix vigorously, incubate at RT for max. 
5min, combine with DNA/OptiMEM, incubate for 20min, 
apply dropwise to cells, incubate overnight or at least 6h  
supply with full RPMI  
the following day 
 2.5 ml 20 ml 
 
2.3.5 Generation of virus producer cells 
1µg of high quality maxiEBV DNA was transfected to 293 cells as described. After 2 
days, success of transfection was verified by GFP fluorescence, cells were trypsinized and 
plated on a 14cm culture dish. The addition of 80µg of hygromycin (Invitrogen) per ml 
medium selected for stably transfected clones and during the first week repeated change of 
medium removed large amounts of dead cells. After 3 weeks of culture, visible clones of 
growing cells formed. GFP+ clones were transferred by trypsin-soaked whatman snippets to 
24-well plates and were further expanded. They were tested for virus production capacities by 
transfection as described in the next chapter. Frozen stocks were prepared for best virus 
producers and their respective genotypes were confirmed by southern blotting.  
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2.3.6 Induction of virus production in recombinant producer cell lines 
For virus induction, producer cells were transfected by standard procedures as described in 
chapter 2.3.4. The transfection of a BZLF1 expression plasmid (p509, 1µg/6well) induced the 
lytic cycle in producer cells and was combined with the transfection of BALF4 (p2670, 
0.3µg/6-well) that improved virus packaging and infectiousness (Delecluse et al., 1998; 
Neuhierl et al., 2002). Virus containing supernatant was harvested 3 days after transfection 
and centrifuged at 300 g for 5min to pellet accidentally transferred cells, followed by 
centrifugation at 2000 g for 10min to pellet cellular debris. Supernatants were stored at 4°C 
and did not show significant change in functional virus titers up to one year after production. 
2.3.7 Virus titration 
Recombinantly produced EBV encodes GFP as a phenotypic marker. Hence, cells express 
GFP upon infection with recombinant virus that serves to determine the titers of recombinant 
virus supernatants. To this end, 5x104 Raji cells were infected with 50, 100 and 200 µl of the 
recombinant supernatant and the percentage of GFP+ was assessed by FACS on day 3 after 
infection. The percentage of GFP+ cells was used to calculate how many of the Raji cells had 
turned green and thus how many infectious events, termed “green Raji units” (GRU), had 
been contained in the applied amount of supernatant. A certain variance of this method was 
kept to a minimum by subsequent back-titrations. Therein, the infection of 10% out of 5x104 
Raji cells was intended and the calculated amount of supernatant was applied. The amount of 
infected cells was again assessed by FACS 3dpi and repetitions with empirical adjustment of 
applied virus supernatants were performed, until a certain volume of each assessed virus 
supernatant had been determined that led to the intended infection rate (tolerated variance: 
±10% of the observed value). This represented the basis for the comparisons of virus 
functions in subsequent experiments.  
 
A schematic workflow of the procedure to generate recombinant EBV is depicted in figure 
5.3. 
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2.3.8 Harvest of virus from spontaneously lytic B95.8 cells 
The marmoset derived lymphoblastoid cell line B95.8 was identified to spontaneously 
produce EBV in significant amounts and gave rise to the laboratory virus strain B95.8 (Miller 
et al., 1972). Virus production peaks when cultures are stressed due to high density, starvation 
and acidic medium, for example. Production of B95.8 supernatants was thus realized by 
raising dense cultures until splitting was indicated, but were incubated for another 8-10 days. 
Supernatants were harvested and disburdened from cells and debris by centrifugation as 
described in chapter 2.3.6. Titers of functional virus were assessed by limiting dilution assays 
as described in chapter 2.4.6.  
2.3.9 Enrichment of virus particles by ultracentrifugation 
For virus concentration, supernatants were harvested as described. Following pelleting of 
debris, the supernantants were filtered through a PVDF membrane of 0.8µm pore size to 
further eliminate fine debris. Fractions of 35ml per bucket were subjected to 
ultracentrifugation at 100000 g (25000rpm in SW28 rotor) for 2.5h, supernatants were soaked 
of and pellets were carefully resuspended. This technique allowed for approximately 50x 
enrichment of virus particle load. These concentrated supernatants were either used for 
infection or further processed for RNA preparation.  
2.3.10 Preparation of particles for RNA purification 
Particle concentrates were subjected to RNAse (Sigma) and DNAseI (Roche) digestion 
(both at 10µg/ml final concentration) for 20min at RT to eliminate unprotected nucleic acids 
in the supernatant. Subsequently, the supernatant was distributed to 1.5ml tubes for 
ultracentrifugation and centrifuged at 48000 rpm at 4°C for 1h. Pelleted particles were then 
subjected to standard preparation of total RNA or microRNA using the RNeasy kit (Qiagen, 
see chapter 2.1.11).  
 
A schematic workflow of particle concentration and RNA preparation is depicted in figure 
5.4. 
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2.3.11 Preparation of PBMCs from blood 
Peripheral blood monocytic cells (PBMCs) were derived from voluntary blood donations 
of healthy adults or from buffy coats purchased from the university clinics in Ulm, Germany. 
Buffy coats were diluted 1:1 with PBS prior to PBMC preparation. 35ml of blood or buffy 
coat dilution were underlaid by 12ml of Ficoll-Hypaque (“Biocoll”, Biochrom AG). PBMCs 
were enriched at the separating layer between Ficoll and blood plasma by centrifugation at 
1000 g for 25min. PBMCs were transferred to a new tube, washed 4 times in PBS and used 
for experiments or subjected to cell sorting. PBMCs of an healthy individual contained among 
other cells 40-60% CD4+ T cells, 10-20% CD8+ T cells, 5-15% B cells and 10-25% NK 
cells. 
2.3.12 Preparation of cells from human adenoids 
Adenoids are tissue of lymphoid origin that eventually grows in the oropharynx and 
predominantly contains B cells. Adenoids eventually develop in young children, can hamper 
breathing and need to be surgically removed. Anonymized tissue samples were provided by 
the departments of orthorhinolaryngology of the Klinikum Grosshadern, Munich, and the 
Klinikum Dritter Orden, Munich. The tissue was mechanically dissected and passed through a 
mesh filter to obtain a single cell suspension. T cells were rosetted by addition of 1ml sheep 
blood. The volume was adjusted to 35ml by PBS and monocytic cells were separated by a 
Ficoll-Hypaque gradient as described. 
2.3.13 FACS analysis of cells 
Size, granularity and fluorescence features of single cells can be assessed by fluorescence 
activated cell sorting (FACS). Enodgenously expressed fluorescing molecules can be assessed 
directly, but surface molecules of the cell require staining with antibodies that are conjugated 
to or counterstained with fluorophores. For FACS analysis, up to 5x105 cells were washed in 
PBS and stained with 30µl of antibody diluted in PBS and incubated 15min on ice in the dark. 
Cells were washed with excess of PBS and either counterstained with a secondary antibody in 
the same manner or directly subjected to FACS analysis. In this study, FACS data were 
acquired on a FACSCalibur (BD, USA) featuring two lasers with 408nm and 633nm 
excitation wavelength, respectively, and a beam setup that allowed for 4 different 
fluorescence detection channels.  
2.3.14 Specific TCR staining by multimers 
T cell specificity was assessed by staining of the TCR with multimers (ProImmune, 
Oxford, UK) that mimic peptide loaded MHC complexes and bind specifically to T cells with 
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matching TCR. To this end, 3x105 cells were washed in PBS and stained in 30µl multimer 
dilution (1:100) in PBS at RT for 15min. The samples were washed again in PBS and 
counterstained with Pro5 Fluorotag R-PE (ProImmune, Oxford, UK) dilution (1:100) in PBS 
on ice for 10min. In parallel, samples were stained for CD8 as a pan-specific marker for 
cytotoxic T cells. These stainings confirmed T cell clonality by showing exclusively CD8+ 
multimer+ double stained cells and deficiency in CD8+ cells of non-multimer specificity. 
2.3.15 Cell sorting 
Fluorescence based – FACSAria 
The term ‘fluorescence acquired cell sorting’ (FACS) refers to the acquistion of data on 
cell populations without recovering the cells after this process. It was then expanded for the 
option to recover these populations as purified fractions of living cells. Staining procedures 
are similar to normal FACS analysis, but require upscaling, as usually higher cell numbers are 
assessed, and mesh-filtration of the suspension to prevent clogging. The FACSAria cell sorter 
has a similar setup as the FACSCalibur, however extended for the option to sort cell 
containing drops into tubes or plates at defined positions. For reliable sorting, it is of essential 
importance to establish a stable stream with constant drop positions and to initially define the 
positions where these drops have to be sorted to. The desired cell populations need to be 
defined with regards to their fluorescence properties and are assigned to the tube they are 
sorted to. The detection of fluorescence and the applied pressure to the cells limits the sorting 
speed to some extent and, most importantly, also the cell types that support sorting (large cells 
or trypsinized cells are less suitable). In a final step, the result of sorting is evaluated by 
reanalysis of the fractions that should show highly enriched populations of the desired cell 
types. 
Magnetic cell sorting – MACS 
Magnetic cell sorting provides a convenient and gentle option to fractionize cells. 
However, it is limited to one parameter per sort. In this study, B cells were separated by the B 
cell isolation kit II (negative sort), NK and NKT cells were sorted by the CD56+ isolation kit 
and CD4+ T cells were sorted by the CD4+ isolation kit (Miltenyi Biotech). In brief, cells 
were stained with antibodies that were directly coupled to magnetic beads or biotin coupled 
and subsequently counterstained with streptavidin coupled magnetic beads. Cells were then 
applied to a matrix that was located in a magnetic field. Labeled cells (= positive sort) were 
retained in the field and separated from unlabeled cells (= negative sort) by repeated washing 
of the column. Retained cells were eluted after the column had been detached from the 
magnetic field. The purity of the obtained fractions was assessed by subsequent FACS 
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analysis. In this study, MACS separations with a purity of >90% were accepted for further 
experimentation. 
2.3.16 Assessment of cell vitality by MTT 
The vitality of cells can be assessed by an MTT assay (Mosmann, 1983). Living cells 
catalyze MTT (dimethyl-thiazolyl-diphenyl-tetrazolium-bromide, yellow) by mitochondrial 
reductases to formazan that precipitates as purple crystals in the cell. To test for the presence 
of living cells, 10µl of a MTT stock solution (5mg/ml in PBS) were added per 100µl of cell 
culture volume and incubated for 3 hours in a standard cell incubator. 10µl of 10%SDS were 
added per 100µl cell culture and incubated o/n at RT to dissolve cells and formazan crystals. 
Absorption of light at 595 nm was assessed and an OD595 ≥ 0.5 indicated a vital culture. 
2.3.17 Cell counting 
Cells were counted in a Neubauer counting chamber. 10µl of the cell suspension were 
mixed with 10µl of 0.2% (w/v) trypan blue in PBS to stain dead cells. Unstained cells of all 
quadrants were counted, the value divided by two and the resulting number multiplied with 
1x104 to obtain the amount of present living cells per ml. PBMCs and adenoid cells were 
counted after staining with Türk’s solution (ready to use, Merck) that lysed contaminating 
erythrocytes. 
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2.4 Functional assays with living cells 
2.4.1 Infection of B cells 
B cells were infected with EBV at highest efficiency when a multiplicity of infection 
(MoI) of 0.1 GRU/B cell was applied. Primary B cells show an infection rate of 
approximately 80% at this MoI, due to a 10-fold less efficient infection of Raji cells with 
EBV. Infectious supernatant of defined GRU content were added to primary B cells and 
incubated overnight at 37°C and continuous rotation. On the next day, cells were centrifuged, 
supplied with fresh medium and plated in standard wells for continued culture in a standard 
cell incubator. This strategy resulted in less dead cells upon infection, equal infection even 
with low titer supernatants and provided the cells with completely fresh medium after several 
hours in virus containing supernatant of low nutritive quality.  
2.4.2 Inhibition of transcription and translation. 
The chemical compounds ActinomycinD (Calbiochem) and Cycloheximide (Sigma) were 
used to inhibit transcription or translation, respectively. The necessary concentrations were 
elucidated by titration and the assessment of c-MYC transcripts and protein. In this study, 5µg 
ActD/ml were determined to inhibit transcription and 25µg CHX/ml were determined to 
inhibit translation in 5x106 Daudi cells /ml. In infection experiments, the complete inhibition 
was ascertained by pre-incubation of the cells with the respective inhibitor 15min prior to 
addition of the virus. 
2.4.3 T cell recognition assays 
Recognition of EBV infected B cells by EBV specific CD+ T cell clones was analyzed by 
Ifn-γ ELISA. B cells were isolated using the B cell isolation Kit II (Miltenyi) from blood of 
donors with a matching HLA allele. They were infected with a MoI of 0.1 GRU/cell and 
assayed for recognition at the indicated day after infection. For recognition assays, triplicates 
of 10000 specific T cells and 20000 infected B cells were co-incubated for 18 hours on 96-
well V-bottom plates in total volumes of 200µl. Ifn-γ levels were measured by ELISA 
(Mabtech) with 100µl of cell free supernatant from these co-cultures. Sample values were 
subtracted from putatively obtained basal Ifn-γ secretion of 10000 T cells without targets. In 
time course analyses, Ifn-γ values were normalized to the value of T cells that were 
coincubated with established LCLs of matching HLA (this value was set to 1). The 
normalization corrected for putative unequal performance of the T cells during the time 
course and inaccuracies of T cell counting. 
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2.4.4 Cytokine response of complete PBMCs to EBV infection 
5x106 PBMCs of an EBV-positive donor were infected at a MoI of 0.1 GRU/B cell and 
incubated in 2ml, which of 500µl were sampled for analysis and replaced with fresh medium 
every three days. For analysis of Th1 and Th2 cytokines, the Th1/Th2 11plex FlowCytomix 
Kit (BenderMedSystems) was used according to the manufacturers instructions. Antibody 
coated beads of the kit were mixed and incubated with the sample. Soluble biotin-coupled 
antibodies against the analytes were added, followed by counterstaining with streptavidin-PE. 
Analyte prevalence was derived from PE signal intensity of the sample. Size and APC 
fluorescence of the beads defined the respective analyte. Data were acquired on a 
FACSCalibur (BD) and analyzed with FlowCytomixTM Pro 2.4 software 
(BenderMedSystems).  
2.4.5 Killing assays with NK cells 
The cytotoxic activity of NK cells towards infected B cells was assessed by Calcein 
release from lysed cells as described in a previous report (Wiesner et al., 2008). B cells were 
isolated from PBMCs as described above, EBV infected and cultured for three days. On day 3 
after infection, autologous CD56+ cells and CD4+ cells were isolated by positive MACS sort 
(Miltenyi). Infected B cells were labeled with calcein (Calcein-AM, Invitrogen) by incubation 
of 2x106 cells in 500µl medium containing 10µg/m Calcein-AM for 30min at 37°C. 
Subsequently, cells were washed three times in an excess of PBS and counted. Defined ratios 
of effector (NK) and target (B) cells were then incubated together in 96-well V-bottom plates, 
with 1 unit representing 1000 cells in a total volume of 200µl. After three hours, fluorescence 
Figure 5.5: FACS based Multiplex ELISA. Different bead sizes resulted in two distinct populations in 
the FSC/SSC analysis (left panel). Both populations were gated and plotted for APC and PE values. The 
combination of bead size and defined APC values discriminated the eleven analytes, respective PE 
signal intensity indicated the prevalence of the analyte in the sample.  
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of the supernatant was measured in a Wallac Victor plate reader (Perkin-Elmer). Values were 
corrected for spontaneous release of calcein by subtraction of the value obtained with labeled 
cells without effectors (negative control). Maximum lysis of cells was induced by addition of 
detergent (TritonX, 0.5% final, positive control) and also corrected for spontaneous release. 
Specific lysis represents the ratio of corrected sample values to corrected maximum lysis 
values. 
2.4.6 Limiting dilutions and regression assays 
The transformation capacities of the recombinant viruses were assessed by limiting 
dilution of the virus as described (Wilson and May, 2001). In brief, serial dilutions of virus 
were added to 48 replicates of 1x105 B cells prepared from adenoids in 96-well flat bottom 
plates and incubated for 6 weeks with weekly supply of fresh medium. The presence of living 
cells was analyzed by MTT assay. 
Regression assays assessed the successful establishment of virus infections in the presence 
of immune effectors. To this end, PBMCs were used in total or depleted of the CD56+ or 
CD4+ cells by magnetic cell sorting (Miltenyi) and infected overnight with a MoI of 0.1 
GRU/B cell. After supplying fresh medium, cells were plated in 24 replicates on 96-well flat 
bottom plates in doubling dilutions, ranging from 100000 to 100 cells/well. After 6 weeks of 
culture with weekly supply of fresh medium, the number of wells with growing cells was 
assessed by MTT assay. 
The principle of this assay has been described before (Rickinson et al., 1984) and in case 
of complete PBMCs leads to a characteristic distribution of wells with growing cells: i) at low 
cell numbers/well the present amount of B cells is insufficient to form a growing culture, ii) at 
intermediate cell numbers/well, infected B cells can form a LCL culture and insufficient 
amounts of effectors do not hamper B cell growth, iii) at high cell numbers/well, the amount 
of B cells would be sufficient for outgrowth, but effectors are present in sufficient amounts to 
eliminate infected cells. The sequence of (i) not growing / (ii) growing / (iii) not growing cells 
follows a logarithmic Gaussian distribution. The effects of virus mutants on succesful 
outgrowth in presence of effector cells was determined by comparison of these distributions 
for similarity (see also figures 2.10 and 2.11). 
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 ABBREVIATIONS 
 
aa  Amino acid 
ActD Actinomycin D 
AP Alkaline phosphatase 
APC Allophycocyanin 
APS Ammonium persulfate 
ARE AU rich element 
ARM Arginine rich motif 
BAC Bacterial artificial chromosome 
BL Burkitt lymphoma 
bp Base pair 
CD Cluster of differentiation 
cDNA Complementary DNA 
CHX Cycloheximide 
Cy5 Cyanine 5 
dpi Day(s) post infection 
E Early 
EBV Epstein-Barr virus 
ELISA Enzyme linked immunosorbent assay 
ER endoplasmatic reticulum 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
g Relative centrifugal force 
GFP Green fluorescent protein 
gp Glycoprotein 
GRU Green Raji unit 
Gy Gray, absorbed dose of ionizing 
radiation 
hCMV Human Cytomegalovirus 
HHV Human Herpes virus 
HLA Human leukocyte antigen 
hpi Hour(s) post infection 
HSV I Herpes simplex virus I 
IE Immediate early 
Ifn Interferon 
Ig Immunoglobulin 
IL Interleukin 
IM Infectious mononucleosis 
IS Immune system 
KSHV Kaposi sarcoma Herpes virus 
KIR Killing inhibitory receptor 
LCL Lymphoblastoid cell line 
maxiEBV EBV-genome encoding BAC 
MFI Mean fluorescence intensity 
MHC  Major histocompatibility complex 
miR MicroRNA 
MoI Multiplicity of infection 
mRNA Messenger RNA 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
n.d. Not detected 
NK Natural killer cell 
NKT Natural killer T cells 
NPC Naso-pharynx carcinoma 
nt Nucleotide 
o/n Overnight 
OD Optical density 
ORF Open reading frame 
p-NPP  Phospho-nitrophenyl phosphate 
PAGE Polyacrylamide gelelectrophoresis 
PAMP Pathogen associated molecular pattern 
PBMC  Peripheral blood monocytic cells 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PEI Polyethylenimine 
PEL Primary effusion lymphoma 
PerCP Peridinin Chlorophyll protein complex 
PRR PAMP recognition receptor 
PTLD Post transplant lymphoproliferative 
disease 
qPCR Quantitative PCR 
R2 Coefficient of determination 
rpm Rounds per minute 
RT Room temperature 
SDS Sodium dodecylsulfate 
TAP Transporter associated with antigen 
processing 
TBS Tris buffered saline 
TCR T cell receptor 
Th T helper cell 
TNF Tumor necrosis factor 
TR Terminal repeat 
TTP Tristetraprolin 
XLD X-linked lymphoproliferative disease 
LITERATURE  
 125 
 LITERATURE  
 
Akdis, C.A., and Blaser, K. (2001). Mechanisms of interleukin-10-mediated immune 
suppression. Immunology 103, 131-136. 
Al Tabaa, Y., Tuaillon, E., Bollore, K., Foulongne, V., Petitjean, G., Seigneurin, J.M., 
Duperray, C., Desgranges, C., and Vendrell, J.P. (2009). Functional Epstein-Barr virus 
reservoir in plasma cells derived from infected peripheral blood memory B cells. Blood 113, 
604-611. 
Altmann, M., and Hammerschmidt, W. (2005). Epstein-Barr virus provides a new paradigm: a 
requirement for the immediate inhibition of apoptosis. PLoS Biol 3, e404. 
Ambagala, A.P., Gopinath, R.S., and Srikumaran, S. (2003). Inhibition of TAP by pseudorabies 
virus is independent of its vhs activity. Virus Res 96, 37-48. 
Amon, W., Binne, U.K., Bryant, H., Jenkins, P.J., Karstegl, C.E., and Farrell, P.J. (2004). Lytic 
cycle gene regulation of Epstein-Barr virus. J Virol 78, 13460-13469. 
Baer, R., Bankier, A.T., Biggin, M.D., Deininger, P.L., Farrell, P.J., Gibson, T.J., Hatfull, G., 
Hudson, G.S., Satchwell, S.C., Seguin, C., and et al. (1984). DNA sequence and expression 
of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211. 
Barth, S., Pfuhl, T., Mamiani, A., Ehses, C., Roemer, K., Kremmer, E., Jaker, C., Hock, J., 
Meister, G., and Grasser, F.A. (2008). Epstein-Barr virus-encoded microRNA miR-BART2 
down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 36, 666-675. 
Batisse, J., Manet, E., Middeldorp, J., Sergeant, A., and Gruffat, H. (2005). Epstein-Barr virus 
mRNA export factor EB2 is essential for intranuclear capsid assembly and production of 
gp350. J Virol 79, 14102-14111. 
Bayliss, G.J., and Wolf, H. (1981). The regulated expression of Epstein-Barr virus. III. Proteins 
specified by EBV during the lytic cycle. J Gen Virol 56, 105-118. 
Bechtel, J., Grundhoff, A., and Ganem, D. (2005). RNAs in the virion of Kaposi's sarcoma-
associated herpesvirus. J Virol 79, 10138-10146. 
Beck, S., and Barrell, B.G. (1988). Human cytomegalovirus encodes a glycoprotein 
homologous to MHC class-I antigens. Nature 331, 269-272. 
Bejarano, M.T., and Masucci, M.G. (1998). Interleukin-10 abrogates the inhibition of Epstein-
Barr virus-induced B-cell transformation by memory T-cell responses. Blood 92, 4256-
4262. 
Berg, D.J., Leach, M.W., Kuhn, R., Rajewsky, K., Muller, W., Davidson, N.J., and Rennick, D. 
(1995). Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous 
inflammatory responses. The Journal of experimental medicine 182, 99-108. 
Bergbauer, M., Kalla, M., Schmeinck, A., Gobel, C., Rothbauer, U., Eck, S., Benet-Pages, A., 
Strom, T.M., and Hammerschmidt, W. (2010). CpG-methylation regulates a class of 
Epstein-Barr virus promoters. PLoS Pathog 6. 
LITERATURE  
 126 
Biron, C.A. (1994). Cytokines in the generation of immune responses to, and resolution of, 
virus infection. Curr Opin Immunol 6, 530-538. 
Blackshear, P.J. (2002). Tristetraprolin and other CCCH tandem zinc-finger proteins in the 
regulation of mRNA turnover. Biochemical Society transactions 30, 945-952. 
Blazar, B., Patarroyo, M., Klein, E., and Klein, G. (1980). Increased sensitivity of human 
lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by 
superinfection or sodium butyrate. J Exp Med 151, 614-627. 
Bogedain, C., Wolf, H., Modrow, S., Stuber, G., and Jilg, W. (1995). Specific cytotoxic T 
lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 
69, 4872-4879. 
Bollard, C.M., Cooper, L.J., and Heslop, H.E. (2008). Immunotherapy targeting EBV-
expressing lymphoproliferative diseases. Best practice & research. Clinical haematology 21, 
405-420. 
Boname, J.M., de Lima, B.D., Lehner, P.J., and Stevenson, P.G. (2004). Viral degradation of 
the MHC class I peptide loading complex. Immunity 20, 305-317. 
Bouaziz, J.D., Yanaba, K., and Tedder, T.F. (2008). Regulatory B cells as inhibitors of immune 
responses and inflammation. Immunol Rev 224, 201-214. 
Bouillie, S., Barel, M., Drane, P., Cassinat, B., Balbo, M., Holers, V.M., and Frade, R. (1995). 
Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates 
pp105 phosphorylation through two distinct pathways. Eur J Immunol 25, 2661-2667. 
Bresnahan, W.A., and Shenk, T. (2000). A subset of viral transcripts packaged within human 
cytomegalovirus particles. Science 288, 2373-2376. 
Burrows, S.R., Gardner, J., Khanna, R., Steward, T., Moss, D.J., Rodda, S., and Suhrbier, A. 
(1994). Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear 
antigen 3. J Gen Virol 75 ( Pt 9), 2489-2493. 
Busch, L.K., and Bishop, G.A. (1999). The EBV transforming protein, latent membrane protein 
1, mimics and cooperates with CD40 signaling in B lymphocytes. J Immunol 162, 2555-
2561. 
Callan, M.F., Steven, N., Krausa, P., Wilson, J.D., Moss, P.A., Gillespie, G.M., Bell, J.I., 
Rickinson, A.B., and McMichael, A.J. (1996). Large clonal expansions of CD8+ T cells in 
acute infectious mononucleosis. Nature medicine 2, 906-911. 
Carballo, E., Lai, W.S., and Blackshear, P.J. (1998). Feedback inhibition of macrophage tumor 
necrosis factor-alpha production by tristetraprolin. Science 281, 1001-1005. 
Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z. Lee, D.H., Nguyen, J.T., Barbisin, M, Xu, 
N.L., Mahuvakar, V.R., Andersen, M.R., Lao, K.Q., Livak, K.J. and Guegler, K.J. (2005). 
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acid Res. 33, e179. 
Cheung, R.K., Miyazaki, I., and Dosch, H.M. (1993). Unexpected patterns of Epstein-Barr 
virus gene expression during early stages of B cell transformation. Int Immunol 5, 707-716. 
LITERATURE  
 127 
Cohen, J.I. (1999). The biology of Epstein-Barr virus: lessons learned from the virus and the 
host. Curr Opin Immunol 11, 365-370. 
Cooper, M.A., Fehniger, T.A., and Caligiuri, M.A. (2001). The biology of human natural killer-
cell subsets. Trends in immunology 22, 633-640. 
Countryman, J., Jenson, H., Seibl, R., Wolf, H., and Miller, G. (1987). Polymorphic proteins 
encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J 
Virol 61, 3672-3679. 
Croft, N.P., Shannon-Lowe, C., Bell, A.I., Horst, D., Kremmer, E., Ressing, M.E., Wiertz, E.J., 
Middeldorp, J.M., Rowe, M., Rickinson, A.B., and Hislop, A.D. (2009). Stage-specific 
inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during 
virus lytic cycle. PLoS Pathog 5, e1000490. 
de Brouwer, A.P., van Bokhoven, H. and Kremer, H. (2006). Comparison of 12 reference genes 
for normalization of gene expression levels in Epstein-Barr virus-transformed 
lymphoblastoid cell lines and fibroblasts. Mol Diagn Ther 10, 197-204 
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C.G., and de Vries, J.E. (1991a). 
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory 
role of IL-10 produced by monocytes. The Journal of experimental medicine 174, 1209-
1220. 
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M.G., te Velde, A., Figdor, C., Johnson, 
K., Kastelein, R., Yssel, H., and de Vries, J.E. (1991b). Interleukin 10 (IL-10) and viral IL-
10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-
presenting capacity of monocytes via downregulation of class II major histocompatibility 
complex expression. J Exp Med 174, 915-924. 
Delecluse, H.J., Feederle, R., Behrends, U., and Mautner, J. (2008). Contribution of viral 
recombinants to the study of the immune response against the Epstein-Barr virus. Semin 
Cancer Biol 18, 409-415. 
Delecluse, H.J., Hilsendegen, T., Pich, D., Zeidler, R., and Hammerschmidt, W. (1998). 
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human 
cells. Proc Natl Acad Sci U S A 95, 8245-8250. 
Delecluse, H.J., Pich, D., Hilsendegen, T., Baum, C., and Hammerschmidt, W. (1999). A first-
generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci U 
S A 96, 5188-5193. 
Deutsch, M.J., Ott, E., Papior, P., and Schepers, A. (2010). The latent origin of replication of 
Epstein-Barr virus directs viral genomes to active regions of the nucleus. Journal of virology 
84, 2533-2546. 
Ding, Y., Qin, L., Kotenko, S.V., Pestka, S., and Bromberg, J.S. (2000). A single amino acid 
determines the immunostimulatory activity of interleukin 10. J Exp Med 191, 213-224. 
Dolken, L., Malterer, G., Erhard, F., Kothe, S., Friedel, C.C., Suffert, G., Marcinowski, L., 
Motsch, N., Barth, S., Beitzinger, M., et al. (2010). Systematic analysis of viral and cellular 
microRNA targets in cells latently infected with human gamma-herpesviruses by RISC 
immunoprecipitation assay. Cell Host Microbe 7, 324-334. 
LITERATURE  
 128 
Epstein, M.A., and Achong, B.G. (1979). The Epstein-Barr virus (Berlin ; New York: Springer-
Verlag). 
Fiorentino, D.F., Bond, M.W., and Mosmann, T.R. (1989). Two types of mouse T helper cell. 
IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. The Journal 
of experimental medicine 170, 2081-2095. 
Fiorentino, D.F., Zlotnik, A., Vieira, P., Mosmann, T.R., Howard, M., Moore, K.W., and 
O'Garra, A. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production 
by Th1 cells. Journal of immunology 146, 3444-3451. 
Flamand, L., Stefanescu, I., Ablashi, D.V., and Menezes, J. (1993). Activation of the Epstein-
Barr virus replicative cycle by human herpesvirus 6. J Virol 67, 6768-6777. 
Fleming, S.B., McCaughan, C.A., Andrews, A.E., Nash, A.D., and Mercer, A.A. (1997). A 
homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 71, 4857-4861. 
Fowlkes, B.J., Kruisbeek, A.M., Ton-That, H., Weston, M.A., Coligan, J.E., Schwartz, R.H., 
and Pardoll, D.M. (1987). A novel population of T-cell receptor alpha beta-bearing 
thymocytes which predominantly expresses a single V beta gene family. Nature 329, 251-
254. 
Gazzinelli, R.T., Oswald, I.P., James, S.L., and Sher, A. (1992). IL-10 inhibits parasite killing 
and nitrogen oxide production by IFN-gamma-activated macrophages. Journal of 
immunology 148, 1792-1796. 
Germain, R.N. (1994). MHC-dependent antigen processing and peptide presentation: providing 
ligands for T lymphocyte activation. Cell 76, 287-299. 
Go, N.F., Castle, B.E., Barrett, R., Kastelein, R., Dang, W., Mosmann, T.R., Moore, K.W., and 
Howard, M. (1990). Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X 
chromosome-linked immunodeficiency B cells. The Journal of experimental medicine 172, 
1625-1631. 
Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J., and Van Kaer, L. (2004). NKT 
cells: what's in a name? Nat Rev Immunol 4, 231-237. 
Gottschalk, S., Heslop, H.E., and Rooney, C.M. (2005a). Adoptive immunotherapy for EBV-
associated malignancies. Leukemia & lymphoma 46, 1-10. 
Gottschalk, S., Rooney, C.M., and Heslop, H.E. (2005b). Post-transplant lymphoproliferative 
disorders. Annual review of medicine 56, 29-44. 
Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics of a human cell 
line transformed by DNA from human adenovirus type 5. J Gen Virol 36, 59-74. 
Gregorovic, G., Bosshard, R., Karstegl, C.E., White, R.E., Pattle, S., Chiang, A.K., Dittrich-
Breiholz, O., Kracht, M., Russ, R., and Farrell, P.J. (2011). Cell gene expression correlating 
with EBER expression in Epstein-Barr virus infected lymphoblastoid cell lines. J Virol. 
Greijer, A.E., Dekkers, C.A., and Middeldorp, J.M. (2000). Human cytomegalovirus virions 
differentially incorporate viral and host cell RNA during the assembly process. J Virol 74, 
9078-9082. 
LITERATURE  
 129 
Griffin, B.D., Verweij, M.C., and Wiertz, E.J. (2010). Herpesviruses and immunity: the art of 
evasion. Veterinary microbiology 143, 89-100. 
Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J.E., and Roncarolo, 
M.G. (1997). A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents 
colitis. Nature 389, 737-742. 
Gruffat, H., Batisse, J., Pich, D., Neuhierl, B., Manet, E., Hammerschmidt, W., and Sergeant, 
A. (2002). Epstein-Barr virus mRNA export factor EB2 is essential for production of 
infectious virus. J Virol 76, 9635-9644. 
Grundhoff, A., Sullivan, C.S., and Ganem, D. (2006). A combined computational and 
microarray-based approach identifies novel microRNAs encoded by human gamma-
herpesviruses. Rna 12, 733-750. 
Guo, Q., Qian, L., Guo, L., Shi, M., Chen, C., Lv, X., Yu, M., Hu, M., Jiang, G., and Guo, N. 
(2010). Transactivators Zta and Rta of Epstein-Barr virus promote G0/G1 to S transition in 
Raji cells: a novel relationship between lytic virus and cell cycle. Mol Immunol 47, 1783-
1792. 
Hammerschmidt, W., and Sugden, B. (1989). Genetic analysis of immortalizing functions of 
Epstein-Barr virus in human B lymphocytes. Nature 340, 393-397. 
Hansen, T.H., and Bouvier, M. (2009). MHC class I antigen presentation: learning from viral 
evasion strategies. Nat Rev Immunol 9, 503-513. 
Hardy, M.P., Owczarek, C.M., Jermiin, L.S., Ejdeback, M., and Hertzog, P.J. (2004). 
Characterization of the type I interferon locus and identification of novel genes. Genomics 
84, 331-345. 
He, L., and Hannon, G.J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. 
Nature reviews. Genetics 5, 522-531. 
Hettich, E., Janz, A., Zeidler, R., Pich, D., Hellebrand, E., Weissflog, B., Moosmann, A., and 
Hammerschmidt, W. (2006). Genetic design of an optimized packaging cell line for gene 
vectors transducing human B cells. Gene therapy 13, 844-856. 
Hill, A., Jugovic, P., York, I., Russ, G., Bennink, J., Yewdell, J., Ploegh, H., and Johnson, D. 
(1995). Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-
415. 
Hiriart, E., Bardouillet, L., Manet, E., Gruffat, H., Penin, F., Montserret, R., Farjot, G., and 
Sergeant, A. (2003a). A region of the Epstein-Barr virus (EBV) mRNA export factor EB2 
containing an arginine-rich motif mediates direct binding to RNA. J Biol Chem 278, 37790-
37798. 
Hiriart, E., Farjot, G., Gruffat, H., Nguyen, M.V., Sergeant, A., and Manet, E. (2003b). A novel 
nuclear export signal and a REF interaction domain both promote mRNA export by the 
Epstein-Barr virus EB2 protein. J Biol Chem 278, 335-342. 
Hislop, A.D., Palendira, U., Leese, A.M., Arkwright, P.D., Rohrlich, P.S., Tangye, S.G., 
Gaspar, H.B., Lankester, A.C., Moretta, A., and Rickinson, A.B. (2010). Impaired Epstein-
LITERATURE  
 130 
Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is 
restricted to SLAM family-positive B-cell targets. Blood 116, 3249-3257. 
Hislop, A.D., Ressing, M.E., van Leeuwen, D., Pudney, V.A., Horst, D., Koppers-Lalic, D., 
Croft, N.P., Neefjes, J.J., Rickinson, A.B., and Wiertz, E.J. (2007). A CD8+ T cell immune 
evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J 
Exp Med 204, 1863-1873. 
Horst, D., van Leeuwen, D., Croft, N.P., Garstka, M.A., Hislop, A.D., Kremmer, E., Rickinson, 
A.B., Wiertz, E.J., and Ressing, M.E. (2009). Specific targeting of the EBV lytic phase 
protein BNLF2a to the transporter associated with antigen processing results in impairment 
of HLA class I-restricted antigen presentation. J Immunol 182, 2313-2324. 
Hsu, D.H., de Waal Malefyt, R., Fiorentino, D.F., Dang, M.N., Vieira, P., de Vries, J., Spits, 
H., Mosmann, T.R., and Moore, K.W. (1990). Expression of interleukin-10 activity by 
Epstein-Barr virus protein BCRF1. Science 250, 830-832. 
Iskra, S., Kalla, M., Delecluse, H.J., Hammerschmidt, W., and Moosmann, A. (2010). Toll-like 
receptor agonists synergistically increase proliferation and activation of B cells by epstein-
barr virus. J Virol 84, 3612-3623. 
Iwakiri, D., and Takada, K. (2010). Role of EBERs in the pathogenesis of EBV infection. 
Advances in cancer research 107, 119-136. 
Iwakiri, D., Zhou, L., Samanta, M., Matsumoto, M., Ebihara, T., Seya, T., Imai, S., Fujieda, 
M., Kawa, K., and Takada, K. (2009). Epstein-Barr virus (EBV)-encoded small RNA is 
released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp 
Med 206, 2091-2099. 
Janeway, C. (2005). Immunobiology : the immune system in health and disease, 6th edn (New 
York: Garland Science). 
Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G., and Schoenberger, 
S.P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T 
lymphocytes. Nature 421, 852-856. 
Joseph, A.M., Babcock, G.J., and Thorley-Lawson, D.A. (2000). EBV persistence involves 
strict selection of latently infected B cells. Journal of immunology 165, 2975-2981. 
Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D., and Hammerschmidt, W. (2010). AP-1 
homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the 
epigenetic state of the viral genome. Proc Natl Acad Sci U S A 107, 850-855. 
Kanai, K., Satoh, Y., Yamanaka, H., Kawaguchi, A., Horie, K., Sugata, K., Hoshikawa, Y., 
Sata, T., and Sairenji, T. (2007). The vIL-10 gene of the Epstein-Barr virus (EBV) is 
conserved in a stable manner except for a few point mutations in various EBV isolates. 
Virus Genes 35, 563-569. 
Kanda, T., Otter, M., and Wahl, G.M. (2001). Coupling of mitotic chromosome tethering and 
replication competence in epstein-barr virus-based plasmids. Mol Cell Biol 21, 3576-3588. 
Kawai, T., and Akira, S. (2008). Toll-like receptor and RIG-I-like receptor signaling. Annals of 
the New York Academy of Sciences 1143, 1-20. 
LITERATURE  
 131 
Klein, E., Klein, G., Nadkarni, J.S., Nadkarni, J.J., Wigzell, H., and Clifford, P. (1968). Surface 
IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. 
Cancer Res 28, 1300-1310. 
Komano, J., Sugiura, M., and Takada, K. (1998). Epstein-Barr virus contributes to the 
malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J 
Virol 72, 9150-9156. 
Kotenko, S.V., Gallagher, G., Baurin, V.V., Lewis-Antes, A., Shen, M., Shah, N.K., Langer, 
J.A., Sheikh, F., Dickensheets, H., and Donnelly, R.P. (2003). IFN-lambdas mediate 
antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4, 
69-77. 
Kotenko, S.V., Saccani, S., Izotova, L.S., Mirochnitchenko, O.V., and Pestka, S. (2000). 
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad 
Sci U S A 97, 1695-1700. 
Krishnan, H.H., Naranatt, P.P., Smith, M.S., Zeng, L., Bloomer, C., and Chandran, B. (2004). 
Concurrent expression of latent and a limited number of lytic genes with immune 
modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early 
during infection of primary endothelial and fibroblast cells and subsequent decline of lytic 
gene expression. J Virol 78, 3601-3620. 
Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., and Muller, W. (1993). Interleukin-10-
deficient mice develop chronic enterocolitis. Cell 75, 263-274. 
Kuppers, R. (2003). B cells under influence: transformation of B cells by Epstein-Barr virus. 
Nat Rev Immunol 3, 801-812. 
Lautscham, G., Mayrhofer, S., Taylor, G., Haigh, T., Leese, A., Rickinson, A., and Blake, N. 
(2001). Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) 
T cell recognition reveals a proteasome-dependent, transporter associated with antigen 
processing-independent pathway. J Exp Med 194, 1053-1068. 
Lautscham, G., Rickinson, A., and Blake, N. (2003). TAP-independent antigen presentation on 
MHC class I molecules: lessons from Epstein-Barr virus. Microbes Infect 5, 291-299. 
Lauw, F.N., Pajkrt, D., Hack, C.E., Kurimoto, M., van Deventer, S.J., and van der Poll, T. 
(2000). Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165, 2783-
2789. 
Lee, S.P., Thomas, W.A., Blake, N.W., and Rickinson, A.B. (1996). Transporter (TAP)-
independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus 
latent membrane protein 2. Eur J Immunol 26, 1875-1883. 
Lee, S.P., Thomas, W.A., Murray, R.J., Khanim, F., Kaur, S., Young, L.S., Rowe, M., Kurilla, 
M., and Rickinson, A.B. (1993). HLA A2.1-restricted cytotoxic T cells recognizing a range 
of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J 
Virol 67, 7428-7435. 
Lerner, M.R., Andrews, N.C., Miller, G., and Steitz, J.A. (1981). Two small RNAs encoded by 
Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients 
with systemic lupus erythematosus. Proc Natl Acad Sci U S A 78, 805-809. 
LITERATURE  
 132 
Liu, Y., de Waal Malefyt, R., Briere, F., Parham, C., Bridon, J.M., Banchereau, J., Moore, 
K.W., and Xu, J. (1997). The EBV IL-10 homologue is a selective agonist with impaired 
binding to the IL-10 receptor. J Immunol 158, 604-613. 
Lo, A.K., To, K.F., Lo, K.W., Lung, R.W., Hui, J.W., Liao, G., and Hayward, S.D. (2007). 
Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci 
U S A 104, 16164-16169. 
London, C.A., Lodge, M.P., and Abbas, A.K. (2000). Functional responses and costimulator 
dependence of memory CD4+ T cells. Journal of immunology 164, 265-272. 
Long, E.O. (1999). Regulation of immune responses through inhibitory receptors. Annu Rev 
Immunol 17, 875-904. 
Long, H.M., Taylor, G.S., and Rickinson, A.B. (2011). Immune defence against EBV and 
EBV-associated disease. Curr Opin Immunol. 
Luscher, B., and Eisenman, R.N. (1988). c-myc and c-myb protein degradation: effect of 
metabolic inhibitors and heat shock. Mol Cell Biol 8, 2504-2512. 
MacNeil, I.A., Suda, T., Moore, K.W., Mosmann, T.R., and Zlotnik, A. (1990). IL-10, a novel 
growth cofactor for mature and immature T cells. J Immunol 145, 4167-4173. 
Mahot, S., Sergeant, A., Drouet, E., and Gruffat, H. (2003). A novel function for the Epstein-
Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen 
Virol 84, 965-974. 
Maldonado, R.A., Irvine, D.J., Schreiber, R., and Glimcher, L.H. (2004). A role for the 
immunological synapse in lineage commitment of CD4 lymphocytes. Nature 431, 527-532. 
Maldonado, R.A., Soriano, M.A., Perdomo, L.C., Sigrist, K., Irvine, D.J., Decker, T., and 
Glimcher, L.H. (2009). Control of T helper cell differentiation through cytokine receptor 
inclusion in the immunological synapse. J Exp Med 206, 877-892. 
Mancao, C., Altmann, M., Jungnickel, B., and Hammerschmidt, W. (2005). Rescue of 
"crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106, 4339-
4344. 
Marcu, K.B., Bossone, S.A., and Patel, A.J. (1992). myc function and regulation. Annual 
review of biochemistry 61, 809-860. 
Martorelli, D., Muraro, E., Merlo, A., Turrini, R., Rosato, A., and Dolcetti, R. (2010). Role of 
CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 
29, 371-402. 
McKenna, S.A., Lindhout, D.A., Shimoike, T., Aitken, C.E., and Puglisi, J.D. (2007). Viral 
dsRNA inhibitors prevent self-association and autophosphorylation of PKR. J Mol Biol 372, 
103-113. 
Meijer, E., and Cornelissen, J.J. (2008). Epstein-Barr virus-associated lymphoproliferative 
disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and 
early treatment of high-risk patients. Current opinion in hematology 15, 576-585. 
LITERATURE  
 133 
Messeguer, X., Escudero, R., Farre, D., Nunez, O., Martinez, J., and Alba, M.M. (2002). 
PROMO: detection of known transcription regulatory elements using species-tailored 
searches. Bioinformatics 18, 333-334. 
Metzger, H. (1990). Fc receptors and the action of antibodies (Washington, D.C.: American 
Society for Microbiology). 
Meylan, E., and Tschopp, J. (2006). Toll-like receptors and RNA helicases: two parallel ways 
to trigger antiviral responses. Mol Cell 22, 561-569. 
Miller, G., El-Guindy, A., Countryman, J., Ye, J., and Gradoville, L. (2007). Lytic cycle 
switches of oncogenic human gammaherpesviruses. Advances in cancer research 97, 81-
109. 
Miller, G., and Lipman, M. (1973). Release of infectious Epstein-Barr virus by transformed 
marmoset leukocytes. Proc Natl Acad Sci U S A 70, 190-194. 
Miller, G., Shope, T., Lisco, H., Stitt, D., and Lipman, M. (1972). Epstein-Barr virus: 
transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset 
leukocytes. Proc Natl Acad Sci U S A 69, 383-387. 
Miyazaki, I., Cheung, R.K., and Dosch, H.M. (1993). Viral interleukin 10 is critical for the 
induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 178, 439-447. 
Mocellin, S., Marincola, F., Rossi, C.R., Nitti, D., and Lise, M. (2004). The multifaceted 
relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. 
Cytokine Growth Factor Rev 15, 61-76. 
Modlin, R.L., and Nutman, T.B. (1993). Type 2 cytokines and negative immune regulation in 
human infections. Curr Opin Immunol 5, 511-517. 
Moore, K.W., de Waal Malefyt, R., Coffman, R.L., and O'Garra, A. (2001). Interleukin-10 and 
the interleukin-10 receptor. Annu Rev Immunol 19, 683-765. 
Moore, K.W., Vieira, P., Fiorentino, D.F., Trounstine, M.L., Khan, T.A., and Mosmann, T.R. 
(1990). Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus 
gene BCRFI. Science 248, 1230-1234. 
Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., 
Prevalsek, D., Jaeger, G., Ledderose, G., et al. (2010). Effective and long-term control of 
EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960-2970. 
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63. 
Mosser, D.M., and Zhang, X. (2008). Interleukin-10: new perspectives on an old cytokine. 
Immunol Rev 226, 205-218. 
Murphy, S. (1999). The HLA system : basic biology and clinical applications (Bethesda, Md.: 
American Association of Blood Banks). 
LITERATURE  
 134 
Nachmani, D., Stern-Ginossar, N., Sarid, R., and Mandelboim, O. (2009). Diverse herpesvirus 
microRNAs target the stress-induced immune ligand MICB to escape recognition by natural 
killer cells. Cell Host Microbe 5, 376-385. 
Nakayama, S., Murata, T., Murayama, K., Yasui, Y., Sato, Y., Kudoh, A., Iwahori, S., Isomura, 
H., Kanda, T., and Tsurumi, T. (2009). Epstein-Barr virus polymerase processivity factor 
enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early 
protein. J Biol Chem 284, 21557-21568. 
Nanbo, A., Inoue, K., Adachi-Takasawa, K., and Takada, K. (2002). Epstein-Barr virus RNA 
confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 21, 
954-965. 
Nemerow, G.R., Mold, C., Schwend, V.K., Tollefson, V., and Cooper, N.R. (1987). 
Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus 
(EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 
complement fragment C3d. Journal of virology 61, 1416-1420. 
Neuhierl, B., and Delecluse, H.J. (2006). The Epstein-Barr virus BMRF1 gene is essential for 
lytic virus replication. J Virol 80, 5078-5081. 
Neuhierl, B., Feederle, R., Hammerschmidt, W., and Delecluse, H.J. (2002). Glycoprotein 
gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl 
Acad Sci U S A 99, 15036-15041. 
O'Garra, A., and Arai, N. (2000). The molecular basis of T helper 1 and T helper 2 cell 
differentiation. Trends Cell Biol 10, 542-550. 
Ojala, P.M., Sodeik, B., Ebersold, M.W., Kutay, U., and Helenius, A. (2000). Herpes simplex 
virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the 
nuclear pore complex in vitro. Mol Cell Biol 20, 4922-4931. 
Opal, S.M., Wherry, J.C., and Grint, P. (1998). Interleukin-10: potential benefits and possible 
risks in clinical infectious diseases. Clin Infect Dis 27, 1497-1507. 
Pan, S.H., Tai, C.C., Lin, C.S., Hsu, W.B., Chou, S.F., Lai, C.C., Chen, J.Y., Tien, H.F., Lee, 
F.Y., and Wang, W.B. (2009). Epstein-Barr virus nuclear antigen 2 disrupts mitotic 
checkpoint and causes chromosomal instability. Carcinogenesis 30, 366-375. 
Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., 
Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., and et al. (1994). Infusions of 
donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after 
allogeneic bone marrow transplantation. N Engl J Med 330, 1185-1191. 
Pappworth, I.Y., Wang, E.C., and Rowe, M. (2007). The switch from latent to productive 
infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell 
killing. J Virol 81, 474-482. 
Parato, K.G., Kumar, A., Badley, A.D., Sanchez-Dardon, J.L., Chambers, K.A., Young, C.D., 
Lim, W.T., Kravcik, S., Cameron, D.W., and Angel, J.B. (2002). Normalization of natural 
killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. 
AIDS 16, 1251-1256. 
LITERATURE  
 135 
Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., 
Blankenstein, T., and Kiessling, R. (1998). Constitutive IL-10 production accounts for the 
high NK sensitivity, low MHC class I expression, and poor transporter associated with 
antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161, 
2099-2105. 
Pfeffer, S., Sewer, A., Lagos-Quintana, M., Sheridan, R., Sander, C., Grasser, F.A., van Dyk, 
L.F., Ho, C.K., Shuman, S., Chien, M., et al. (2005). Identification of microRNAs of the 
herpesvirus family. Nature methods 2, 269-276. 
Pfeffer, S., Zavolan, M., Grasser, F.A., Chien, M., Russo, J.J., Ju, J., John, B., Enright, A.J., 
Marks, D., Sander, C., and Tuschl, T. (2004). Identification of virus-encoded microRNAs. 
Science 304, 734-736. 
Pieters, J. (2000). MHC class II-restricted antigen processing and presentation. Adv Immunol 
75, 159-208. 
Pudney, V.A., Leese, A.M., Rickinson, A.B., and Hislop, A.D. (2005). CD8+ 
immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the 
efficiency of antigen presentation in lytically infected cells. J Exp Med 201, 349-360. 
Pulvertaft, J.V. (1964). Cytology of Burkitt's Tumour (African Lymphoma). Lancet 1, 238-240. 
Purcell, A.W., and Elliott, T. (2008). Molecular machinations of the MHC-I peptide loading 
complex. Curr Opin Immunol 20, 75-81. 
Ragoczy, T., Heston, L., and Miller, G. (1998). The Epstein-Barr virus Rta protein activates 
lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72, 7978-7984. 
Ralph, P., Nakoinz, I., Sampson-Johannes, A., Fong, S., Lowe, D., Min, H.Y., and Lin, L. 
(1992). IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor 
necrosis factor. Journal of immunology 148, 808-814. 
Ressing, M.E., Horst, D., Griffin, B.D., Tellam, J., Zuo, J., Khanna, R., Rowe, M., and Wiertz, 
E.J. (2008). Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via 
concerted actions of multiple gene products. Semin Cancer Biol 18, 397-408. 
Rickinson, A., and Kieff, E. (2007). Epstein Barr Virus. In Fields virology, B.N. Fields, D.M. 
Knipe, P.M. Howley, D.E. Griffin, M.A. Martin, and R.A. Lamb, eds. (Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins), pp. 2575-2672. 
Rickinson, A.B., and Moss, D.J. (1997). Human cytotoxic T lymphocyte responses to Epstein-
Barr virus infection. Annu Rev Immunol 15, 405-431. 
Rickinson, A.B., Rowe, M., Hart, I.J., Yao, Q.Y., Henderson, L.E., Rabin, H., and Epstein, 
M.A. (1984). T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-
induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol 87, 646-
658. 
Rock, K.L., and Shen, L. (2005). Cross-presentation: underlying mechanisms and role in 
immune surveillance. Immunol Rev 207, 166-183. 
LITERATURE  
 136 
Rode, H.J., Janssen, W., Rosen-Wolff, A., Bugert, J.J., Thein, P., Becker, Y., and Darai, G. 
(1993). The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. 
Virus Genes 7, 111-116. 
Roizman, B. (2000). Redefining virology. Science 288, 2327-2328. 
Romagnani, S. (1999). Th1/Th2 cells. Inflamm Bowel Dis 5, 285-294. 
Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., 
Bowman, L.C., Krance, R.A., Brenner, M.K., and Heslop, H.E. (1998). Infusion of cytotoxic 
T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in 
allogeneic transplant recipients. Blood 92, 1549-1555. 
Rosa, M.D., Gottlieb, E., Lerner, M.R., and Steitz, J.A. (1981). Striking similarities are 
exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-
associated ribonucleic acids VAI and VAII. Mol Cell Biol 1, 785-796. 
Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D.H., Kastelein, R., Moore, 
K.W., and Banchereau, J. (1992a). Interleukin 10 is a potent growth and differentiation 
factor for activated human B lymphocytes. Proceedings of the National Academy of 
Sciences of the United States of America 89, 1890-1893. 
Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D.H., Kastelein, R., Moore, 
K.W., and Banchereau, J. (1992b). Interleukin 10 is a potent growth and differentiation 
factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89, 1890-1893. 
Rowe, M., Glaunsinger, B., van Leeuwen, D., Zuo, J., Sweetman, D., Ganem, D., Middeldorp, 
J., Wiertz, E.J., and Ressing, M.E. (2007). Host shutoff during productive Epstein-Barr virus 
infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci 
U S A 104, 3366-3371. 
Ruf, I.K., Rhyne, P.W., Yang, H., Borza, C.M., Hutt-Fletcher, L.M., Cleveland, J.L., and 
Sample, J.T. (1999). Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in 
Burkitt lymphoma. Mol Cell Biol 19, 1651-1660. 
Ruiss, R., Jochum, S., Reisbach, G., Battke, C., Hammerschmidt, W., and Zeidler, R. (2011). A 
VLP-based Epstein Barr Virus vaccine. Proc Natl Acad Sci U S A submitted. 
Salek-Ardakani, S., Arrand, J.R., and Mackett, M. (2002). Epstein-Barr virus encoded 
interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: 
implications for immune evasion by EBV. Virology 304, 342-351. 
Samanta, M., Iwakiri, D., Kanda, T., Imaizumi, T., and Takada, K. (2006). EB virus-encoded 
RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 25, 
4207-4214. 
Samanta, M., and Takada, K. (2010). Modulation of innate immunity system by Epstein-Barr 
virus-encoded non-coding RNA and oncogenesis. Cancer science 101, 29-35. 
Sambrook, J., and Russell, D.W. (2001). Molecular cloning : a laboratory manual, 3rd edn 
(Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press). 
LITERATURE  
 137 
Saulquin, X., Ibisch, C., Peyrat, M.A., Scotet, E., Hourmant, M., Vie, H., Bonneville, M., and 
Houssaint, E. (2000). A global appraisal of immunodominant CD8 T cell responses to 
Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol 30, 2531-2539. 
Schoenborn, J.R., and Wilson, C.B. (2007). Regulation of interferon-gamma during innate and 
adaptive immune responses. Adv Immunol 96, 41-101. 
Schroder, K., Hertzog, P.J., Ravasi, T., and Hume, D.A. (2004). Interferon-gamma: an 
overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-189. 
Sciortino, M.T., Suzuki, M., Taddeo, B., and Roizman, B. (2001). RNAs extracted from herpes 
simplex virus 1 virions: apparent selectivity of viral but not cellular RNAs packaged in 
virions. J Virol 75, 8105-8116. 
Sciortino, M.T., Taddeo, B., Poon, A.P., Mastino, A., and Roizman, B. (2002). Of the three 
tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the 
mRNA to uninfected cells for expression prior to viral infection. Proc Natl Acad Sci U S A 
99, 8318-8323. 
Seto, E., Moosmann, A., Gromminger, S., Walz, N., Grundhoff, A., and Hammerschmidt, W. 
(2010). Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent 
apoptosis of primary human B cells. PLoS Pathog 6. 
Shannon-Lowe, C., Adland, E., Bell, A.I., Delecluse, H.J., Rickinson, A.B., and Rowe, M. 
(2009). Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: 
viral genome expression, genome maintenance, and genome amplification. J Virol 83, 7749-
7760. 
Sharma, A., Kumar, M., Aich, J., Hariharan, M., Brahmachari, S.K., Agrawal, A., and Ghosh, 
B. (2009). Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc 
Natl Acad Sci U S A 106, 5761-5766. 
Shedlock, D.J., and Shen, H. (2003). Requirement for CD4 T cell help in generating functional 
CD8 T cell memory. Science 300, 337-339. 
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.E., 
Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003). IL-28, IL-29 and their 
class II cytokine receptor IL-28R. Nat Immunol 4, 63-68. 
Siegel, M.R., and Sisler, H.D. (1963). Inhibition of Protein Synthesis in Vitro by 
Cycloheximide. Nature 200, 675-676. 
Sitkovsky, M.V. (1988). Mechanistic, functional and immunopharmacological implications of 
biochemical studies of antigen receptor-triggered cytolytic T-lymphocyte activation. 
Immunological reviews 103, 127-160. 
Snow, A.L., and Martinez, O.M. (2007). Epstein-Barr virus: evasive maneuvers in the 
development of PTLD. American journal of transplantation : official journal of the 
American Society of Transplantation and the American Society of Transplant Surgeons 7, 
271-277. 
Sobell, H.M. (1985). Actinomycin and DNA transcription. Proc Natl Acad Sci U S A 82, 5328-
5331. 
LITERATURE  
 138 
Sodeik, B., Ebersold, M.W., and Helenius, A. (1997). Microtubule-mediated transport of 
incoming herpes simplex virus 1 capsids to the nucleus. The Journal of cell biology 136, 
1007-1021. 
Spellberg, B., and Edwards, J.E., Jr. (2001). Type 1/Type 2 immunity in infectious diseases. 
Clin Infect Dis 32, 76-102. 
Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J., and Enk, A.H. (1997). Induction of tolerance 
by IL-10-treated dendritic cells. J Immunol 159, 4772-4780. 
Steven, N.M., Leese, A.M., Annels, N.E., Lee, S.P., and Rickinson, A.B. (1996). Epitope 
focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to 
T cell memory. J Exp Med 184, 1801-1813. 
Stoecklin, G., Tenenbaum, S.A., Mayo, T., Chittur, S.V., George, A.D., Baroni, T.E., 
Blackshear, P.J., and Anderson, P. (2008). Genome-wide analysis identifies interleukin-10 
mRNA as target of tristetraprolin. J Biol Chem 283, 11689-11699. 
Strowig, T., Brilot, F., Arrey, F., Bougras, G., Thomas, D., Muller, W.A., and Munz, C. (2008). 
Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. 
PLoS Pathog 4, e27. 
Suzuki, T., Tahara, H., Narula, S., Moore, K.W., Robbins, P.D., and Lotze, M.T. (1995). Viral 
interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local 
anergy to allogeneic and syngeneic tumors. J Exp Med 182, 477-486. 
Swaminathan, S. (2008). Noncoding RNAs produced by oncogenic human herpesviruses. 
Journal of cellular physiology 216, 321-326. 
Swaminathan, S., Tomkinson, B., and Kieff, E. (1991). Recombinant Epstein-Barr virus with 
small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl 
Acad Sci U S A 88, 1546-1550. 
Terhune, S.S., Schroer, J., and Shenk, T. (2004). RNAs are packaged into human 
cytomegalovirus virions in proportion to their intracellular concentration. J Virol 78, 10390-
10398. 
Theofilopoulos, A.N., Baccala, R., Beutler, B., and Kono, D.H. (2005). Type I interferons 
(alpha/beta) in immunity and autoimmunity. Annual review of immunology 23, 307-336. 
Thomson, A.W., and Lotze, M.T. (2003). The cytokine handbook, 4th edn (Amsterdam ; 
Boston: Academic Press). 
Vieira, P., de Waal-Malefyt, R., Dang, M.N., Johnson, K.E., Kastelein, R., Fiorentino, D.F., 
deVries, J.E., Roncarolo, M.G., Mosmann, T.R., and Moore, K.W. (1991). Isolation and 
expression of human cytokine synthesis inhibitory factor cDNA clones: homology to 
Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 88, 1172-1176. 
Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, 
W.M., and Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer 
cells. Science 331, 44-49. 
LITERATURE  
 139 
Vivier, E., and Ugolini, S. (2009). Regulatory natural killer cells: new players in the IL-10 anti-
inflammatory response. Cell Host Microbe 6, 493-495. 
Wagner, C.S., Ljunggren, H.G., and Achour, A. (2008). Immune modulation by the human 
cytomegalovirus-encoded molecule UL18, a mystery yet to be solved. J Immunol 180, 19-
24. 
Wang, X., and Hutt-Fletcher, L.M. (1998). Epstein-Barr virus lacking glycoprotein gp42 can 
bind to B cells but is not able to infect. Journal of virology 72, 158-163. 
Wang, X., Kenyon, W.J., Li, Q., Mullberg, J., and Hutt-Fletcher, L.M. (1998). Epstein-Barr 
virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and 
epithelial cells. Journal of virology 72, 5552-5558. 
Warming, S., Costantino, N., Court, D.L., Jenkins, N.A., and Copeland, N.G. (2005). Simple 
and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33, e36. 
Wiesner, M., Zentz, C., Mayr, C., Wimmer, R., Hammerschmidt, W., Zeidler, R., and 
Moosmann, A. (2008). Conditional immortalization of human B cells by CD40 ligation. 
PLoS One 3, e1464. 
Wills, M.R., Ashiru, O., Reeves, M.B., Okecha, G., Trowsdale, J., Tomasec, P., Wilkinson, 
G.W., Sinclair, J., and Sissons, J.G. (2005). Human cytomegalovirus encodes an MHC class 
I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 175, 7457-7465. 
Wilson, A.D., and Morgan, A.J. (2002). Primary immune responses by cord blood CD4(+) T 
cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. J Virol 76, 5071-
5081. 
Wilson, J.B., and May, G.H.W. (2001). Epstein-Barr virus protocols (Totowa, N.J.: Humana 
Press). 
Xia, T., O'Hara, A., Araujo, I., Barreto, J., Carvalho, E., Sapucaia, J.B., Ramos, J.C., Luz, E., 
Pedroso, C., Manrique, M., et al. (2008). EBV microRNAs in primary lymphomas and 
targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68, 1436-1442. 
Yoon, S.I., Jones, B.C., Logsdon, N.J., and Walter, M.R. (2005). Same structure, different 
function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 
chain. Structure 13, 551-564. 
Young, L.S., and Rickinson, A.B. (2004). Epstein-Barr virus: 40 years on. Nature reviews. 
Cancer 4, 757-768. 
Yuan, J., Cahir-McFarland, E., Zhao, B., and Kieff, E. (2006). Virus and cell RNAs expressed 
during Epstein-Barr virus replication. J Virol 80, 2548-2565. 
Zeidler, R., Eissner, G., Meissner, P., Uebel, S., Tampe, R., Lazis, S., and Hammerschmidt, W. 
(1997). Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-
encoded interleukin-10. Blood 90, 2390-2397. 
 
 
DANKSAGUNG  
 140 
 DANKSAGUNG 
 
Ich möchte mich ganz besonders bedanken bei 
 
• Prof. Dr. Reinhard Zeidler für die Projekte und die freie Hand, die er mir ließ, um 
diese umzusetzen, sowie die vielen fruchtbaren Diskussionen, in denen nicht selten 
Pläne für neue Projekte entstanden, 
• Prof. Dr. Wolfgang Hammerschmidt für die Diskussionen im Laborseminar oder 
auch zwischen Tür und Angel, für sehr hilfreiche, konstruktive Kritik und 
Überlegungen sowie für das Einarbeiten in die Technik der maxi-EBV Klonierung, 
• Prof. Dr. Horst Domdey für die Übernahme der universitären Schirmherrschaft über 
meine Arbeit und die Fachvertretung an der Fakultät, 
• Prof. Dr. Wagner, Prof. Dr Förstemann, Prof. Dr. Martin und Prof. Dr. Hopfner 
dafür, dass sie sich ebenfalls Zeit genommen haben, meine Arbeit zu begutachten, 
• Dr. Andreas Moosmann für die T Zell Klone und weitere Schätze aus seinem Cryo-
Stock- und Antikörper-Fundus, für tiefschürfende Diskussionen und sein 
beeindruckendes Detailwissen bezüglich immunologischer Zusammenhänge, 
Kristallisationsvorgängen und anderer philosophischer Fragestellungen,  
• Dagmar Pich, die mir viele technischen Tipps und Tricks vermittelte, welche 
entscheidend zum Erfolg der Arbeit beitrugen, 
• Prof. Dr. Dirk Eick für sein Interesse an meiner Arbeit und seiner Arbeitsgruppe für 
das Aushelfen mit Antikörpern und verschiedenen Inhibitoren.  
 
 
Außerdem gilt mein Dank 
 
Andrea Schub für die hilfreichen Diskussionen diverser Projekte und dessen, was sich davon 
eventuell realisieren lässt, die unumstößliche gute Laune, die wiederholten Hinweise, das 
Kaffepausen zwar nicht die Datenlage, aber auf jeden Fall die Stimmung verbessern, den 
Olympic-Games-News-Ticker und die Übernahme der Stammtisch-Organisation; 
Antje Arnold, die das BNLF2a-Paper im Journal Club vorgestellt hat und zumindest für 
einige Zeit die Fraktion der Labor-Zug’roastn verdoppelte; 
Sebastian Grömminger für die EBV-microRNA Primer und die Einarbeitung in die 
Geheimnisse der qPCR; 
Larissa Martin, für das stets bereitwillige Zur-Verfügung-Stellen ihrer persönlichen Flow, das 
Wechseln von Medium, wenn ich gerade verhindert war, der Gewährung labortechnischen 
Asyls beim Pipettieren des ein oder anderen PCRchens, sowie der Aktualisierung meines 
Kenntnisstandes bezüglich des tagesaktuellen Geschehens frei nach Radio Gong; 
Marc Borath für meist gute Musik, für die Fachsimpeleien über egal was, als drittem „Big 
Player“ in der Kaffeepause, als Mückenwiesen-Flügelflitzer und „Core Processor“ des 
Stammtischs; 
Markus Kalla für die hilfsbereite Unterstützung, das klaglose Ertragen wiederholten 
Schnorrens, das gemeinsame Klonieren induzierbarer Vektoren, die uns fast zum 
Durchbruch verholfen hätten, weitsichtiger Rad-Touren-Pläne, die bald schon in Erfüllung 
gehen könnten,  und dafür, dass ich immer zuerst durch die Tür gehen musste; 
der gesamten AG Moosmann dafür, dass sie mich in ihrem Labor wie einen der Ihren 
gewähren ließen – trotz meines Status als „externem Mitarbeiter“; 
 
 
DANKSAGUNG  
 141 
 
... und nicht zu vergessen: 
 
Manuel Deutsch dafür, dass wir richtige Mikroskop-Freunde wurden und ich von jetzt an 
einen echten Scotch-Single-Malt höchstens alternierend mit einem Schluck seines 
Quellwassers genieße; Andi Thomae für die Erkenntnis, dass jedes Protein individuell ist; 
Stoffl Meyer für das mitunter unvermittelte Vermitteln vieler Fakten und noch mehr Wissen 
über Österreich und seine schlafwandlerische Kenntnis der Chemikalienvorräte; Christoph 
Hinzen für nerdige Mittagspausen, feinsten italienischen Caffé und weltbeste Sprüche in der 
Disziplin „locker bis lässig“; Kai, Stoffl und Sebastian (aka „Die drei von der Halle“) für 
meine Aufnahme in die Top-four der Badminton-Asse trotz nicht ganz hinreichender 
Fähigkeiten meinerseits; Christine, weil sie immer dafür sorgt, dass der Käse gegessen ist; 
Ugur für das Kicken auf der Mückenwiese (präsentiert mit freundlicher Unterstützung von der 
Abteilung Kommunikation, Schirmherr: Prof. Dr. Wess); der AG Imhof für die Socca5 
Beteiligung; der Wanderschuh-Lobby; allen Labor-Kollegen für die klaglose Einsicht, dass 
sich fünf Minuten bei mir gelegentlich höchst relativ verhalten 
 
...und natürlich allen anderen Kollegen der AGV, die immer für ein nettes, lustiges – aber 
natürlich nicht zu kuscheliges! ;-) – Arbeitsklima sorgten. 
 
Ganz besonders bedanke ich mich bei 
meinen Eltern und meiner Schwester, die sich immer tapfer nach dem Stand der Dinge 
erkundigten und meiner Motivation immer mal wieder neue Energie geben konnten, 
 
und vor allem bei 
meiner Freundin Anne Julie für ihr geduldiges Verständnis, dass ich so viele Stunden im 
Labor verbracht habe, ihr Interesse an meiner Arbeit und ihre Freude, wenn sie wusste, um 
was es in den Versuchen ging. Ihre Unterstützung hat ganz entscheidend dazu beigetragen, 
dass ich in allen Phasen der Arbeit am Ball blieb und es tatsächlich geschafft habe, auf dieser 
Seite anzukommen. 
CURRICULUM VITAE  
 142 
 CURRICULUM VITAE 
 
 
  
Name Simon Jochum 
  
Date of birth 
Place of birth 
Nationality 
5. April 1980 
Koblenz, Germany 
German 
  
1986-1992 
1992-1999 
Primary school, Waldesch, Germany 
Secondary School, „Gymnasium auf der Karthause“, Koblenz, Germany 
  
1999-2000 Civilian Service as a Paramedic, Deutsches Rotes Kreuz,  
Koblenz, Germany 
  
2000-2006 Studies of Biology, Albert-Ludwigs-Universität, Freiburg, Germany 
Graduation in Immunobiology, Cellular Biology, Developmental Biology, 
Virology and Business Administration 
2006-2007 Diploma Thesis: 
„Analysis of CDK Inhibitors in B-Cells  
during proliferation and development“ 
AG Prof. Dr. Hassan Jumaa,  
Department Prof. Dr. Michael Reth 
Max-Planck-Institute for Immunobiology, Freiburg, Germany 
  
2007-2011 Doctoral Thesis: 
„RNA transfer by Epstein-Barr virus triggers early events  
that regulate cell fate and promote immune evasion“ 
AG Prof. Dr. Reinhard Zeidler,  
Department Prof. Dr. Wolfgang Hammerschmidt 
Helmholtz Zentrum München and  
Ludwig-Maximilians University, München, Germany 
  
PUBLICATIONS AND PRESENTATIONS  
 143 
 PUBLICATIONS AND PRESENTATIONS 
 
• Jochum S., Ruiss R.,Moosmann A., Hammerschmidt W. and Zeidler R. (2012) 
RNAs in Epstein-Barr virions control early steps of infection. 
Proceedings of the National Academy of Sciences 109: E1396-E1404. 
• Jochum S., Moosmann A., Lang S., Hammerschmidt W. and Zeidler R. (2012) 
The EBV immune evasion proteins vIL-10 and BNLF2a protect newly infected B cells 
from immune recognition and elimination. 
PLoS Pathogens 8: e1002704. 
• Ruiss R., Jochum S., Wanner G., Reisbach G., Hammerschmidt W. and Zeidler R. (2011) 
A virus-like particle-based Epstein-Barr virus vaccine. J Virol 85, 13105-13. 
• Ruiss R., Jochum S., Mocikat R., Hammerschmidt W., Zeidler R. (2011) 
EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal 
and malignant B cells – a new option for the treatment of B-CLL. PLoS One 6, e25294 
• Battke C., Ruiss R., Welsch U., Wimberger P., Lang S., Jochum S., Zeidler R. (2011) 
Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and 
reduce ADCC. Cancer Immunol. Immunother. 60, 639-48 
 
• Talk at the 14th International Congress of Immunology, 22.-27.8.2010 in Kobe, Japan, 
workshop “Immunity to Virus Infections,  title “The Impact of BCRF1 (viral IL-10) and 
BNLF2a on the Immune Evasion of Epstein-Barr Virus” 
(supported by a travel grant of the Glaxo-Smith-Kline Foundation) 
• Talk at the 3rd European EBV Meeting, 16. - 17.6.2011 in Lyon, France, 
with the title “EBV Particles Contain Functional RNAs that Trigger Early Events in 
Infection” 
